cancer_type,TMB (FMOne mutation burden per MB),Neoantigen burden per MB,Immune phenotype,response_label,user_question,full_query
BLCA,18.0,4.68627451,excluded,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 18.0. Based on this finding, how likely is the patient to benefit from Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 18.0. Based on this finding, how likely is the patient to benefit from Atezolizumab therapy? Examine the transcriptomic data and use the Compass tool to forecast the patient's likely response to immune checkpoint inhibitor (ICI) therapy. Assess the Compass results by focusing on key immune functionality indicators such as macrophage activity, the IFNG signaling pathway, genome integrity, cell proliferation rates, and cytotoxic T cell levels. Next, synthesize these findings with the Compass forecasting and the patient’s clinical information to compile a detailed overview of the immune profile. Finally, develop a comprehensive explanation that incorporates the predicted responder status in the context of the observed immune markers, thereby justifying whether the patient is expected to respond to ICI therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0257bb-ar-0257bbb.pkl. "
BLCA,1.0,0.31372549,desert,NR,"For a white male patient with bladder urothelial carcinoma whose biopsy transcriptomic analysis of the tumor immune microenvironment shows a TMB of 1.0, how likely is it that he will respond to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose biopsy transcriptomic analysis of the tumor immune microenvironment shows a TMB of 1.0, how likely is it that he will respond to atezolizumab therapy? Review the patient’s transcriptomic data using the Compass tool to predict their response to immune checkpoint inhibitor therapy. Focus on evaluating macrophage activity, interferon gamma signaling, genome stability, cell proliferation, and cytotoxic T cell levels. Then, combine these insights with the Compass forecast and the patient’s clinical history to create a detailed immune profile. Finally, provide a comprehensive explanation that interprets the immune markers in the context of the predicted response to ICI therapy, justifying your assessment of whether the patient is likely to benefit from this treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/025b45-ar-025b45c.pkl. "
BLCA,44.0,6.196078431,inflamed,NR,"I have a Caucasian female patient with bladder urothelial carcinoma (BLCA) whose transcriptomic profiling from a bladder biopsy indicates a tumor mutation burden (TMB) of 44.0. Based on this information, could you help assess her likelihood of responding to Atezolizumab therapy?","I have a Caucasian female patient with bladder urothelial carcinoma (BLCA) whose transcriptomic profiling from a bladder biopsy indicates a tumor mutation burden (TMB) of 44.0. Based on this information, could you help assess her likelihood of responding to Atezolizumab therapy? Review the patient’s transcriptomic profile using the Compass tool to assess their likely response to immune checkpoint inhibitor therapy. In your analysis, specifically evaluate macrophage activity, interferon gamma signaling, genome stability, cell proliferation, and cytotoxic T cell levels. Integrate these findings with the Compass predictions and the patient’s clinical history to develop a detailed immune profile. Finally, provide a comprehensive explanation that interprets these immune markers in the context of the patient's predicted response to ICI therapy, clearly justifying whether they are likely to benefit from this treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/032c64-ar-032c642.pkl. "
BLCA,2.0,1.470588235,excluded,NR,I have a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA) whose lymph node biopsy transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 2.0. Could you please assess her likelihood of responding to Atezolizumab therapy?,"I have a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA) whose lymph node biopsy transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 2.0. Could you please assess her likelihood of responding to Atezolizumab therapy? Please review the patient's transcriptomic data using the Compass tool, with particular attention to macrophage activity, interferon gamma signaling, genome stability, cell proliferation, and cytotoxic T cell levels. Combine these results with the Compass tool predictions and the patient's clinical history to construct a comprehensive immune profile. Then, provide a detailed interpretation of these immune markers in relation to the patient’s predicted response to immune checkpoint inhibitor therapy, clearly explaining the rationale for their likely benefit or lack thereof.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0571f1-ar-0571f17.pkl. "
BLCA,8.0,,inflamed,R,"I am evaluating a Caucasian male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 8.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy?","I am evaluating a Caucasian male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 8.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy? Review the patient's transcriptomic profile with the Compass tool, focusing on markers of macrophage activity, interferon gamma signaling, genome stability, cell proliferation, and cytotoxic T cell levels. Integrate these findings with the tool's predictions and the patient’s clinical history to develop a detailed immune profile. Then, evaluate and explain how these immune markers might influence the patient’s response to immune checkpoint inhibitor therapy, providing clear rationale for whether a beneficial response is anticipated.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/065890-ar-0658907.pkl. "
BLCA,6.0,0.921568627,,R,"For a white female patient with bladder urothelial carcinoma (BLCA) and a tumor biopsy revealing a tumor mutational burden (TMB) of 6.0, how likely is it that she will respond to atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma (BLCA) and a tumor biopsy revealing a tumor mutational burden (TMB) of 6.0, how likely is it that she will respond to atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data by focusing on key indicators such as macrophage activity, interferon gamma signaling, genome stability, cell proliferation, and levels of cytotoxic T cells. Combine these findings with the tool’s predictive output and the patient’s clinical background to construct a comprehensive immune profile. Then, assess how these immune markers might affect the patient’s anticipated response to immune checkpoint inhibitor therapy, providing a clear explanation and rationale for whether a beneficial response is expected.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0684af-ar-0684af7.pkl. "
BLCA,11.0,0.745098039,excluded,R,"For a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic analysis of the tumor’s immune microenvironment obtained via kidney biopsy shows a tumor mutational burden of 11.0. How might we assess the likelihood of a favorable response to atezolizumab therapy in this case?","For a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic analysis of the tumor’s immune microenvironment obtained via kidney biopsy shows a tumor mutational burden of 11.0. How might we assess the likelihood of a favorable response to atezolizumab therapy in this case? Please utilize the Compass tool to analyze the patient’s transcriptomic data, with an emphasis on evaluating macrophage activity, interferon gamma signaling, genome stability, cell proliferation, and cytotoxic T cell levels. Integrate these findings with the predictive output from the Compass tool and the patient’s clinical history to develop a detailed immune profile. Based on this comprehensive assessment, determine and explain how these immune markers may influence the patient’s response to immune checkpoint inhibitor therapy, and provide a clear, evidence-based rationale as to whether a favorable response is likely.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/075e03-ar-075e037.pkl. "
BLCA,18.0,2.117647059,excluded,R,"A white patient diagnosed with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment showing a tumor mutational burden (TMB) of 18.0 from a bladder biopsy. Based on these findings, what is the likelihood of a positive response to atezolizumab therapy?","A white patient diagnosed with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment showing a tumor mutational burden (TMB) of 18.0 from a bladder biopsy. Based on these findings, what is the likelihood of a positive response to atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic data, focusing specifically on macrophage activity, interferon gamma signaling, genome stability, cell proliferation, and cytotoxic T cell levels. Integrate these results with the Compass tool’s predictive analysis and the patient’s clinical history to construct a comprehensive immune profile. Then, based on this integrated assessment, determine how these immune markers might affect the patient’s response to immune checkpoint inhibitor therapy and provide a clear, evidence-based explanation on whether a favorable response is anticipated.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/07a93a-ar-07a93a2.pkl. "
BLCA,,,excluded,NR,"I have a white female patient with bladder urothelial carcinoma. Transcriptomic profiling of her tumor immune microenvironment from a bladder biopsy indicates that the tumor mutation burden (TMB) is not available. Based on this information, how likely is she to respond to Atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma. Transcriptomic profiling of her tumor immune microenvironment from a bladder biopsy indicates that the tumor mutation burden (TMB) is not available. Based on this information, how likely is she to respond to Atezolizumab therapy? Use the Compass tool to analyze the patient's transcriptomic data, specifically examining macrophage activity, interferon gamma signaling, genome stability, cell proliferation, and cytotoxic T cell levels. Combine these findings with the tool's predictive analysis and the patient’s clinical history to create a detailed immune profile. Based on this comprehensive assessment, evaluate how the identified immune markers may influence the patient's response to immune checkpoint inhibitor therapy, and provide an evidence-based explanation regarding the likelihood of a favorable treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/08cce2-ar-08cce2f.pkl. "
BLCA,,,inflamed,NR,"For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a nano biopsy shows a tumor mutational burden (TMB) of nan, how likely is it that he will respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a nano biopsy shows a tumor mutational burden (TMB) of nan, how likely is it that he will respond to Atezolizumab therapy? Review the patient’s transcriptomic data using the Compass tool, focusing specifically on macrophage activity, interferon gamma signaling, genome stability, cell proliferation, and cytotoxic T cell levels. Integrate these molecular findings with the tool’s predictive analysis and the patient’s clinical history to construct a comprehensive immune profile. Then, assess how these immune markers might impact the patient’s response to immune checkpoint inhibitor therapy, and provide an evidence-based rationale regarding the likelihood of a positive treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/09c84e-ar-09c84ec.pkl. "
BLCA,2.0,0.215686275,,NR,"In a Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment (obtained via kidney biopsy) revealed a tumor mutation burden of 2.0. Based on these findings, is the patient likely to respond favorably to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment (obtained via kidney biopsy) revealed a tumor mutation burden of 2.0. Based on these findings, is the patient likely to respond favorably to Atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data, with careful attention to markers of macrophage activity, interferon gamma signaling, genome stability, cell proliferation, and cytotoxic T cell levels. Combine these findings with the tool's predictive analytics and the patient's clinical history to develop an integrated immune profile. Then, evaluate how these specific immune parameters may influence the patient’s response to immune checkpoint inhibitor therapy, and provide an evidence-based assessment of the probability of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0a0f2b-ar-0a0f2ba.pkl. "
BLCA,8.0,1.274509804,excluded,NR,"We have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 8.0. Based on these findings, how likely is he to respond to Atezolizumab therapy?","We have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 8.0. Based on these findings, how likely is he to respond to Atezolizumab therapy? Please use the Compass tool to review the patient’s transcriptomic data, specifically evaluating markers of macrophage activity, interferon gamma signaling, genome stability, cell proliferation, and levels of cytotoxic T cells. Integrate these data with the tool’s predictive analytics and the patient’s clinical history to create a comprehensive immune profile. Based on this profile, assess how these immune parameters might impact the patient's response to immune checkpoint inhibitor therapy, and provide an evidence-based estimate of the likelihood of a favorable treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0a7c20-ar-0a7c209.pkl. "
BLCA,,,,NR,"For a white female patient with bladder urothelial carcinoma, whose tumor immune microenvironment profile from a lymph node biopsy reported a TMB of ""nan,"" how likely is she to benefit from Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, whose tumor immune microenvironment profile from a lymph node biopsy reported a TMB of ""nan,"" how likely is she to benefit from Atezolizumab therapy? Please employ the Compass tool to analyze the patient's transcriptomic data, focusing on indicators of macrophage activity, interferon gamma signaling, genome stability, and cell proliferation, as well as the quantity of cytotoxic T cells. Combine these insights with the tool’s predictive analytics and the patient’s clinical history to generate a detailed immune profile. Then, evaluate how these immune characteristics might influence the patient's response to immune checkpoint inhibitor therapy, and provide an evidence-based estimate of the probability of achieving a favorable treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0bdb34-ar-0bdb342.pkl. "
BLCA,9.0,,excluded,NR,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma and a tumor mutation burden of 9.0 determined from a ureter biopsy, how likely is it that he would respond to Atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma and a tumor mutation burden of 9.0 determined from a ureter biopsy, how likely is it that he would respond to Atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic data with a focus on markers of macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and the number of cytotoxic T cells. Integrate these findings with the tool's predictive analytics and the patient's clinical history to develop a comprehensive immune profile. Finally, assess how these immune features may influence the patient's response to immune checkpoint inhibitor therapy and provide an evidence-based estimate of the likelihood of a favorable treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0ce9c9-ar-0ce9c98.pkl. "
BLCA,4.0,0.137254902,desert,NR,"For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis reveals a tumor mutational burden of 4.0, what is the likelihood that she will respond to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis reveals a tumor mutational burden of 4.0, what is the likelihood that she will respond to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data with an emphasis on markers for macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell quantity. Integrate these results with the tool's predictive analytics and the patient's clinical history to develop a detailed immune profile. Then, assess how these immune parameters could impact the patient’s response to immune checkpoint inhibitor therapy and offer an evidence-based prediction regarding the likelihood of a favorable treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0d855c-ar-0d855cf.pkl. "
BLCA,32.0,4.098039216,excluded,NR,"For a White male patient with bladder urothelial carcinoma and a tumor mutational burden of 32.0 determined from a ureter biopsy transcriptomic profile, how might these findings influence the likelihood of a favorable response to Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma and a tumor mutational burden of 32.0 determined from a ureter biopsy transcriptomic profile, how might these findings influence the likelihood of a favorable response to Atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic profile with particular attention to markers related to macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and the abundance of cytotoxic T cells. Combine these findings with the tool's predictive analytics and the patient's clinical history to generate a comprehensive immune profile. Then, determine how these immune metrics might affect the patient's response to immune checkpoint inhibitor therapy and provide an evidence-based estimate of the likelihood of a positive treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/0f956e-ar-0f956e7.pkl. "
BLCA,21.0,3.529411765,desert,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor biopsy revealed a tumor mutational burden of 21.0. Based on these findings, how likely is he to respond to atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor biopsy revealed a tumor mutational burden of 21.0. Based on these findings, how likely is he to respond to atezolizumab therapy? Please use the Compass tool to assess the patient's transcriptomic data, focusing specifically on markers of macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and the presence of cytotoxic T cells. Integrate these findings with the tool's predictive analytics and the patient's clinical history to develop a comprehensive immune profile. Based on this profile, evaluate how these immune parameters might influence the patient’s response to immune checkpoint inhibitor therapy, and provide an evidence-based estimate of the likelihood of a positive outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/110501-ar-110501d.pkl. "
BLCA,10.0,1.078431373,inflamed,NR,"For a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment obtained from a kidney biopsy revealed a tumor mutational burden of 10.0 mutations per megabase. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment obtained from a kidney biopsy revealed a tumor mutational burden of 10.0 mutations per megabase. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data, specifically examining markers related to macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell presence. Combine these molecular findings with the tool’s predictive analytics and the patient's clinical history to create a detailed immune profile. Then, assess how these immune characteristics may affect the patient’s response to immune checkpoint inhibitor therapy, and provide an evidence-based estimate regarding the potential for a favorable treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/12502d-ar-12502d9.pkl. "
BLCA,38.0,6.68627451,desert,R,"For a white male patient diagnosed with bladder urothelial carcinoma, whose transcriptomic analysis from a bladder biopsy reveals a tumor mutational burden of 38, how likely is he to respond to atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, whose transcriptomic analysis from a bladder biopsy reveals a tumor mutational burden of 38, how likely is he to respond to atezolizumab therapy? Use the Compass tool to evaluate the patient’s transcriptomic data, focusing on markers such as macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell presence. Integrate these molecular insights with the tool’s predictive analytics and the patient’s clinical history to build a comprehensive immune profile. Then, determine how these immune factors might impact the patient’s response to immune checkpoint inhibitor therapy and provide an evidence-based estimate of the likelihood of a favorable treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/149386-ar-1493861.pkl. "
BLCA,7.0,0.568627451,excluded,R,"For a female Caucasian patient diagnosed with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic analysis reveals a tumor mutational burden (TMB) of 7.0, could you evaluate the likelihood of her responding to Atezolizumab therapy?","For a female Caucasian patient diagnosed with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic analysis reveals a tumor mutational burden (TMB) of 7.0, could you evaluate the likelihood of her responding to Atezolizumab therapy? Utilize the Compass tool to analyze the patient’s transcriptomic data, specifically examining markers like macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and the presence of cytotoxic T cells. Combine these molecular findings with the tool’s predictive analytics and the patient’s clinical history to create a detailed immune profile. Then, assess how these immune factors may influence the patient’s response to immune checkpoint inhibitor therapy and provide an evidence-based estimate of the likelihood of achieving a favorable treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/14df63-ar-14df63a.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"For our Caucasian male patient with bladder urothelial carcinoma (BLCA), transcriptomic analysis of his tumor immune microenvironment from a biopsy indicates a tumor mutational burden (TMB) of 5.0. Based on these findings, what is your assessment of his likely response to Atezolizumab therapy?","For our Caucasian male patient with bladder urothelial carcinoma (BLCA), transcriptomic analysis of his tumor immune microenvironment from a biopsy indicates a tumor mutational burden (TMB) of 5.0. Based on these findings, what is your assessment of his likely response to Atezolizumab therapy? Use the Compass tool to evaluate the patient’s transcriptomic data by focusing on specific biomarkers, including macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and the prevalence of cytotoxic T cells. Integrate these molecular findings with the tool's predictive analytics and the patient’s clinical history to construct a detailed profile of the patient’s immune status. Finally, analyze how these immune parameters might affect the patient’s response to immune checkpoint inhibitor therapy and provide an evidence-based estimate of their potential for a favorable treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/166a41-ar-166a419.pkl. "
BLCA,15.0,,desert,NR,"For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden (TMB) of 15, how would you assess the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden (TMB) of 15, how would you assess the likelihood of a favorable response to Atezolizumab therapy? Use the Compass tool to analyze the patient’s transcriptomic data, specifically examining biomarkers related to macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell levels. Combine these molecular findings with the tool’s predictive analytics and the patient's clinical history to develop a comprehensive profile of the individual's immune status. Finally, assess how this immune profile could influence the patient’s response to immune checkpoint inhibitors and provide an evidence-based prediction regarding the likelihood of a favorable treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/180398-ar-1803982.pkl. "
BLCA,,0.215686275,excluded,NR,"We have a Caucasian male patient with bladder urothelial carcinoma. A kidney biopsy for transcriptomic profiling of the tumor microenvironment was performed, but the tumor mutational burden (TMB) result was not available. Based on these findings, how likely is it that this patient will respond to Atezolizumab therapy?","We have a Caucasian male patient with bladder urothelial carcinoma. A kidney biopsy for transcriptomic profiling of the tumor microenvironment was performed, but the tumor mutational burden (TMB) result was not available. Based on these findings, how likely is it that this patient will respond to Atezolizumab therapy? Employ the Compass tool to review the patient’s transcriptomic data, focusing on biomarkers for macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Integrate these molecular findings with the tool’s predictive analytics and the patient’s clinical history to build a comprehensive profile of their immune status. Then, evaluate how this immune profile may affect the patient’s response to immune checkpoint inhibitors, providing an evidence-based prediction on the likelihood of a favorable treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/181b63-ar-181b638.pkl. "
BLCA,,,,NR,"In a Caucasian male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a lung biopsy reported a TMB value of ""nan."" How should we interpret this finding in terms of predicting response to atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a lung biopsy reported a TMB value of ""nan."" How should we interpret this finding in terms of predicting response to atezolizumab therapy? Please use the Compass tool to examine the patient's transcriptomic data, paying particular attention to biomarkers related to macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Combine these molecular insights with the tool’s predictive analytics and the patient’s clinical history to construct a detailed profile of their immune status. Finally, assess how this immune profile might influence the patient's response to immune checkpoint inhibitors, and provide an evidence-based prediction regarding the likelihood of a favorable treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/187e05-ar-187e056.pkl. "
BLCA,18.0,2.039215686,excluded,NR,I have a white male patient diagnosed with Bladder Urothelial Carcinoma (BLCA). A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 18. Could you provide an assessment of his likelihood to respond to Atezolizumab therapy based on this information?,"I have a white male patient diagnosed with Bladder Urothelial Carcinoma (BLCA). A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 18. Could you provide an assessment of his likelihood to respond to Atezolizumab therapy based on this information? Please use the Compass tool to analyze the patient's transcriptomic data, focusing on biomarkers associated with macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Integrate this molecular data with the tool’s predictive analytics and the patient’s clinical history to develop a comprehensive immune profile. Then, evaluate how this profile might affect the patient's response to immune checkpoint inhibitors and provide an evidence-based prediction regarding the likelihood of achieving a positive treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18a4da-ar-18a4dab.pkl. "
BLCA,7.0,0.392156863,inflamed,NR,I have an African American male patient diagnosed with bladder urothelial carcinoma. A ureter biopsy of his tumor revealed a tumor mutational burden (TMB) of 7.0. Could you evaluate whether Atezolizumab therapy would be a suitable treatment option for him?,"I have an African American male patient diagnosed with bladder urothelial carcinoma. A ureter biopsy of his tumor revealed a tumor mutational burden (TMB) of 7.0. Could you evaluate whether Atezolizumab therapy would be a suitable treatment option for him? Using the Compass tool, please examine the patient's transcriptomic data with a focus on biomarkers that indicate macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Combine this information with the tool’s predictive analytics and the patient's clinical history to construct a detailed immune profile. Then, assess how this immune profile may influence the patient's response to immune checkpoint inhibitors and provide an evidence-based prediction regarding the likelihood of a positive treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18b935-ar-18b9351.pkl. "
BLCA,19.0,1.803921569,,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, a bladder biopsy has revealed a transcriptomic profile showing a tumor mutational burden (TMB) of 19. Could you assess how likely it is that this patient will respond to atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, a bladder biopsy has revealed a transcriptomic profile showing a tumor mutational burden (TMB) of 19. Could you assess how likely it is that this patient will respond to atezolizumab therapy? Review the patient's transcriptomic data using the Compass tool and identify relevant biomarkers related to macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Integrate these findings with predictive analytics and the patient’s clinical history to develop a comprehensive immune profile. Finally, evaluate how this profile might affect the patient's response to immune checkpoint inhibitors and provide an evidence-based prediction regarding the probability of a favorable treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18bc10-ar-18bc107.pkl. "
BLCA,5.0,0.470588235,excluded,NR,"A white male with bladder urothelial carcinoma has a tumor microenvironment transcriptomic profile from a bladder biopsy showing a TMB of 5.0. Based on this data, how likely is it that he will respond to Atezolizumab therapy?","A white male with bladder urothelial carcinoma has a tumor microenvironment transcriptomic profile from a bladder biopsy showing a TMB of 5.0. Based on this data, how likely is it that he will respond to Atezolizumab therapy? Analyze the patient's transcriptomic data using the Compass tool to identify biomarkers associated with macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Combine these molecular insights with predictive analytics and the patient’s clinical history to construct a detailed immune profile. Then, assess how this profile may influence the patient’s response to immune checkpoint inhibitors, and provide an evidence-based estimate of the likelihood of a positive treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/18be5b-ar-18be5b3.pkl. "
BLCA,5.0,0.431372549,excluded,NR,"I have a Caucasian patient with a diagnosis of bladder urothelial carcinoma. The transcriptomic analysis from a bladder biopsy revealed a tumor mutational burden (TMB) of 5.0. Based on these findings, would you expect this patient to respond favorably to atezolizumab therapy?","I have a Caucasian patient with a diagnosis of bladder urothelial carcinoma. The transcriptomic analysis from a bladder biopsy revealed a tumor mutational burden (TMB) of 5.0. Based on these findings, would you expect this patient to respond favorably to atezolizumab therapy? Review the patient’s transcriptomic data with the Compass tool to identify biomarkers related to macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Next, integrate these molecular findings with predictive analytics and the patient’s clinical history to develop a comprehensive immune profile. Finally, use this profile to evaluate the patient’s potential response to immune checkpoint inhibitors and provide an evidence-based estimate of the likelihood of achieving a positive treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/19fec8-ar-19fec8f.pkl. "
BLCA,8.0,1.176470588,excluded,NR,"We have a White male patient with bladder urothelial carcinoma whose tumor transcriptomic analysis from a bladder biopsy indicates a tumor mutational burden (TMB) of 8.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","We have a White male patient with bladder urothelial carcinoma whose tumor transcriptomic analysis from a bladder biopsy indicates a tumor mutational burden (TMB) of 8.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Using the Compass tool, analyze the patient's transcriptomic data to detect biomarkers indicative of macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Then, integrate these molecular findings with predictive analytics and the patient’s clinical history to create a detailed immune profile. Finally, utilize this profile to assess the likelihood of the patient responding favorably to immune checkpoint inhibitors, providing an evidence-based prediction of treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1a87df-ar-1a87df7.pkl. "
BLCA,13.0,0.294117647,desert,NR,"In a Caucasian female patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy revealed a TMB of 13.0 mutations per megabase. Based on this data, how likely is the patient to respond to Atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy revealed a TMB of 13.0 mutations per megabase. Based on this data, how likely is the patient to respond to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data for biomarkers related to macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Next, combine these molecular findings with predictive analytics and the patient’s clinical history to develop a comprehensive immune profile. Finally, use this profile to evaluate the patient’s likelihood of a favorable response to immune checkpoint inhibitors, ensuring that your prediction is supported by evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1ab1b2-ar-1ab1b28.pkl. "
BLCA,16.0,1.862745098,excluded,R,"A white male patient diagnosed with bladder urothelial carcinoma had his tumor immune microenvironment profiled via transcriptomic analysis from a kidney biopsy, which revealed a tumor mutational burden of 16.0. Could you assess his likelihood of responding to Atezolizumab therapy?","A white male patient diagnosed with bladder urothelial carcinoma had his tumor immune microenvironment profiled via transcriptomic analysis from a kidney biopsy, which revealed a tumor mutational burden of 16.0. Could you assess his likelihood of responding to Atezolizumab therapy? Utilize the Compass tool to examine the patient’s transcriptomic data for biomarkers indicative of macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Then, integrate these molecular findings with predictive analytics and the patient's clinical history to construct a comprehensive immune profile. Finally, use this profile to assess the patient's likelihood of responding favorably to immune checkpoint inhibitors, ensuring that all predictions are firmly supported by evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1abf01-ar-1abf01d.pkl. "
BLCA,2.0,0.647058824,excluded,NR,"I have a Caucasian male patient with bladder urothelial carcinoma. Transcriptomic profiling from a kidney biopsy of his tumor immune microenvironment revealed a tumor mutational burden of 2.0 mutations per megabase. Based on this TMB level, what is the likelihood that he will respond favorably to atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma. Transcriptomic profiling from a kidney biopsy of his tumor immune microenvironment revealed a tumor mutational burden of 2.0 mutations per megabase. Based on this TMB level, what is the likelihood that he will respond favorably to atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data, focusing on biomarkers related to macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Next, combine these molecular data with predictive analytics and the patient’s clinical history to develop a detailed immune profile. Finally, evaluate this profile to determine the patient’s likelihood of a positive response to immune checkpoint inhibitors, ensuring all conclusions are backed by solid evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1ac4e3-ar-1ac4e3d.pkl. "
BLCA,,,excluded,NR,"A white female patient diagnosed with bladder urothelial carcinoma underwent transcriptomic profiling of her tumor immune microenvironment via bladder biopsy, which reported an indeterminate tumor mutation burden. Based on this information, what is her likelihood of responding to Atezolizumab therapy?","A white female patient diagnosed with bladder urothelial carcinoma underwent transcriptomic profiling of her tumor immune microenvironment via bladder biopsy, which reported an indeterminate tumor mutation burden. Based on this information, what is her likelihood of responding to Atezolizumab therapy? Please use the Compass tool to examine the patient’s transcriptomic data for biomarkers that indicate macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Then, integrate these molecular findings with predictive analytics and the patient’s clinical history to establish a detailed immune profile. Finally, assess this immune profile to estimate the patient’s potential response to immune checkpoint inhibitors, ensuring that all conclusions are supported by robust evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1c0ecf-ar-1c0ecfb.pkl. "
BLCA,7.0,0.549019608,excluded,NR,"A white male patient with bladder urothelial carcinoma has a tumor mutational burden of 7.0, as determined by transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy. Could you assess the likelihood of a positive response to Atezolizumab therapy in this case?","A white male patient with bladder urothelial carcinoma has a tumor mutational burden of 7.0, as determined by transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy. Could you assess the likelihood of a positive response to Atezolizumab therapy in this case? Please use the Compass tool to analyze the patient’s transcriptomic data for markers associated with macrophage activity, interferon gamma signaling, genomic stability, cell growth, and cytotoxic T cell function. Next, combine these molecular data with predictive analytics and the patient’s clinical history to create a comprehensive immune profile. Finally, evaluate this profile to predict the patient’s likely response to immune checkpoint inhibitors, ensuring that your conclusions are well-supported by robust evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1c8b08-ar-1c8b086.pkl. "
BLCA,20.0,4.019607843,desert,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 20 mutations per megabase. Based on these findings, what is the likelihood that this patient will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 20 mutations per megabase. Based on these findings, what is the likelihood that this patient will respond to Atezolizumab therapy? Utilize the Compass tool to examine the patient’s transcriptomic data for markers that indicate macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Next, integrate these molecular findings with predictive analytics and the patient’s clinical history to develop a comprehensive immune profile. Finally, use this profile to forecast the patient’s response to immune checkpoint inhibitors, ensuring that your conclusions are supported by robust evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1dda30-ar-1dda30f.pkl. "
BLCA,5.0,1.431372549,inflamed,NR,"For a Caucasian female patient with bladder urothelial carcinoma whose biopsy-based tumor transcriptomic profile indicates a tumor mutational burden of 5.0, what is the likelihood of a favorable response to atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma whose biopsy-based tumor transcriptomic profile indicates a tumor mutational burden of 5.0, what is the likelihood of a favorable response to atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data, specifically evaluating markers for macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Once you have this molecular information, integrate it with predictive analytics and the patient’s clinical history to construct a detailed immune profile. Finally, use this profile to predict the patient’s likely response to immune checkpoint inhibitors, ensuring that your conclusions are thoroughly supported by robust evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1e9c4d-ar-1e9c4d1.pkl. "
BLCA,38.0,4.509803922,inflamed,R,"We have a Caucasian male patient diagnosed with bladder urothelial carcinoma. Transcriptomic profiling of his tumor microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 38.0. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy?","We have a Caucasian male patient diagnosed with bladder urothelial carcinoma. Transcriptomic profiling of his tumor microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 38.0. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy? Utilize the Compass tool to examine the patient’s transcriptomic data, focusing on markers related to macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Combine these molecular findings with predictive analytics and the patient’s clinical history to develop a comprehensive immune profile. Then, evaluate this profile to estimate the patient’s likely response to immune checkpoint inhibitors, ensuring that all conclusions are firmly supported by robust evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1f66db-ar-1f66db5.pkl. "
BLCA,6.0,0.549019608,desert,NR,"In a white male patient diagnosed with bladder urothelial carcinoma whose kidney biopsy transcriptomic profile indicates a tumor mutational burden of 6.0 mutations per megabase, how likely is it that this patient will respond to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma whose kidney biopsy transcriptomic profile indicates a tumor mutational burden of 6.0 mutations per megabase, how likely is it that this patient will respond to Atezolizumab therapy? Employ the Compass tool to analyze the patient’s transcriptomic data, specifically targeting markers of macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Integrate these molecular findings with predictive analytics and the patient’s clinical history to construct a detailed immune profile. Then, review this profile to predict the patient’s likely response to immune checkpoint inhibitors, ensuring that all conclusions are strongly supported by robust evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1f83eb-ar-1f83ebd.pkl. "
BLCA,8.0,1.235294118,inflamed,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, the tumor biopsy showed a transcriptomic profile with a tumor mutational burden (TMB) of 8.0. Based on this data, what is the likelihood of his response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, the tumor biopsy showed a transcriptomic profile with a tumor mutational burden (TMB) of 8.0. Based on this data, what is the likelihood of his response to Atezolizumab therapy? Use the Compass tool to evaluate the patient’s transcriptomic data, specifically analyzing markers related to macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Combine these molecular findings with predictive analytics and the patient’s clinical history to build a comprehensive immune profile. Review this profile to estimate the patient’s probable response to immune checkpoint inhibitors, ensuring that each conclusion is supported by strong, evidence-based data.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/1fa6bc-ar-1fa6bcb.pkl. "
BLCA,13.0,2.392156863,inflamed,R,"A Caucasian male diagnosed with bladder urothelial carcinoma has a transcriptomic profile of his tumor’s immune microenvironment from a biopsy showing a tumor mutational burden (TMB) of 13.0. Based on these findings, what is the expected likelihood of his response to Atezolizumab therapy?","A Caucasian male diagnosed with bladder urothelial carcinoma has a transcriptomic profile of his tumor’s immune microenvironment from a biopsy showing a tumor mutational burden (TMB) of 13.0. Based on these findings, what is the expected likelihood of his response to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data, focusing specifically on markers associated with macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Then, integrate these molecular insights with predictive analytics and the patient’s clinical history to construct a comprehensive immune profile. Review this profile carefully to assess the patient’s likely response to immune checkpoint inhibitors, ensuring that each conclusion is firmly grounded in robust, evidence-based data.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/203dcf-ar-203dcf1.pkl. "
BLCA,5.0,0.294117647,excluded,NR,"In a white male patient with bladder urothelial carcinoma, a kidney biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden (TMB) of 5.0 mutations per megabase. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a kidney biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden (TMB) of 5.0 mutations per megabase. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy? Use the Compass tool to evaluate the patient’s transcriptomic data with a particular focus on markers indicating macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. After gathering these molecular insights, combine them with the patient’s clinical history and predictive analytics to develop a detailed immune profile. Finally, review this profile thoroughly to determine the patient’s likely response to immune checkpoint inhibitors, ensuring every conclusion is supported by robust, evidence-based data.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2070b4-ar-2070b41.pkl. "
BLCA,5.0,0.235294118,desert,NR,I have a white female patient diagnosed with bladder urothelial carcinoma. Her bladder biopsy transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutation burden (TMB) of 5.0. Could you evaluate the likelihood of her responding to atezolizumab therapy based on these findings?,"I have a white female patient diagnosed with bladder urothelial carcinoma. Her bladder biopsy transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutation burden (TMB) of 5.0. Could you evaluate the likelihood of her responding to atezolizumab therapy based on these findings? Please use the Compass tool to analyze the patient's transcriptomic data, paying special attention to markers related to macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Integrate these molecular findings with the patient's clinical history and predictive analytics to construct a comprehensive immune profile. Finally, review the profile in detail to assess the patient’s potential response to immune checkpoint inhibitors, ensuring that all conclusions are based on robust evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/230959-ar-2309593.pkl. "
BLCA,5.0,0.333333333,excluded,NR,"I have a white female patient diagnosed with bladder urothelial carcinoma. Transcriptomic profiling of her tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 5.0. Based on these findings, what is her potential likelihood of responding to Atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma. Transcriptomic profiling of her tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 5.0. Based on these findings, what is her potential likelihood of responding to Atezolizumab therapy? Utilize the Compass tool to examine the patient’s transcriptomic data, with a focus on markers associated with macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Incorporate these molecular insights with the patient’s clinical history and predictive analytics to develop a detailed and integrated immune profile. Subsequently, review this profile thoroughly to evaluate the patient’s likely response to immune checkpoint inhibitors, ensuring that your conclusions are supported by strong evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/23aa15-ar-23aa15d.pkl. "
BLCA,,1.823529412,desert,R,"For a white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of a separate biopsy of the tumor immune microenvironment indicated that the tumor mutational burden (TMB) is not available. Based on this data, can we determine whether the patient is likely to respond to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of a separate biopsy of the tumor immune microenvironment indicated that the tumor mutational burden (TMB) is not available. Based on this data, can we determine whether the patient is likely to respond to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data, concentrating on markers related to macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Integrate these molecular findings with the patient’s clinical history and predictive analytics to construct a comprehensive immune profile. Then, review this profile in detail to assess the patient’s potential response to immune checkpoint inhibitors, making sure that your evaluation is fully supported by robust evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/25510f-ar-25510f3.pkl. "
BLCA,12.0,1.529411765,inflamed,R,"We have a Caucasian female patient diagnosed with bladder urothelial carcinoma. Her tumor immune microenvironment transcriptomic profile, obtained from a lymph node biopsy, shows a tumor mutational burden of 12.0. How might this information inform her potential response to Atezolizumab therapy?","We have a Caucasian female patient diagnosed with bladder urothelial carcinoma. Her tumor immune microenvironment transcriptomic profile, obtained from a lymph node biopsy, shows a tumor mutational burden of 12.0. How might this information inform her potential response to Atezolizumab therapy? Please utilize the Compass tool to evaluate the patient’s transcriptomic data, specifically examining markers associated with macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Combine these molecular insights with the patient’s clinical background and predictive analytics to develop a thorough immune profile. After constructing the profile, review it in detail to assess the patient’s likely response to immune checkpoint inhibitors, ensuring that all conclusions are supported by solid evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2570ff-ar-2570ff4.pkl. "
BLCA,1.0,0.274509804,excluded,NR,"For an Asian male patient with bladder urothelial carcinoma, where transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a TMB of 1.0, is it reasonable to expect a response to atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma, where transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a TMB of 1.0, is it reasonable to expect a response to atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data with a focus on markers for macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Integrate these molecular findings with the patient's clinical history and predictive analytics to build a comprehensive immune profile. Once the profile is developed, carefully review it to determine the patient's potential response to immune checkpoint inhibitors, ensuring that every conclusion is well-supported by evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/26104d-ar-26104d5.pkl. "
BLCA,6.0,0.431372549,excluded,NR,A Caucasian patient diagnosed with bladder urothelial carcinoma has a tumor mutation burden of 6.0 based on transcriptomic profiling of a bladder biopsy. Could you provide an assessment of the likelihood of this patient responding to Atezolizumab therapy?,"A Caucasian patient diagnosed with bladder urothelial carcinoma has a tumor mutation burden of 6.0 based on transcriptomic profiling of a bladder biopsy. Could you provide an assessment of the likelihood of this patient responding to Atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic data with specific attention to markers of macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Integrate these molecular insights with the patient’s clinical history and predictive analytics to develop a detailed immune profile. Once the profile is complete, review the findings thoroughly to assess the patient's likely response to immune checkpoint inhibitors, ensuring that every conclusion is strongly supported by the evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/262422-ar-2624229.pkl. "
BLCA,8.0,0.745098039,excluded,R,"I have a female patient diagnosed with bladder urothelial carcinoma, and a transcriptomic analysis of her tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden (TMB) of 8.0. Could you assess whether this TMB level suggests a likely benefit from Atezolizumab therapy?","I have a female patient diagnosed with bladder urothelial carcinoma, and a transcriptomic analysis of her tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden (TMB) of 8.0. Could you assess whether this TMB level suggests a likely benefit from Atezolizumab therapy? Use the Compass tool to analyze the patient's transcriptomic data, focusing on markers of macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Then, integrate these molecular findings with the patient's clinical history and predictive analytics to construct a comprehensive immune profile. After completing the profile, carefully review all findings to evaluate the patient's potential response to immune checkpoint inhibitors, ensuring that every conclusion is well-supported by the evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/27299a-ar-27299ae.pkl. "
BLCA,6.0,0.568627451,inflamed,NR,"Given a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic analysis from a kidney biopsy indicates a tumor mutation burden of 6.0, how likely is it that he will respond to Atezolizumab therapy?","Given a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic analysis from a kidney biopsy indicates a tumor mutation burden of 6.0, how likely is it that he will respond to Atezolizumab therapy? Employ the Compass tool to evaluate the patient's transcriptomic data, emphasizing markers related to macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Integrate these molecular findings with the patient’s clinical history and available predictive analytics to develop a comprehensive immune profile. Finally, review all the evidence meticulously to assess the patient’s likely response to immune checkpoint inhibitors, ensuring that each conclusion is strongly supported by the data.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/286870-ar-2868703.pkl. "
BLCA,22.0,,desert,NR,A  white male patient with bladder urothelial carcinoma has a transcriptomic profile from a bladder biopsy showing a tumor mutational burden (TMB) of 22. Could this biomarker profile suggest that the patient may respond favorably to Atezolizumab therapy?,"A  white male patient with bladder urothelial carcinoma has a transcriptomic profile from a bladder biopsy showing a tumor mutational burden (TMB) of 22. Could this biomarker profile suggest that the patient may respond favorably to Atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data, specifically focusing on markers of macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Then, integrate these molecular findings with the patient's clinical background and any available predictive analytics to construct a detailed immune profile. Finally, review all the collected evidence carefully to evaluate the patient's potential response to immune checkpoint inhibitors, ensuring that each conclusion is well-supported by the data.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/28e603-ar-28e6031.pkl. "
BLCA,1.0,,excluded,NR,"I have a white male patient with a diagnosis of bladder urothelial carcinoma. The transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 1.0. Based on this information, what is the likelihood that he will respond favorably to Atezolizumab therapy?","I have a white male patient with a diagnosis of bladder urothelial carcinoma. The transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 1.0. Based on this information, what is the likelihood that he will respond favorably to Atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic data, with particular attention to markers of macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Next, integrate these molecular findings with the patient's clinical history and any predictive analytics available to develop a comprehensive immune profile. Finally, thoroughly review all of the gathered evidence to assess the likelihood of a positive response to immune checkpoint inhibitors, ensuring that each conclusion is robustly supported by the data.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/297c03-ar-297c030.pkl. "
BLCA,,0.490196078,desert,NR,"In a Caucasian female patient with bladder urothelial carcinoma, a ureter biopsy transcriptomic analysis of the tumor immune microenvironment yielded a tumor mutational burden (TMB) value of ""nan."" Given this result, how might we predict her response to Atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma, a ureter biopsy transcriptomic analysis of the tumor immune microenvironment yielded a tumor mutational burden (TMB) value of ""nan."" Given this result, how might we predict her response to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data, focusing specifically on markers related to macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Then, integrate these molecular results with the patient’s clinical history and available predictive analytics to construct a comprehensive immune profile. Finally, review all the compiled data to determine the likelihood that the patient will respond favorably to immune checkpoint inhibitors, ensuring that every conclusion is well-supported by the evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/29da92-ar-29da928.pkl. "
BLCA,2.0,0.156862745,desert,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy reveals a tumor mutational burden (TMB) of 2.0. Based on these findings, is a favorable response to Atezolizumab therapy likely?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy reveals a tumor mutational burden (TMB) of 2.0. Based on these findings, is a favorable response to Atezolizumab therapy likely? Use the Compass tool to analyze the patient's transcriptomic data, focusing on markers linked to macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and the function of cytotoxic T cells. Combine these molecular findings with the patient's clinical history and current predictive analytics to develop a detailed immune profile. Finally, review the integrated data to assess the likelihood of a favorable response to immune checkpoint inhibitors, ensuring that each conclusion is well-supported by the evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2b672f-ar-2b672f4.pkl. "
BLCA,11.0,1.294117647,excluded,NR,I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. His tumor immune microenvironment transcriptomic analysis from a bladder biopsy shows a tumor mutation burden of 11. Could you help assess his potential response to atezolizumab therapy?,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. His tumor immune microenvironment transcriptomic analysis from a bladder biopsy shows a tumor mutation burden of 11. Could you help assess his potential response to atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic data, paying special attention to markers associated with macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Integrate these molecular findings with the patient's clinical history and current predictive analytics to construct a comprehensive immune profile. After synthesizing this data, review your conclusions to determine the probability of a favorable response to immune checkpoint inhibitors, ensuring that every decision is backed by robust evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2bba8c-ar-2bba8cb.pkl. "
BLCA,9.0,0.431372549,desert,NR,"Given a white male patient with bladder urothelial carcinoma (BLCA) whose tumor transcriptomic analysis reveals a tumor mutational burden (TMB) of 9.0, how likely is he to respond to Atezolizumab therapy?","Given a white male patient with bladder urothelial carcinoma (BLCA) whose tumor transcriptomic analysis reveals a tumor mutational burden (TMB) of 9.0, how likely is he to respond to Atezolizumab therapy? Using the Compass tool, please analyze the patient’s transcriptomic data with a focus on markers indicative of macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Combine these molecular insights with the patient’s clinical history and current predictive analytics to develop a comprehensive immune profile. Based on this integrated assessment, evaluate the likelihood that the patient will respond favorably to immune checkpoint inhibitors, ensuring that your conclusions are grounded in robust evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2c9586-ar-2c95861.pkl. "
BLCA,,,inflamed,NR,"I have a white male patient with bladder urothelial carcinoma. The transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy shows a tumor mutation burden (TMB) reported as ""nan."" How should we interpret this finding in relation to predicting his response to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. The transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy shows a tumor mutation burden (TMB) reported as ""nan."" How should we interpret this finding in relation to predicting his response to atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic data, specifically examining markers related to macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Integrate these molecular findings with the patient's clinical history and current predictive analytics to form a comprehensive immune profile. Based on this combined assessment, determine the likelihood that the patient will respond well to immune checkpoint inhibitors, ensuring that your conclusions are supported by robust evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2dc3f0-ar-2dc3f04.pkl. "
BLCA,14.0,2.705882353,excluded,NR,"I am evaluating a Caucasian male diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment, obtained via kidney biopsy, revealed a tumor mutation burden of 14.0. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy?","I am evaluating a Caucasian male diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment, obtained via kidney biopsy, revealed a tumor mutation burden of 14.0. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data, focusing on markers that indicate macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular findings with the patient's clinical history and current predictive analytics to develop a detailed immune profile. Based on this comprehensive assessment, determine the probability of a favorable response to immune checkpoint inhibitor therapy, making sure that your conclusions are firmly grounded in robust evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2e7aa8-ar-2e7aa8f.pkl. "
BLCA,18.0,1.764705882,,R,"In a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 18 identified from a biopsy, how likely is a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 18 identified from a biopsy, how likely is a favorable response to Atezolizumab therapy? Please utilize the Compass tool to evaluate the transcriptomic data, concentrating on markers related to macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular insights with the patient’s clinical history and current predictive analytics to construct a comprehensive immune profile. Based on this integrated assessment, estimate the likelihood of a favorable response to immune checkpoint inhibitor therapy, ensuring that your conclusions are supported by robust evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2e9ac0-ar-2e9ac0b.pkl. "
BLCA,13.0,1.137254902,inflamed,R,"I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 13.0. Based on these findings, how likely is he to respond to atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 13.0. Based on these findings, how likely is he to respond to atezolizumab therapy? Please use the Compass tool to analyze the transcriptomic data, specifically focusing on markers indicating macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Next, integrate these molecular findings with the patient’s clinical history and current predictive analytics to develop a detailed immune profile. Based on this comprehensive assessment, provide an estimation of the patient's likelihood of responding favorably to immune checkpoint inhibitor therapy, supported by robust evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2eb07d-ar-2eb07de.pkl. "
BLCA,8.0,0.450980392,excluded,NR,"I have a Black or African American female patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a biopsy indicates a tumor mutation burden (TMB) of 8.0. Based on these findings, what is the likelihood that she will respond to Atezolizumab therapy?","I have a Black or African American female patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a biopsy indicates a tumor mutation burden (TMB) of 8.0. Based on these findings, what is the likelihood that she will respond to Atezolizumab therapy? Please utilize the Compass tool to evaluate the transcriptomic data, paying particular attention to markers of macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, correlate these molecular findings with the patient’s clinical history and current predictive analytics to develop a comprehensive immune profile. Based on this integrated assessment, estimate the patient’s potential responsiveness to immune checkpoint inhibitor therapy, ensuring that your evaluation is thoroughly supported by robust evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/2f2289-ar-2f22893.pkl. "
BLCA,6.0,,excluded,R,"I have a white female patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of her tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 6.0. Based on these findings, could you assess whether she is likely to respond to Atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of her tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 6.0. Based on these findings, could you assess whether she is likely to respond to Atezolizumab therapy? Please use the Compass tool to review the transcriptomic data, focusing on markers indicating macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular findings with the patient’s clinical background and current predictive analytics to construct a complete immune profile. Finally, based on this comprehensive analysis, assess the patient’s likely response to immune checkpoint inhibitor therapy, ensuring that your conclusions are supported by robust evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/30b5c6-ar-30b5c6c.pkl. "
BLCA,,,excluded,NR,"A Caucasian male patient diagnosed with bladder urothelial carcinoma underwent a transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy. However, his tumor mutational burden (TMB) is not available (reported as ""nan""). Could you provide insight on whether he might respond to Atezolizumab therapy?","A Caucasian male patient diagnosed with bladder urothelial carcinoma underwent a transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy. However, his tumor mutational burden (TMB) is not available (reported as ""nan""). Could you provide insight on whether he might respond to Atezolizumab therapy? Using the Compass tool, examine the transcriptomic data with particular attention to markers for macrophage activity, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Next, integrate these molecular insights with the patient’s clinical history and current predictive analytics to develop a comprehensive immune profile. Finally, based on this integrated analysis, evaluate the patient's potential response to immune checkpoint inhibitor therapy, ensuring that your conclusions are well-supported by the evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/30cf07-ar-30cf07d.pkl. "
BLCA,23.0,4.235294118,inflamed,R,"We have a Caucasian male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor's immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 23.0. Based on these findings, what is the likelihood that he will benefit from treatment with Atezolizumab?","We have a Caucasian male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor's immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 23.0. Based on these findings, what is the likelihood that he will benefit from treatment with Atezolizumab? Using the Compass tool, review the patient's transcriptomic data with a focus on macrophage markers, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these molecular observations with the patient's clinical history and current predictive analytics to build a detailed immune profile. Finally, use this comprehensive analysis to assess the patient’s potential response to immune checkpoint inhibitor therapy, ensuring that your conclusions are supported by the evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/31d917-ar-31d9176.pkl. "
BLCA,,0.705882353,,NR,"I have a white female patient with bladder urothelial carcinoma. A transcriptomic analysis of her tumor immune microenvironment from a lymph node biopsy reported a tumor mutation burden (TMB) value of ""nan."" Could you help assess the likelihood of her responding to Atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma. A transcriptomic analysis of her tumor immune microenvironment from a lymph node biopsy reported a tumor mutation burden (TMB) value of ""nan."" Could you help assess the likelihood of her responding to Atezolizumab therapy? Please use the Compass tool to examine the patient’s transcriptomic data, focusing on key areas such as macrophage markers, interferon gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and current predictive analytics to develop a robust immune profile. Finally, assess the patient’s likely response to immune checkpoint inhibitor therapy based on this comprehensive analysis, ensuring that your conclusions are thoroughly supported by the evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/31f41d-ar-31f41dd.pkl. "
BLCA,2.0,,,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor, obtained from a lymph node biopsy, revealed a tumor mutation burden of 2.0. Based on these findings, what is the predicted likelihood of a positive response to atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor, obtained from a lymph node biopsy, revealed a tumor mutation burden of 2.0. Based on these findings, what is the predicted likelihood of a positive response to atezolizumab therapy? Use the Compass tool to analyze the patient's transcriptomic profile, paying close attention to macrophage markers, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, combine these molecular insights with the patient's clinical history and current predictive analytics to develop a detailed immune profile. Finally, based on this integrated analysis, evaluate the likely response to immune checkpoint inhibitor therapy, ensuring your conclusions are well-supported by the available evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3330c0-ar-3330c03.pkl. "
BLCA,,,,NR,"Given a White male patient with bladder urothelial carcinoma, the tumor immune microenvironment profiling from a bladder biopsy returned a TMB value of ""nan."" Based on this finding, how might we predict his response to atezolizumab therapy?","Given a White male patient with bladder urothelial carcinoma, the tumor immune microenvironment profiling from a bladder biopsy returned a TMB value of ""nan."" Based on this finding, how might we predict his response to atezolizumab therapy? Review the patient's transcriptomic data using the Compass tool, specifically examining macrophage markers, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and current predictive analytics to construct a comprehensive immune profile. Finally, assess the likely response to immune checkpoint inhibitor therapy based on this integrated evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/34430e-ar-34430ef.pkl. "
BLCA,7.0,0.333333333,excluded,NR,"I have a White male patient with bladder urothelial carcinoma. His bladder biopsy provided transcriptomic data on the tumor immune microenvironment, revealing a tumor mutational burden (TMB) of 7.0. Based on this information, can you evaluate his potential responsiveness to atezolizumab therapy?","I have a White male patient with bladder urothelial carcinoma. His bladder biopsy provided transcriptomic data on the tumor immune microenvironment, revealing a tumor mutational burden (TMB) of 7.0. Based on this information, can you evaluate his potential responsiveness to atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data with a focus on macrophage markers, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these molecular results with the patient's clinical history and recent predictive analytics to develop a comprehensive immune profile. Finally, determine the expected response to immune checkpoint inhibitor therapy based on this combined evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36851b-ar-36851bc.pkl. "
BLCA,1.0,0.607843137,inflamed,NR,"I have an Asian male patient diagnosed with bladder urothelial carcinoma. A bladder biopsy was performed, and the transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutation burden (TMB) of 1.0. Can you provide an assessment of his likelihood to respond to Atezolizumab therapy?","I have an Asian male patient diagnosed with bladder urothelial carcinoma. A bladder biopsy was performed, and the transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutation burden (TMB) of 1.0. Can you provide an assessment of his likelihood to respond to Atezolizumab therapy? Please use the Compass tool to evaluate the patient’s transcriptomic data, specifically examining macrophage markers, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient's clinical history and recent predictive analytics to construct a comprehensive immune profile. Finally, assess the expected response to immune checkpoint inhibitor therapy based on this combined evidence.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36a922-ar-36a9225.pkl. "
BLCA,7.0,0.352941176,excluded,NR,"In a white male with bladder urothelial carcinoma, a ureter biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutation burden of 7.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","In a white male with bladder urothelial carcinoma, a ureter biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutation burden of 7.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data, focusing on macrophage markers, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular insights with the patient’s clinical history and recent predictive analytics to develop a detailed immune profile. Finally, evaluate the potential response to immune checkpoint inhibitor therapy based on the combined data.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/36d873-ar-36d8739.pkl. "
BLCA,5.0,,excluded,NR,"For a white male patient with bladder urothelial carcinoma whose tumor biopsy shows a tumor mutational burden of 5.0, what is the likelihood that he will respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose tumor biopsy shows a tumor mutational burden of 5.0, what is the likelihood that he will respond to Atezolizumab therapy? Please use the Compass tool to examine the patient’s transcriptomic data with particular attention to macrophage markers, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular findings with the patient’s clinical history and recent predictive analytics to create a comprehensive immune profile. Based on this integrated assessment, evaluate the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3894ac-ar-3894ac3.pkl. "
BLCA,6.0,,excluded,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) of 6.0. Based on these findings, would you expect him to respond favorably to atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) of 6.0. Based on these findings, would you expect him to respond favorably to atezolizumab therapy? Please analyze the patient’s transcriptomic data using the Compass tool, focusing specifically on macrophage markers, interferon-gamma signaling, genomic stability, cell proliferation, and the activity of cytotoxic T-cells. Next, combine these molecular findings with the patient’s clinical history and the latest predictive analytics data to formulate a thorough immune profile. Based on this comprehensive evaluation, assess the likely effectiveness of immune checkpoint inhibitor therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/39eb94-ar-39eb94f.pkl. "
BLCA,,,,NR,"A white male patient diagnosed with bladder urothelial carcinoma has undergone transcriptomic profiling of his tumor immune microenvironment using a lung biopsy, and his tumor mutational burden (TMB) is reported as nan. Based on this information, could you evaluate his potential response to Atezolizumab therapy?","A white male patient diagnosed with bladder urothelial carcinoma has undergone transcriptomic profiling of his tumor immune microenvironment using a lung biopsy, and his tumor mutational burden (TMB) is reported as nan. Based on this information, could you evaluate his potential response to Atezolizumab therapy? Please evaluate the patient's transcriptomic data with the Compass tool, ensuring special attention is given to macrophage markers, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient's clinical history and the most current predictive analytics data to develop a comprehensive immune profile. Use this integrated assessment to determine the potential effectiveness of immune checkpoint inhibitor therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3a1c96-ar-3a1c963.pkl. "
BLCA,2.0,0.176470588,excluded,NR,"In a White male patient diagnosed with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile, obtained from a lymph node biopsy, indicates a tumor mutational burden of 2.0, how likely is it that the patient will respond to Atezolizumab therapy?","In a White male patient diagnosed with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile, obtained from a lymph node biopsy, indicates a tumor mutational burden of 2.0, how likely is it that the patient will respond to Atezolizumab therapy? Please analyze the patient's transcriptomic data using the Compass tool with a focus on macrophage markers, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular insights with the patient's clinical history and the latest predictive analytics to create a detailed immune profile. This comprehensive assessment should help determine the potential efficacy of immune checkpoint inhibitor therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3b1066-ar-3b1066e.pkl. "
BLCA,44.0,5.823529412,inflamed,R,"A white male patient with bladder urothelial carcinoma has a tumor biopsy showing a transcriptomic profile with a tumor mutational burden (TMB) of 44.0. Based on these results, what is the likelihood of a favorable response to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a tumor biopsy showing a transcriptomic profile with a tumor mutational burden (TMB) of 44.0. Based on these results, what is the likelihood of a favorable response to Atezolizumab therapy? Review the patient's transcriptomic data using the Compass tool, specifically assessing macrophage marker expression, interferon-gamma signaling activity, genomic integrity, cell proliferation rates, and cytotoxic T-cell function. Integrate these molecular findings with the patient's clinical history and current predictive analytics to develop a comprehensive immune profile. This detailed evaluation will inform the potential effectiveness of immune checkpoint inhibitor therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3b15b4-ar-3b15b4c.pkl. "
BLCA,15.0,2.235294118,excluded,NR,"For a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 15, based on transcriptomic analysis from a kidney biopsy, is he likely to benefit from Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 15, based on transcriptomic analysis from a kidney biopsy, is he likely to benefit from Atezolizumab therapy? Examine the patient’s transcriptomic data using the Compass tool. Pay particular attention to markers of macrophage expression, interferon-gamma signaling activity, genomic integrity, cell proliferation rates, and the functionality of cytotoxic T cells. Then, correlate these molecular findings with the patient’s clinical history and current predictive analytics to create a comprehensive immune profile. This integrated evaluation is essential for assessing the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3cb94b-ar-3cb94b0.pkl. "
BLCA,17.0,1.411764706,excluded,R,"In a Caucasian male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy revealed a tumor mutational burden (TMB) of 17.0. How likely is it that he will respond to atezolizumab therapy based on this profile?","In a Caucasian male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy revealed a tumor mutational burden (TMB) of 17.0. How likely is it that he will respond to atezolizumab therapy based on this profile? Review the patient's transcriptomic data with the Compass tool. Specifically, evaluate markers related to macrophage expression, interferon-gamma signaling, genomic stability, cell proliferation, and the performance of cytotoxic T cells. Then, integrate these molecular findings with the patient's clinical history and current predictive analytics to develop a comprehensive immune profile. This combined assessment is critical for determining the likely efficacy of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3e04eb-ar-3e04eb9.pkl. "
BLCA,11.0,1.215686275,desert,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. A kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, revealing a tumor mutational burden (TMB) of 11. Could you assess his likelihood of responding to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, revealing a tumor mutational burden (TMB) of 11. Could you assess his likelihood of responding to Atezolizumab therapy? Please review the patient's transcriptomic data using the Compass tool. Focus specifically on assessing markers for macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell performance. Next, integrate these molecular findings with the patient’s clinical history and current predictive analytics to create a detailed immune profile. This comprehensive evaluation is essential for judging the potential success of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3e8baf-ar-3e8baff.pkl. "
BLCA,,,desert,NR,"In a white male patient with bladder urothelial carcinoma (BLCA), the transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates that the tumor mutational burden (TMB) is not available. Based on this finding, could you evaluate the likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA), the transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates that the tumor mutational burden (TMB) is not available. Based on this finding, could you evaluate the likelihood of a positive response to Atezolizumab therapy? Review the patient's transcriptomic data using the Compass tool, focusing on markers that indicate macrophage activity, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular findings with the patient's clinical history and current predictive analytics to develop a detailed immune profile. This thorough evaluation is crucial for determining the likely success of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/3ee5dc-ar-3ee5dcd.pkl. "
BLCA,,0.431372549,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy yielded an indeterminate tumor mutational burden (TMB) value. Based on this finding, what can be inferred regarding his potential response to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy yielded an indeterminate tumor mutational burden (TMB) value. Based on this finding, what can be inferred regarding his potential response to Atezolizumab therapy? Please analyze the patient’s transcriptomic data using the Compass tool, paying close attention to biomarkers related to macrophage activation, interferon-gamma signaling, genomic integrity, cellular proliferation, and cytotoxic T-cell activity. Afterwards, correlate these molecular insights with the patient’s clinical history and current predictive data to construct a comprehensive immune profile. This detailed assessment is essential for evaluating the potential efficacy of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/415f36-ar-415f36a.pkl. "
BLCA,12.0,0.392156863,desert,NR,"In a white male patient with bladder urothelial carcinoma, tumor profiling reveals a tumor mutation burden of 12.0. Based on this transcriptomic immune microenvironment analysis, what is the likelihood of a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, tumor profiling reveals a tumor mutation burden of 12.0. Based on this transcriptomic immune microenvironment analysis, what is the likelihood of a favorable response to Atezolizumab therapy? Please evaluate the patient's transcriptomic data using the Compass tool, focusing on biomarkers that indicate macrophage activation, interferon-gamma signaling, genomic integrity, cellular proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and available predictive data to create a detailed immune profile. This thorough assessment is critical for determining the likely success of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4305ab-ar-4305ab9.pkl. "
BLCA,6.0,0.921568627,excluded,NR,"I have a white male patient with bladder urothelial carcinoma whose transcriptomic analysis from a bladder biopsy shows a tumor mutational burden (TMB) of 6.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose transcriptomic analysis from a bladder biopsy shows a tumor mutational burden (TMB) of 6.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Please analyze the patient's transcriptomic data using the Compass tool, specifically examining biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these molecular findings with the patient’s clinical history and any available prognostic data to develop a comprehensive immune profile. This detailed assessment is essential for evaluating the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4501e4-ar-4501e41.pkl. "
BLCA,5.0,1.392156863,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, a bladder biopsy reveals a tumor immune microenvironment with a tumor mutational burden of 5.0. Considering these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a bladder biopsy reveals a tumor immune microenvironment with a tumor mutational burden of 5.0. Considering these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy? Please utilize the Compass tool to analyze the patient's transcriptomic data, focusing on biomarkers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, correlate these molecular findings with the patient's clinical history and available prognostic data to construct a detailed immune profile. This comprehensive evaluation is crucial for assessing the suitability of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/45c8e6-ar-45c8e64.pkl. "
BLCA,8.0,,desert,NR,"A white male patient diagnosed with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment obtained via nanobiopsy, indicating a tumor mutational burden of 8.0. Based on these findings, how likely is the patient to respond to atezolizumab therapy?","A white male patient diagnosed with bladder urothelial carcinoma has a transcriptomic profile of the tumor immune microenvironment obtained via nanobiopsy, indicating a tumor mutational burden of 8.0. Based on these findings, how likely is the patient to respond to atezolizumab therapy? Please use the Compass tool to examine the patient's transcriptomic data, concentrating on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once these molecular insights are obtained, integrate them with the patient's clinical history and prognostic information to create a detailed immune profile. This comprehensive evaluation is vital for determining whether immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/468a9e-ar-468a9e1.pkl. "
BLCA,8.0,0.803921569,inflamed,NR,"A white male patient with bladder urothelial carcinoma has a transcriptomic tumor immune microenvironment profile indicating a tumor mutational burden of 8.0. Based on these findings, what is the anticipated likelihood of response to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a transcriptomic tumor immune microenvironment profile indicating a tumor mutational burden of 8.0. Based on these findings, what is the anticipated likelihood of response to Atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data, specifically focusing on biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After gathering these molecular insights, combine them with the patient's clinical history and prognostic data to create a comprehensive immune profile. This detailed evaluation is critical for determining the suitability of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/47fc46-ar-47fc46c.pkl. "
BLCA,0.0,0.607843137,excluded,NR,"In a male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden (TMB) of 0.0. Based on this information, is he likely to benefit from Atezolizumab therapy?","In a male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden (TMB) of 0.0. Based on this information, is he likely to benefit from Atezolizumab therapy? Utilize the Compass tool to examine the patient's transcriptomic data with an emphasis on indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Integrate these molecular findings with the patient's clinical history and prognostic information to formulate a detailed immune profile. This thorough assessment is essential for determining if immune checkpoint inhibitor therapy is an appropriate treatment option.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/49d487-ar-49d4875.pkl. "
BLCA,5.0,1.450980392,excluded,NR,I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 5.0. Could you please advise on the likelihood of a favorable response to Atezolizumab therapy in this case?,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 5.0. Could you please advise on the likelihood of a favorable response to Atezolizumab therapy in this case? Please use the Compass tool to evaluate this patient’s transcriptomic data. Focus on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, combine these molecular insights with the patient’s clinical history and prognostic details to develop a comprehensive immune profile. This in-depth evaluation will help determine whether immune checkpoint inhibitor therapy is a suitable treatment option.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/49f9b2-ar-49f9b2e.pkl. "
BLCA,6.0,,desert,NR,"We have a white male patient with bladder urothelial carcinoma, and his tumor transcriptomic profile from a kidney biopsy indicates a tumor mutational burden of 6.0. Based on this information, how likely is it that he will respond to Atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma, and his tumor transcriptomic profile from a kidney biopsy indicates a tumor mutational burden of 6.0. Based on this information, how likely is it that he will respond to Atezolizumab therapy? Please utilize the Compass tool to analyze the patient’s transcriptomic data. Focus on markers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell functionality. Once you have obtained these molecular details, integrate them with the patient’s clinical history and prognosis to develop a detailed immune profile. This thorough evaluation will help assess whether immune checkpoint inhibitor therapy is an appropriate treatment option.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4b0175-ar-4b0175e.pkl. "
BLCA,,,excluded,NR,"I have a white female patient with bladder urothelial carcinoma (BLCA). A kidney biopsy was performed to assess the tumor immune microenvironment, and the transcriptomic analysis revealed an undefined tumor mutational burden (TMB). Based on these findings, could you provide guidance on her potential response to Atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma (BLCA). A kidney biopsy was performed to assess the tumor immune microenvironment, and the transcriptomic analysis revealed an undefined tumor mutational burden (TMB). Based on these findings, could you provide guidance on her potential response to Atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic data, specifically examining markers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and the functionality of cytotoxic T cells. After obtaining these molecular insights, integrate them with the patient’s clinical history and prognosis to construct a comprehensive immune profile. This detailed evaluation will assist in determining whether immune checkpoint inhibitor therapy is a suitable treatment option.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4b7ea0-ar-4b7ea01.pkl. "
BLCA,59.0,11.68627451,excluded,R,"We have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA). Transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy shows a tumor mutational burden (TMB) of 59.0. Based on these findings, what is the likelihood that this patient will respond to Atezolizumab therapy?","We have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA). Transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy shows a tumor mutational burden (TMB) of 59.0. Based on these findings, what is the likelihood that this patient will respond to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data, specifically focusing on markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular insights with the patient’s clinical history and prognosis to develop a comprehensive immune profile. This evaluation is essential for assessing whether immune checkpoint inhibitor therapy is an appropriate treatment option.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/4caabd-ar-4caabd6.pkl. "
BLCA,13.0,0.31372549,desert,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy shows a tumor mutational burden of 13.0 mutations per megabase. Based on this observation, how likely is the patient to respond to atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy shows a tumor mutational burden of 13.0 mutations per megabase. Based on this observation, how likely is the patient to respond to atezolizumab therapy? Utilize the Compass tool to examine the patient's transcriptomic data, paying particular attention to markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After gathering these molecular insights, please correlate them with the patient’s clinical history and prognosis to compile a detailed immune profile. This comprehensive analysis is crucial for determining the suitability of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/523468-ar-5234688.pkl. "
BLCA,12.0,0.745098039,excluded,NR,"I have a patient diagnosed with bladder urothelial carcinoma whose tumor immune microenvironment was characterized via transcriptomic profiling from a ureter biopsy, revealing a tumor mutation burden (TMB) of 12.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","I have a patient diagnosed with bladder urothelial carcinoma whose tumor immune microenvironment was characterized via transcriptomic profiling from a ureter biopsy, revealing a tumor mutation burden (TMB) of 12.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data, focusing on markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular findings with the patient’s clinical history and prognosis to develop a comprehensive immune profile. This detailed evaluation is essential for determining whether immune checkpoint inhibitor therapy is appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/52500c-ar-52500ca.pkl. "
BLCA,4.0,0.254901961,,NR,"In a white male patient with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy revealed a tumor mutation burden (TMB) of 4.0 mutations per megabase. Based on this information, what is the anticipated likelihood of a favorable response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy revealed a tumor mutation burden (TMB) of 4.0 mutations per megabase. Based on this information, what is the anticipated likelihood of a favorable response to atezolizumab therapy? Please use the Compass tool to evaluate the patient’s transcriptomic data with a focus on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After analyzing these molecular indicators, integrate the results with the patient’s clinical history and prognosis to develop a comprehensive immune profile. This detailed assessment is crucial for determining the suitability of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/52e3fa-ar-52e3fa3.pkl. "
BLCA,11.0,1.823529412,desert,R,"For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profiling indicates a tumor mutational burden (TMB) of 11.0, what is the likelihood that he would respond favorably to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profiling indicates a tumor mutational burden (TMB) of 11.0, what is the likelihood that he would respond favorably to atezolizumab therapy? Use the Compass tool to analyze the patient’s transcriptomic data, specifically focusing on markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Once you’ve evaluated these molecular indicators, please correlate the findings with the patient’s clinical history and prognosis to create a comprehensive immune profile. This detailed evaluation is essential for assessing the appropriateness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/548551-ar-548551e.pkl. "
BLCA,5.0,,desert,NR,"In a white male patient with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile from a bladder biopsy shows a tumor mutational burden (TMB) of 5.0. Based on this information, how likely is the patient to respond to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile from a bladder biopsy shows a tumor mutational burden (TMB) of 5.0. Based on this information, how likely is the patient to respond to atezolizumab therapy? Please use the Compass tool to examine the patient's transcriptomic data, paying particular attention to markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After analyzing these molecular features, correlate the results with the patient's clinical history and prognosis to develop a full immune profile. This comprehensive analysis is crucial for determining the suitability of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/54e58f-ar-54e58f1.pkl. "
BLCA,,,,NR,"In a Caucasian female patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor microenvironment obtained via kidney biopsy indicates that the tumor mutational burden (TMB) is not available. Based on this information, how might we predict her response to Atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor microenvironment obtained via kidney biopsy indicates that the tumor mutational burden (TMB) is not available. Based on this information, how might we predict her response to Atezolizumab therapy? Use the Compass tool to assess the patient's transcriptomic data with a focus on markers indicating macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once you have analyzed these features, compare the molecular findings with the patient’s clinical history and prognosis to build a comprehensive immune profile. This detailed integration is essential for evaluating the potential benefits of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/553c3c-ar-553c3c3.pkl. "
BLCA,5.0,,excluded,NR,"I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment, analyzed via transcriptomic profiling from a ureter biopsy, shows a tumor mutation burden of 5.0. Based on these findings, is he likely to respond favorably to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment, analyzed via transcriptomic profiling from a ureter biopsy, shows a tumor mutation burden of 5.0. Based on these findings, is he likely to respond favorably to atezolizumab therapy? Please use the Compass tool to evaluate the patient’s transcriptomic profile, focusing on markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After this analysis, compare these molecular findings with the patient’s clinical history and prognosis in order to develop a comprehensive immune profile. This thorough integration is crucial for determining the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/557dde-ar-557dde1.pkl. "
BLCA,19.0,0.647058824,inflamed,R,I have a Native Hawaiian or other Pacific Islander patient with bladder urothelial carcinoma (BLCA) whose tumor transcriptomic profiling shows a tumor mutational burden of 19.0. Could you assess the likelihood that this patient would respond to atezolizumab therapy?,"I have a Native Hawaiian or other Pacific Islander patient with bladder urothelial carcinoma (BLCA) whose tumor transcriptomic profiling shows a tumor mutational burden of 19.0. Could you assess the likelihood that this patient would respond to atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data with a focus on markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After completing this analysis, correlate the molecular findings with the patient’s clinical history and prognosis to develop an integrated immune profile. This comprehensive assessment is essential for evaluating the potential responsiveness to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/560f23-ar-560f23d.pkl. "
BLCA,,0.607843137,,NR,"In a Caucasian male patient with bladder urothelial carcinoma, the transcriptomic analysis of the tumor microenvironment from a bladder biopsy reported a TMB value of ""nan."" Could you evaluate how this finding might influence the patient's likelihood of responding to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, the transcriptomic analysis of the tumor microenvironment from a bladder biopsy reported a TMB value of ""nan."" Could you evaluate how this finding might influence the patient's likelihood of responding to Atezolizumab therapy? Please use the Compass tool to evaluate the transcriptomic data from the patient, with particular emphasis on markers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once you complete this molecular analysis, integrate these findings with the patient’s clinical history and prognosis to create a comprehensive immune profile. This detailed evaluation is critical for determining the likelihood of effectiveness from immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/563d62-ar-563d623.pkl. "
BLCA,,,,NR,"A White female patient diagnosed with bladder urothelial carcinoma has undergone transcriptomic profiling of her tumor immune microenvironment from a bladder biopsy, which indicated that the tumor mutational burden (TMB) data is not available. Based on this profile, what is the likelihood that she would respond to Atezolizumab therapy?","A White female patient diagnosed with bladder urothelial carcinoma has undergone transcriptomic profiling of her tumor immune microenvironment from a bladder biopsy, which indicated that the tumor mutational burden (TMB) data is not available. Based on this profile, what is the likelihood that she would respond to Atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data, with a specific focus on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once you have completed the molecular analysis, integrate these findings with the patient’s clinical history and prognosis to construct a comprehensive immune profile. This meticulous evaluation is essential in assessing the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/568ce1-ar-568ce16.pkl. "
BLCA,33.0,5.509803922,excluded,R,"I have a white male patient with bladder urothelial carcinoma. His tumor immune microenvironment transcriptomic analysis, obtained from a kidney biopsy, revealed a tumor mutational burden (TMB) of 33.0. Based on these findings, how would you assess his potential response to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. His tumor immune microenvironment transcriptomic analysis, obtained from a kidney biopsy, revealed a tumor mutational burden (TMB) of 33.0. Based on these findings, how would you assess his potential response to Atezolizumab therapy? Please utilize the Compass tool to examine the patient's transcriptomic data, focusing specifically on markers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After completing this molecular analysis, please integrate the results with the patient’s clinical history and prognosis to develop a comprehensive immune profile. This detailed evaluation is crucial for determining the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/572f19-ar-572f197.pkl. "
BLCA,32.0,,excluded,R,"We have a Caucasian male patient with bladder urothelial carcinoma, and transcriptomic profiling of a separate biopsy of his tumor immune microenvironment reveals a tumor mutational burden (TMB) of 32.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","We have a Caucasian male patient with bladder urothelial carcinoma, and transcriptomic profiling of a separate biopsy of his tumor immune microenvironment reveals a tumor mutational burden (TMB) of 32.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Please use the Compass tool to review the patient’s transcriptomic data, concentrating on markers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once this molecular analysis is complete, combine these findings with the patient’s clinical history and prognosis to build a comprehensive immune profile. This thorough evaluation is essential for assessing the potential benefit of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5767dd-ar-5767dd7.pkl. "
BLCA,2.0,0.333333333,desert,R,"Given a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment profile from a bladder biopsy shows a tumor mutational burden of 2.0 mutations per megabase, what is the likelihood that he would benefit from Atezolizumab therapy?","Given a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment profile from a bladder biopsy shows a tumor mutational burden of 2.0 mutations per megabase, what is the likelihood that he would benefit from Atezolizumab therapy? Use the Compass tool to analyze the patient’s transcriptomic data, specifically evaluating markers linked to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After completing this molecular analysis, integrate these findings with the patient’s clinical history and prognosis to develop a detailed immune profile. This comprehensive assessment is critical for determining the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/58e783-ar-58e7832.pkl. "
BLCA,14.0,,excluded,NR,"In a patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic analysis shows a TMB of 14, how would you assess the likelihood of response to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic analysis shows a TMB of 14, how would you assess the likelihood of response to Atezolizumab therapy? Please use the Compass tool to evaluate the patient’s transcriptomic data, focusing on markers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once you have completed this molecular analysis, integrate these results with the patient’s clinical history and prognosis to construct a comprehensive immune profile. This thorough assessment is essential for predicting the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/59f392-ar-59f3928.pkl. "
BLCA,,,,NR,"For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled using a nan biopsy and revealed a tumor mutational burden value of ""nan,"" can you evaluate the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled using a nan biopsy and revealed a tumor mutational burden value of ""nan,"" can you evaluate the likelihood of a favorable response to Atezolizumab therapy? Please employ the Compass tool to analyze the patient's transcriptomic data, specifically examining markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After completing this molecular evaluation, integrate the findings with the patient’s clinical history and prognosis to develop a comprehensive immune profile. This integrated assessment is critical for estimating the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/59fda9-ar-59fda90.pkl. "
BLCA,9.0,1.333333333,desert,NR,"In a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 9.0, as determined by transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, is it reasonable to expect a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 9.0, as determined by transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, is it reasonable to expect a favorable response to Atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic data, paying particular attention to markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once the molecular analysis is complete, integrate these findings with the patient’s clinical history and prognosis to create a detailed immune profile. This comprehensive assessment is essential for determining the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5a2347-ar-5a2347c.pkl. "
BLCA,12.0,,,NR,"I have an Asian female patient diagnosed with bladder urothelial carcinoma. Transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy indicates a tumor mutational burden (TMB) of 12.0. Based on this information, could you provide your assessment of her likely response to atezolizumab therapy?","I have an Asian female patient diagnosed with bladder urothelial carcinoma. Transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy indicates a tumor mutational burden (TMB) of 12.0. Based on this information, could you provide your assessment of her likely response to atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data, with special attention to markers indicating macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After completing the molecular analysis, combine these findings with the patient’s clinical history and prognosis to develop an integrated immune profile. This detailed assessment is crucial for evaluating the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5b57e4-ar-5b57e47.pkl. "
BLCA,,,excluded,NR,"I have a white male patient with bladder urothelial carcinoma. Transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) reported as ""nan."" Based on this finding, could you provide insight into his potential response to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. Transcriptomic profiling of his tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) reported as ""nan."" Based on this finding, could you provide insight into his potential response to atezolizumab therapy? Please utilize the Compass tool to evaluate the patient's transcriptomic profile. Focus specifically on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once this molecular analysis is complete, integrate these results with the patient’s clinical history and prognosis to construct a comprehensive immune profile. This thorough evaluation is essential to assess the potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5c139c-ar-5c139c5.pkl. "
BLCA,11.0,0.411764706,desert,NR,I have a white male patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 11.0 mutations per megabase. Could you provide your assessment of his likelihood to respond to Atezolizumab therapy?,"I have a white male patient diagnosed with bladder urothelial carcinoma. The transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 11.0 mutations per megabase. Could you provide your assessment of his likelihood to respond to Atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic profile. Specifically, assess biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After this molecular analysis is complete, combine these findings with the patient's clinical history and prognosis to develop a comprehensive immune profile. This integrated evaluation is crucial for determining the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5cc2d9-ar-5cc2d90.pkl. "
BLCA,10.0,1.215686275,,NR,"A white male patient diagnosed with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile obtained from a liver biopsy indicating a tumor mutational burden of 10.0. Based on these findings, how likely is he to respond favorably to Atezolizumab therapy?","A white male patient diagnosed with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile obtained from a liver biopsy indicating a tumor mutational burden of 10.0. Based on these findings, how likely is he to respond favorably to Atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic profile, focusing on biomarkers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once you have completed the molecular analysis, integrate these findings with the patient’s clinical history and prognosis to create a comprehensive immune profile. This combined evaluation is critical for assessing the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5cfa16-ar-5cfa169.pkl. "
BLCA,12.0,,,NR,"For a White male patient with bladder urothelial carcinoma whose tumor biopsy transcriptomic profile indicates a tumor mutational burden (TMB) of 12.0, what is the likelihood of a positive response to atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma whose tumor biopsy transcriptomic profile indicates a tumor mutational burden (TMB) of 12.0, what is the likelihood of a positive response to atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data, specifically targeting biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After completing the molecular assessment, integrate these results with the patient's clinical history and prognosis to develop a comprehensive immune profile. This combined analysis is essential for determining the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5d1dfd-ar-5d1dfd5.pkl. "
BLCA,13.0,1.411764706,desert,NR,"A patient with bladder urothelial carcinoma has a tumor biopsy showing a transcriptomic profile with a tumor mutational burden of 13.0. Based on these findings, is it likely that the patient would respond favorably to Atezolizumab therapy?","A patient with bladder urothelial carcinoma has a tumor biopsy showing a transcriptomic profile with a tumor mutational burden of 13.0. Based on these findings, is it likely that the patient would respond favorably to Atezolizumab therapy? Please use the Compass tool to examine the patient's transcriptomic data, focusing on biomarkers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once this molecular analysis is complete, combine the results with the patient’s clinical history and prognosis to create a comprehensive immune profile. This integrated evaluation is critical for assessing the likely efficacy of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5d989c-ar-5d989c8.pkl. "
BLCA,6.0,0.823529412,excluded,NR,"A white male patient with bladder urothelial carcinoma (BLCA) has a tumor immune microenvironment transcriptomic profile obtained via kidney biopsy, revealing a tumor mutational burden (TMB) of 6.0. Based on this information, what is the likelihood that he will respond to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma (BLCA) has a tumor immune microenvironment transcriptomic profile obtained via kidney biopsy, revealing a tumor mutational burden (TMB) of 6.0. Based on this information, what is the likelihood that he will respond to atezolizumab therapy? Please use the Compass tool to analyze the patient's transcriptomic data, concentrating on biomarkers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After completing the molecular analysis, integrate these findings with the patient’s clinical history and prognosis to develop a comprehensive immune profile. This integrated assessment is essential for evaluating the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5e3bae-ar-5e3bae0.pkl. "
BLCA,21.0,3.823529412,inflamed,NR,I have a Caucasian male patient with bladder urothelial carcinoma. Transcriptomic analysis of his tumor immune microenvironment from a ureter biopsy shows a tumor mutational burden of 21.0. Could you help determine if he is likely to respond to Atezolizumab therapy?,"I have a Caucasian male patient with bladder urothelial carcinoma. Transcriptomic analysis of his tumor immune microenvironment from a ureter biopsy shows a tumor mutational burden of 21.0. Could you help determine if he is likely to respond to Atezolizumab therapy? Using the Compass tool, please analyze the patient's transcriptomic data with a focus on biomarkers of macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once the molecular analysis is complete, integrate these findings with the patient's clinical history and prognosis to formulate a comprehensive immune profile. This integrated assessment is crucial for determining the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/5fe7a8-ar-5fe7a81.pkl. "
BLCA,14.0,,inflamed,R,I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy indicates a tumor mutational burden of 14 mutations per megabase. How likely is it that he would respond favorably to atezolizumab therapy?,"I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy indicates a tumor mutational burden of 14 mutations per megabase. How likely is it that he would respond favorably to atezolizumab therapy? Please use the Compass tool to evaluate the patient’s transcriptomic data, emphasizing biomarkers related to macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After completing the molecular analysis, combine these results with the patient’s clinical history and prognosis to establish a detailed immune profile. This comprehensive evaluation will help us assess the likely benefit of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6083aa-ar-6083aac.pkl. "
BLCA,9.0,1.803921569,desert,R,"How likely is it that a white male patient with bladder urothelial carcinoma, whose transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 9.0, will respond to Atezolizumab therapy?","How likely is it that a white male patient with bladder urothelial carcinoma, whose transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 9.0, will respond to Atezolizumab therapy? Please evaluate the patient’s transcriptomic profile using the Compass tool, with particular focus on biomarkers linked to macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After completing this molecular assessment, integrate the findings with the patient’s clinical history and prognosis to create a detailed immune profile. This comprehensive evaluation will aid in determining the likelihood of a beneficial response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6157c8-ar-6157c8f.pkl. "
BLCA,27.0,5.882352941,inflamed,NR,"For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis reveals a tumor mutational burden of 27.0, how likely is he to benefit from Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis reveals a tumor mutational burden of 27.0, how likely is he to benefit from Atezolizumab therapy? Please analyze the patient's transcriptomic data using the Compass tool. Concentrate on biomarkers that indicate macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Once you have completed the molecular assessment, integrate these results with the patient’s clinical history and prognosis to develop a detailed immune profile. This comprehensive evaluation will help determine the patient’s potential benefit from immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/61b9d4-ar-61b9d4d.pkl. "
BLCA,,,desert,NR,"I have a white female patient with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of her tumor immune microenvironment, obtained from a lymph node biopsy, indicates an indeterminate tumor mutational burden. Based on these findings, what is the likelihood of her responding to atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of her tumor immune microenvironment, obtained from a lymph node biopsy, indicates an indeterminate tumor mutational burden. Based on these findings, what is the likelihood of her responding to atezolizumab therapy? Please use the Compass tool to evaluate the patient’s transcriptomic data, with a focus on biomarkers associated with macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After completing this molecular assessment, integrate the findings with the patient's clinical history and prognosis to generate a detailed immune profile. This comprehensive analysis will assist in determining the patient's suitability and potential benefit from immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/61baf9-ar-61baf91.pkl. "
BLCA,5.0,0.784313725,,NR,I am evaluating a white female patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of her tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 5.0. Could you provide insight into her likelihood of responding to Atezolizumab therapy?,"I am evaluating a white female patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of her tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 5.0. Could you provide insight into her likelihood of responding to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic profile, with particular emphasis on biomarkers related to macrophage activation, interferon‐gamma pathways, genomic stability, cell proliferation, and cytotoxic T-cell function. Once you have completed this molecular evaluation, please integrate these results with the patient’s clinical history and prognosis to develop a detailed immune profile. This information will be critical in assessing the patient’s potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/62fb13-ar-62fb138.pkl. "
BLCA,,0.156862745,,NR,"A white male patient with bladder urothelial carcinoma underwent a bladder biopsy, which provided a transcriptomic profile of his tumor immune microenvironment; however, the tumor mutational burden is reported as not available. Based on these findings, how likely is it that he would respond to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma underwent a bladder biopsy, which provided a transcriptomic profile of his tumor immune microenvironment; however, the tumor mutational burden is reported as not available. Based on these findings, how likely is it that he would respond to atezolizumab therapy? Please employ the Compass tool to assess the patient’s transcriptomic profile, specifically focusing on biomarkers linked to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After completing this analysis, please integrate these molecular findings with the patient’s clinical history and prognosis to create a comprehensive immune profile. This integrated assessment is essential for evaluating the patient’s likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/63405b-ar-63405b0.pkl. "
BLCA,14.0,0.980392157,desert,NR,"In a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 14.0 identified through transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 14.0 identified through transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Please utilize the Compass tool to analyze the patient’s transcriptomic profile, concentrating on biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Once this analysis is complete, merge these molecular findings with the patient's clinical history and prognosis to develop a detailed immune profile. This comprehensive evaluation is vital for assessing the likely effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/63b218-ar-63b2189.pkl. "
BLCA,4.0,0.294117647,excluded,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden (TMB) of 4.0 mutations/Mb. Based on this profile, what is the likelihood that the patient will respond to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden (TMB) of 4.0 mutations/Mb. Based on this profile, what is the likelihood that the patient will respond to atezolizumab therapy? Please use the Compass tool to evaluate the patient's transcriptomic profile, focusing specifically on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Once the analysis is complete, integrate these molecular findings with the patient’s clinical history and prognosis to create a detailed immune profile. This comprehensive evaluation is crucial in determining the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/65afda-ar-65afda2.pkl. "
BLCA,5.0,0.490196078,inflamed,NR,"In a white male patient diagnosed with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) of 5.0. How likely is this patient to respond favorably to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) of 5.0. How likely is this patient to respond favorably to Atezolizumab therapy? Please use the Compass tool to analyze the patient’s transcriptomic data, paying special attention to biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After completing the analysis, combine these molecular findings with the patient’s clinical history and prognosis to develop a comprehensive immune profile. This thorough evaluation is critical for assessing the likely effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6662f5-ar-6662f51.pkl. "
BLCA,15.0,2.68627451,excluded,R,"For a white female patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile indicates a tumor mutational burden of 15.0, what is the likelihood that she will respond favorably to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile indicates a tumor mutational burden of 15.0, what is the likelihood that she will respond favorably to Atezolizumab therapy? Please use the Compass tool to evaluate the patient’s transcriptomic profile, focusing on biomarkers related to macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. Once you have completed the molecular analysis, integrate these findings with the patient’s clinical history and prognosis to construct a comprehensive immune profile. This detailed assessment is essential for determining the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/670649-ar-670649e.pkl. "
BLCA,13.0,1.254901961,desert,NR,"For a white male patient with a diagnosis of bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 13.0. How likely is this patient to respond to atezolizumab therapy?","For a white male patient with a diagnosis of bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 13.0. How likely is this patient to respond to atezolizumab therapy? Using the Compass platform, please analyze the patient’s transcriptomic profile with an emphasis on biomarkers associated with macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. After completing the molecular analysis, integrate these results with the patient’s clinical history and prognosis to create a complete immune profile. This comprehensive evaluation is critical for assessing the likely benefit of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/675a12-ar-675a12a.pkl. "
BLCA,14.0,2.549019608,inflamed,NR,"We have a Caucasian female with bladder urothelial carcinoma whose tumor biopsy transcriptomic analysis shows a tumor mutational burden of 14.0. Based on this profile, is she likely to respond effectively to Atezolizumab therapy?","We have a Caucasian female with bladder urothelial carcinoma whose tumor biopsy transcriptomic analysis shows a tumor mutational burden of 14.0. Based on this profile, is she likely to respond effectively to Atezolizumab therapy? Please use the Compass platform to assess the patient's transcriptomic profile, specifically focusing on markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Once the molecular analysis is complete, integrate these findings with the patient's clinical history and prognosis to build a comprehensive immune profile. This detailed assessment is critical for evaluating the potential benefit of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6780ed-ar-6780ed4.pkl. "
BLCA,17.0,1.117647059,desert,NR,"We have a Black/African American male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy revealed a tumor mutation burden of 17. Based on these findings, how likely is he to benefit from Atezolizumab therapy?","We have a Black/African American male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy revealed a tumor mutation burden of 17. Based on these findings, how likely is he to benefit from Atezolizumab therapy? Please use the Compass platform to analyze the patient’s transcriptomic profile, focusing on markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Once the molecular analysis is complete, please combine these findings with the patient’s clinical history and prognosis to develop a comprehensive immune profile. This thorough evaluation is essential for determining the potential benefit of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6792d6-ar-6792d6e.pkl. "
BLCA,7.0,1.862745098,excluded,R,"How likely is it that a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profiling shows a tumor mutational burden of 7.0, will respond to Atezolizumab therapy?","How likely is it that a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profiling shows a tumor mutational burden of 7.0, will respond to Atezolizumab therapy? Please use the Compass platform to evaluate the patient's transcriptomic data, specifically assessing markers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After completing this molecular analysis, integrate these findings with the patient’s clinical history and prognosis to create an overall immune profile. This comprehensive evaluation is crucial for assessing whether immune checkpoint inhibitor therapy may be beneficial.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/681e4b-ar-681e4bf.pkl. "
BLCA,5.0,1.176470588,,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 5.0—could you assess the likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 5.0—could you assess the likelihood of a positive response to Atezolizumab therapy? Please use the Compass platform to analyze the patient’s transcriptomic data, focusing on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After this analysis, combine these molecular findings with the patient’s clinical history and prognosis to develop a complete immune profile. This integrated evaluation is essential to determine the potential benefit of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6964a6-ar-6964a6d.pkl. "
BLCA,20.0,1.039215686,desert,R,We have a white male patient diagnosed with bladder urothelial carcinoma whose lung biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden (TMB) of 20. How should we interpret this TMB in terms of predicting his response to Atezolizumab therapy?,"We have a white male patient diagnosed with bladder urothelial carcinoma whose lung biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden (TMB) of 20. How should we interpret this TMB in terms of predicting his response to Atezolizumab therapy? Please use the Compass platform to evaluate the patient’s transcriptomic data, concentrating on markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once these molecular findings are obtained, integrate them with the patient’s clinical history and prognosis to create a comprehensive immune profile. This combined assessment is crucial for determining if immune checkpoint inhibitor therapy may be beneficial.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6cb230-ar-6cb230f.pkl. "
BLCA,3.0,0.960784314,inflamed,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), and transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy revealed a tumor mutational burden of 3.0. Based on these findings, how likely is he to respond to atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), and transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy revealed a tumor mutational burden of 3.0. Based on these findings, how likely is he to respond to atezolizumab therapy? Please analyze the patient’s transcriptomic data using the Compass platform, with a focus on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular findings with the patient’s clinical history and prognosis to produce a comprehensive immune profile. This integrated assessment is essential for determining whether immune checkpoint inhibitor therapy may be appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6cbc10-ar-6cbc10a.pkl. "
BLCA,,,excluded,NR,"A 45-year-old Black or African American male diagnosed with bladder urothelial carcinoma underwent a lymph node biopsy, and transcriptomic profiling of his tumor immune microenvironment indicated a TMB value reported as ""nan."" Given this information, what is the likelihood that he would benefit from atezolizumab treatment?","A 45-year-old Black or African American male diagnosed with bladder urothelial carcinoma underwent a lymph node biopsy, and transcriptomic profiling of his tumor immune microenvironment indicated a TMB value reported as ""nan."" Given this information, what is the likelihood that he would benefit from atezolizumab treatment? Please use the Compass platform to review the patient’s transcriptomic data. Concentrate on markers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these molecular insights with the patient’s clinical history and prognosis to create a detailed immune profile. This comprehensive analysis is critical for evaluating the potential benefit of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6d2ae0-ar-6d2ae0c.pkl. "
BLCA,,3.568627451,,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy has reported a TMB value of ""nan."" How should we interpret this result regarding his potential response to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy has reported a TMB value of ""nan."" How should we interpret this result regarding his potential response to Atezolizumab therapy? Access the patient's transcriptomic data on the Compass platform and focus on evaluating markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these findings with the patient's clinical history and prognosis to develop a comprehensive immune profile, which is essential for assessing the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6dd7ad-ar-6dd7ad1.pkl. "
BLCA,8.0,2.078431373,,R,We have a Caucasian female patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of her tumor immune microenvironment obtained via a nano-biopsy shows a tumor mutational burden of 8.0 mutations per megabase. Would you consider this TMB level predictive of a favorable response to Atezolizumab therapy?,"We have a Caucasian female patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of her tumor immune microenvironment obtained via a nano-biopsy shows a tumor mutational burden of 8.0 mutations per megabase. Would you consider this TMB level predictive of a favorable response to Atezolizumab therapy? Please log into the Compass platform to retrieve the patient's transcriptomic data. Evaluate key gene expression markers related to macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Use these molecular insights alongside the patient's clinical history and prognosis to construct a comprehensive immune profile, which will inform the assessment of potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6f2a10-ar-6f2a102.pkl. "
BLCA,6.0,1.039215686,excluded,R,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). A kidney biopsy provided the transcriptomic profile of the tumor immune microenvironment, indicating a tumor mutational burden (TMB) of 6.0 mutations/Mb. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). A kidney biopsy provided the transcriptomic profile of the tumor immune microenvironment, indicating a tumor mutational burden (TMB) of 6.0 mutations/Mb. Based on these findings, how likely is the patient to respond to Atezolizumab therapy? Please access the Compass platform and retrieve the patient’s transcriptomic profile. Evaluate critical expression markers associated with macrophage activation, interferon‐gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and prognosis to develop a detailed immune profile that will help assess their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/6ff654-ar-6ff654a.pkl. "
BLCA,17.0,2.176470588,,NR,"A white male patient with biopsy-confirmed bladder urothelial carcinoma underwent transcriptomic profiling of the tumor immune microenvironment, which revealed a tumor mutational burden of 17.0 mutations per megabase. Based on this information, what is the likelihood that the patient will respond to Atezolizumab therapy?","A white male patient with biopsy-confirmed bladder urothelial carcinoma underwent transcriptomic profiling of the tumor immune microenvironment, which revealed a tumor mutational burden of 17.0 mutations per megabase. Based on this information, what is the likelihood that the patient will respond to Atezolizumab therapy? Please log into the Compass platform and download the patient’s transcriptomic dataset. Identify and analyze key expression markers related to macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, correlate these molecular results with the patient's clinical history and prognosis in order to create a comprehensive immune profile, which will help predict their potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7114d9-ar-7114d99.pkl. "
BLCA,6.0,1.568627451,,NR,"For a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment profile from a kidney biopsy shows a tumor mutational burden of 6.0 mutations per megabase, how likely is it that he will respond to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment profile from a kidney biopsy shows a tumor mutational burden of 6.0 mutations per megabase, how likely is it that he will respond to Atezolizumab therapy? Log into the Compass platform to download the patient’s transcriptomic data. Analyze the dataset by focusing on markers associated with macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Afterward, integrate these molecular findings with the patient’s clinical history and prognosis to develop a comprehensive immune profile that can help predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/716f54-ar-716f54e.pkl. "
BLCA,1.0,0.333333333,,R,"I have a Caucasian male patient with bladder urothelial carcinoma. His tumor immune microenvironment was profiled via transcriptomic analysis from a lymph node biopsy, and his tumor mutation burden (TMB) is 1.0. Based on this data, what is the likelihood that he will respond to Atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma. His tumor immune microenvironment was profiled via transcriptomic analysis from a lymph node biopsy, and his tumor mutation burden (TMB) is 1.0. Based on this data, what is the likelihood that he will respond to Atezolizumab therapy? Please log into the Compass platform and download the patient's transcriptomic dataset. In your analysis, pay close attention to markers indicative of macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular insights with the patient's clinical history and prognosis to formulate a comprehensive immune profile that can help forecast their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/727c0e-ar-727c0e9.pkl. "
BLCA,,,excluded,R,"I have a white male patient diagnosed with bladder urothelial carcinoma. A kidney biopsy was performed for transcriptomic profiling of the tumor immune microenvironment, and the analysis indicated a TMB value of ""nan"" (not available). Given these findings, could you help assess whether this patient is likely to respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A kidney biopsy was performed for transcriptomic profiling of the tumor immune microenvironment, and the analysis indicated a TMB value of ""nan"" (not available). Given these findings, could you help assess whether this patient is likely to respond to Atezolizumab therapy? Please access the Compass platform and download the patient’s transcriptomic dataset. While reviewing the data, focus specifically on markers that signal macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular findings with the patient’s clinical history and prognosis to develop a detailed immune profile, which will help estimate their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/73663e-ar-73663ee.pkl. "
BLCA,7.0,0.274509804,excluded,NR,"In a white female patient with bladder urothelial carcinoma whose kidney biopsy transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 7.0, how likely is she to respond to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma whose kidney biopsy transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 7.0, how likely is she to respond to Atezolizumab therapy? Please log into the Compass platform and download the patient’s transcriptomic dataset. Review the data with particular attention to markers indicating macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular observations with the patient’s clinical history and overall prognosis to build a comprehensive immunological profile aimed at predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/75142f-ar-75142fc.pkl. "
BLCA,21.0,2.392156863,inflamed,NR,"In a white female patient diagnosed with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 21. Could you evaluate whether these findings suggest a likely favorable response to Atezolizumab therapy?","In a white female patient diagnosed with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 21. Could you evaluate whether these findings suggest a likely favorable response to Atezolizumab therapy? Please access the Compass platform and download the patient’s transcriptomic dataset. Carefully review the data for indicators such as macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, consider these molecular markers alongside the patient’s clinical history and overall prognosis to construct a thorough immunological profile that will help predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7538ad-ar-7538ad9.pkl. "
BLCA,7.0,,excluded,NR,"I have a white male patient with bladder urothelial carcinoma. A ureter biopsy of his tumor's immune microenvironment revealed a tumor mutational burden (TMB) of 7.0. Based on these findings, can we predict whether he is likely to respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. A ureter biopsy of his tumor's immune microenvironment revealed a tumor mutational burden (TMB) of 7.0. Based on these findings, can we predict whether he is likely to respond to atezolizumab therapy? Please log into the Compass platform and download the patient's transcriptomic dataset. Review the data carefully for signs of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient's clinical history and prognosis to develop a comprehensive immunological profile that can help forecast their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/753d4b-ar-753d4bb.pkl. "
BLCA,6.0,0.333333333,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a lung biopsy indicates a tumor mutational burden of 6.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a lung biopsy indicates a tumor mutational burden of 6.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Please access the Compass platform and download the patient's transcriptomic dataset. Carefully evaluate the data for indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular insights with the patient's clinical history and prognosis to construct a detailed immunological profile that can help predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/75f12d-ar-75f12d1.pkl. "
BLCA,6.0,0.215686275,inflamed,NR,"We have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of his tumor immune microenvironment from a kidney biopsy revealed a tumor mutation burden (TMB) of 6.0. Based on this data, could you assess his potential response to Atezolizumab therapy?","We have a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of his tumor immune microenvironment from a kidney biopsy revealed a tumor mutation burden (TMB) of 6.0. Based on this data, could you assess his potential response to Atezolizumab therapy? Access the Compass platform to download the patient's transcriptomic dataset. Once obtained, review the data for evidence of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these molecular findings with the patient’s clinical history and prognosis to develop a comprehensive immunological profile, which may assist in predicting their likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/76a431-ar-76a431b.pkl. "
BLCA,,0.215686275,inflamed,R,"In a white male patient with bladder urothelial carcinoma, a bladder biopsy transcriptomic analysis of the tumor immune microenvironment reported a tumor mutational burden (TMB) value of ""nan."" How would you evaluate the likelihood of a favorable response to Atezolizumab therapy in this context?","In a white male patient with bladder urothelial carcinoma, a bladder biopsy transcriptomic analysis of the tumor immune microenvironment reported a tumor mutational burden (TMB) value of ""nan."" How would you evaluate the likelihood of a favorable response to Atezolizumab therapy in this context? Please log in to the Compass platform and download the patient’s transcriptomic dataset. Then, carefully evaluate the dataset for indicators such as macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After your review, combine these molecular findings with the patient’s clinical history and prognosis to develop a detailed immunological profile. This comprehensive profile will help guide predictions regarding the patient’s potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/771445-ar-771445e.pkl. "
BLCA,3.0,0.745098039,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 3.0. Based on these findings, would you expect the patient to respond favorably to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 3.0. Based on these findings, would you expect the patient to respond favorably to Atezolizumab therapy? Please access the Compass platform and download the patient’s transcriptomic dataset. Review the dataset for markers such as macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular findings with the patient’s clinical data and prognosis to construct a detailed immunological profile. This profile will be instrumental in predicting the patient’s likely response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7829a3-ar-7829a34.pkl. "
BLCA,5.0,0.941176471,,NR,"In an Asian male patient with bladder urothelial carcinoma, a bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a TMB of 5.0. Based on these findings, how likely is it that the patient will respond to atezolizumab therapy?","In an Asian male patient with bladder urothelial carcinoma, a bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a TMB of 5.0. Based on these findings, how likely is it that the patient will respond to atezolizumab therapy? Log into the Compass platform and download the patient's transcriptomic data. Review the data for key markers including macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular findings with the patient's clinical information and prognosis to develop a detailed immunological profile that will help predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/789319-ar-7893196.pkl. "
BLCA,,1.039215686,excluded,NR,"In a White male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy reported a tumor mutation burden (TMB) of ""nan."" How should we interpret this TMB result when evaluating his potential response to atezolizumab therapy?","In a White male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy reported a tumor mutation burden (TMB) of ""nan."" How should we interpret this TMB result when evaluating his potential response to atezolizumab therapy? Access the Compass platform and download the patient's transcriptomic data. Carefully review the dataset for essential indicators such as macrophage activation, interferon-gamma signaling, genomic stability, cellular proliferation, and cytotoxic T-cell activity. Integrate these molecular findings with the patient’s clinical profile and prognosis to construct a comprehensive immunological profile, which will aid in predicting the patient’s response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7aa01f-ar-7aa01fc.pkl. "
BLCA,12.0,,,R,"I have a white female patient diagnosed with bladder urothelial carcinoma. Transcriptomic analysis from her ureter biopsy indicates a tumor mutation burden of 12.0. Based on this information, can we evaluate her likelihood of responding to Atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma. Transcriptomic analysis from her ureter biopsy indicates a tumor mutation burden of 12.0. Based on this information, can we evaluate her likelihood of responding to Atezolizumab therapy? Log into the Compass platform and download the patient’s transcriptomic dataset. Please review the data for key markers such as macrophage activation, interferon-gamma signaling, genomic stability, cellular proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical profile and prognosis to create a detailed immunological profile that will help predict the patient’s response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7b4000-ar-7b40007.pkl. "
BLCA,,0.725490196,,NR,"I have a Caucasian male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via a ureter biopsy, although the reported tumor mutation burden (TMB) was not available (i.e., nan). Based on these findings, how might I assess his potential response to Atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via a ureter biopsy, although the reported tumor mutation burden (TMB) was not available (i.e., nan). Based on these findings, how might I assess his potential response to Atezolizumab therapy? Please log in to the Compass platform and download the patient’s transcriptomic dataset. Carefully examine the dataset for indicators such as macrophage activation, interferon-gamma signaling, genomic stability, cellular proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical profile and prognosis to develop a comprehensive immunological profile that will help predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7bff23-ar-7bff231.pkl. "
BLCA,5.0,0.529411765,,NR,"Given that a white female patient diagnosed with bladder urothelial carcinoma has a tumor biopsy showing a tumor mutational burden (TMB) of 5.0, what is your assessment regarding her likelihood of responding to Atezolizumab therapy?","Given that a white female patient diagnosed with bladder urothelial carcinoma has a tumor biopsy showing a tumor mutational burden (TMB) of 5.0, what is your assessment regarding her likelihood of responding to Atezolizumab therapy? Please access the Compass platform and download the patient’s transcriptomic dataset. Review the dataset to identify markers including macrophage activation, interferon-gamma signaling, genomic stability, cellular proliferation, and cytotoxic T-cell activity. Then, combine these molecular insights with the patient's clinical details and prognosis to form a detailed immunological profile that can help predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7c67b0-ar-7c67b05.pkl. "
BLCA,4.0,0.156862745,inflamed,NR,I have a white male patient with bladder urothelial carcinoma (BLCA) whose lymph node biopsy revealed a tumor mutational burden (TMB) of 4.0 based on transcriptomic profiling of the tumor immune microenvironment. How likely is this patient to respond to atezolizumab therapy?,"I have a white male patient with bladder urothelial carcinoma (BLCA) whose lymph node biopsy revealed a tumor mutational burden (TMB) of 4.0 based on transcriptomic profiling of the tumor immune microenvironment. How likely is this patient to respond to atezolizumab therapy? Log in to the Compass platform to retrieve the patient’s transcriptomic dataset. Once downloaded, review the dataset to evaluate key markers related to macrophage activation, interferon-gamma signaling, genomic stability, cellular proliferation, and cytotoxic T-cell activity. After this analysis, integrate these molecular findings with the patient’s clinical history and prognosis to develop a comprehensive immunological profile that may help predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7d2dfb-ar-7d2dfba.pkl. "
BLCA,8.0,2.098039216,excluded,R,"A white male patient diagnosed with bladder urothelial carcinoma has undergone a tumor immune microenvironment transcriptomic analysis from a bladder biopsy, revealing a tumor mutational burden of 8.0 mutations per megabase. Could this data indicate that the patient is likely to respond favorably to atezolizumab therapy?","A white male patient diagnosed with bladder urothelial carcinoma has undergone a tumor immune microenvironment transcriptomic analysis from a bladder biopsy, revealing a tumor mutational burden of 8.0 mutations per megabase. Could this data indicate that the patient is likely to respond favorably to atezolizumab therapy? Access the Compass platform to download the patient’s transcriptomic dataset. Once you have the data, review it carefully, focusing on key markers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular findings with the patient’s clinical history and prognosis to develop a comprehensive immunological profile that could help predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7d7c54-ar-7d7c546.pkl. "
BLCA,,,excluded,NR,"For a white male patient with bladder urothelial carcinoma, the transcriptomic analysis from a bladder biopsy reveals that the tumor mutational burden (TMB) value is not available (NaN). Based on the tumor's immune microenvironment characterization, can we estimate his likely response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, the transcriptomic analysis from a bladder biopsy reveals that the tumor mutational burden (TMB) value is not available (NaN). Based on the tumor's immune microenvironment characterization, can we estimate his likely response to Atezolizumab therapy? Please log in to the Compass platform and download the patient’s transcriptomic dataset. Carefully review the data, paying particular attention to markers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these molecular insights with the patient’s clinical history and prognosis to develop a comprehensive immunological profile aimed at predicting their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7f0d9c-ar-7f0d9cc.pkl. "
BLCA,1.0,,excluded,NR,"For a Black or African American male patient diagnosed with bladder urothelial carcinoma, whose biopsy transcriptomic profile reveals a tumor mutational burden of 1.0, what is the likelihood of response to atezolizumab therapy?","For a Black or African American male patient diagnosed with bladder urothelial carcinoma, whose biopsy transcriptomic profile reveals a tumor mutational burden of 1.0, what is the likelihood of response to atezolizumab therapy? Please access the Compass platform and retrieve the patient’s transcriptomic dataset. Once downloaded, examine the dataset thoroughly, focusing on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular findings with the patient's clinical history and prognosis to generate a detailed immunological profile, which will help predict their response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7fb698-ar-7fb6987.pkl. "
BLCA,11.0,0.764705882,excluded,NR,"For an Asian male patient with bladder urothelial carcinoma whose tumor immune microenvironment, obtained via a kidney biopsy, shows a tumor mutation burden of 11.0, what is the likelihood that he will respond to Atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma whose tumor immune microenvironment, obtained via a kidney biopsy, shows a tumor mutation burden of 11.0, what is the likelihood that he will respond to Atezolizumab therapy? Access the Compass platform to download the patient’s transcriptomic dataset. Once you have the dataset, analyze it carefully, paying specific attention to markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular findings with the patient’s clinical history and prognosis to construct a comprehensive immunological profile. This profile will aid in predicting the patient’s response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/7fb7a1-ar-7fb7a13.pkl. "
BLCA,8.0,0.215686275,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of a kidney biopsy revealed a tumor mutational burden of 8.0. Based on this information, what is the anticipated response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of a kidney biopsy revealed a tumor mutational burden of 8.0. Based on this information, what is the anticipated response to Atezolizumab therapy? Please log in to the Compass platform to download the patient’s transcriptomic dataset. Once obtained, review the dataset thoroughly, focusing on biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, correlate these molecular data with the patient's clinical history and prognosis to develop a detailed immunological profile. This profile will be used to evaluate the patient’s potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/80c618-ar-80c6183.pkl. "
BLCA,7.0,1.078431373,,NR,"For a Caucasian female patient diagnosed with bladder urothelial carcinoma, the tumor microenvironment transcriptomic analysis obtained from a bladder biopsy indicates a tumor mutation burden of 7.0. Based on these findings, what is the likelihood that she will respond to Atezolizumab therapy?","For a Caucasian female patient diagnosed with bladder urothelial carcinoma, the tumor microenvironment transcriptomic analysis obtained from a bladder biopsy indicates a tumor mutation burden of 7.0. Based on these findings, what is the likelihood that she will respond to Atezolizumab therapy? Please access the Compass platform and download the transcriptomic dataset for the patient. Once you have the dataset, carefully review the information with an emphasis on biomarkers linked to macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. Next, integrate these molecular findings with the patient’s clinical history and outlook, resulting in a comprehensive immunological profile. This profile will be instrumental in assessing the likelihood of a positive response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/81b715-ar-81b7152.pkl. "
BLCA,,1.098039216,desert,NR,"I have a Caucasian male patient with bladder urothelial carcinoma whose transcriptomic analysis of the tumor immune microenvironment from a separate biopsy did not yield a quantifiable tumor mutation burden. Based on this information, can we assess his likelihood of responding to Atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma whose transcriptomic analysis of the tumor immune microenvironment from a separate biopsy did not yield a quantifiable tumor mutation burden. Based on this information, can we assess his likelihood of responding to Atezolizumab therapy? Please log in to the Compass platform and download the patient’s transcriptomic dataset. Once obtained, review the dataset with a focus on biomarkers associated with macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. Next, correlate these molecular findings with the patient’s clinical history and current health status to develop a detailed immunological profile. This profile will help determine the patient’s potential responsiveness to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/822b22-ar-822b226.pkl. "
BLCA,5.0,1.725490196,desert,R,"In a white male with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis shows a tumor mutational burden of 5.0, how likely is he to benefit from Atezolizumab therapy?","In a white male with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis shows a tumor mutational burden of 5.0, how likely is he to benefit from Atezolizumab therapy? Log into the Compass platform to download the patient’s transcriptomic dataset. Then, examine the dataset carefully, paying particular attention to biomarkers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After reviewing these molecular markers, compare the findings with the patient’s clinical history and current health status to construct a comprehensive immunological profile. This profile will help us assess the likelihood of the patient responding to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8533e5-ar-8533e5e.pkl. "
BLCA,8.0,0.274509804,excluded,NR,"I am managing a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a lung biopsy revealed a tumor mutational burden of 8.0. Based on these findings, what is his likelihood of responding to atezolizumab therapy?","I am managing a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment from a lung biopsy revealed a tumor mutational burden of 8.0. Based on these findings, what is his likelihood of responding to atezolizumab therapy? Please log into the Compass platform and download the patient’s transcriptomic dataset. Once downloaded, carefully review the data, focusing on biomarkers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After identifying these markers, correlate your findings with the patient’s clinical history and current condition to develop a comprehensive immunological profile. This profile will help evaluate the patient’s likelihood of responding to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/85f0a3-ar-85f0a3a.pkl. "
BLCA,14.0,0.31372549,excluded,NR,"In a white female patient with bladder urothelial carcinoma, a bladder biopsy revealed a tumor microenvironment transcriptomic profile with a TMB of 14.0. Based on these findings, how likely is she to benefit from atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma, a bladder biopsy revealed a tumor microenvironment transcriptomic profile with a TMB of 14.0. Based on these findings, how likely is she to benefit from atezolizumab therapy? Log in to the Compass platform and download the patient’s transcriptomic dataset. Once you have the data, review it in detail with a focus on biomarkers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After identifying these specific markers, compare your findings with the patient’s clinical history and current condition to create a comprehensive immunological profile. This profile will be used to assess the patient's potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/87a8e1-ar-87a8e18.pkl. "
BLCA,13.0,6.0,inflamed,R,"A Caucasian male patient with bladder urothelial carcinoma has a tumor biopsy showing a tumor mutation burden of 13.0. Based on this information, is it reasonable to expect a favorable response to atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a tumor biopsy showing a tumor mutation burden of 13.0. Based on this information, is it reasonable to expect a favorable response to atezolizumab therapy? Please log in to the Compass platform and download the patient's transcriptomic dataset. Once you have the data, carefully assess it with particular attention to biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After identifying these markers, compare your results with the patient's clinical history and current condition to develop a detailed immunological profile. This profile will be used to evaluate the patient's potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8884fe-ar-8884fe4.pkl. "
BLCA,14.0,0.843137255,desert,R,"In an Asian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 14.0 mutations/Mb. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","In an Asian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 14.0 mutations/Mb. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy? Please access the Compass platform and download the patient's transcriptomic dataset. Once you have obtained the data, perform a detailed evaluation with a focus on biomarkers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After identifying these markers, integrate your findings with the patient’s clinical history and current condition to create a comprehensive immunological profile. This profile will help assess the likelihood of a favorable response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8a1b0e-ar-8a1b0e0.pkl. "
BLCA,7.0,1.0,excluded,NR,"In a white male patient diagnosed with bladder urothelial carcinoma whose kidney biopsy transcriptomic profile shows a tumor mutation burden of 7.0, what is the anticipated response to atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma whose kidney biopsy transcriptomic profile shows a tumor mutation burden of 7.0, what is the anticipated response to atezolizumab therapy? Please log in to the Compass platform and download the transcriptomic dataset for the patient. Once you have the data, conduct a detailed analysis focusing on biomarkers linked to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After identifying these biomarkers, integrate your findings with the patient’s clinical history and current condition to develop a comprehensive immunological profile. This profile will aid in evaluating the potential for a positive response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8b4b8b-ar-8b4b8b0.pkl. "
BLCA,6.0,,excluded,NR,"A white male patient with bladder urothelial carcinoma has a bladder biopsy showing a tumor mutational burden of 6.0. Based on the transcriptomic analysis of the tumor immune microenvironment, what is the likelihood that this patient will respond favorably to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a bladder biopsy showing a tumor mutational burden of 6.0. Based on the transcriptomic analysis of the tumor immune microenvironment, what is the likelihood that this patient will respond favorably to atezolizumab therapy? Please access the Compass platform and download the patient’s transcriptomic dataset. Then, perform a detailed analysis concentrating on biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After identifying these biomarkers, correlate your findings with the patient’s clinical history and current status to construct a comprehensive immunological profile that will help assess their potential for a favorable response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8e4698-ar-8e46983.pkl. "
BLCA,6.0,0.509803922,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic analysis from a kidney biopsy shows a tumor mutational burden (TMB) of 6.0 mutations per megabase, how likely is it that he will respond to atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic analysis from a kidney biopsy shows a tumor mutational burden (TMB) of 6.0 mutations per megabase, how likely is it that he will respond to atezolizumab therapy? Please log into the Compass platform and download the patient’s transcriptomic dataset. Analyze the data with an emphasis on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, correlate these findings with the patient’s clinical history and current status to develop a comprehensive immunological profile, which will help inform the likelihood of a positive response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8e8ef2-ar-8e8ef23.pkl. "
BLCA,5.0,,desert,NR,"A white male patient with bladder urothelial carcinoma has a bladder biopsy showing a tumor mutational burden of 5.0. Based on the transcriptomic profile of the tumor immune microenvironment, would you anticipate a favorable response to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a bladder biopsy showing a tumor mutational burden of 5.0. Based on the transcriptomic profile of the tumor immune microenvironment, would you anticipate a favorable response to atezolizumab therapy? Access the Compass platform to download the patient’s transcriptomic dataset. Focus your analysis on biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these findings with the patient's clinical history and current condition to create a detailed immunological profile that will help assess the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/8f2275-ar-8f2275c.pkl. "
BLCA,49.0,2.705882353,inflamed,R,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment, obtained via biopsy, indicates a tumor mutational burden of 49.0. Based on these findings, how likely is he to respond to Atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor immune microenvironment, obtained via biopsy, indicates a tumor mutational burden of 49.0. Based on these findings, how likely is he to respond to Atezolizumab therapy? Please log into the Compass platform and download the patient's transcriptomic dataset. Concentrate your analysis on biomarkers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, correlate these molecular insights with the patient's clinical history and current signs to construct a comprehensive immunological profile. This profile will be instrumental in evaluating the likely efficacy of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/91c47b-ar-91c47b0.pkl. "
BLCA,12.0,2.235294118,inflamed,NR,"A white male patient diagnosed with bladder urothelial carcinoma has a tumor mutational burden of 12.0 based on transcriptomic profiling of his tumor microenvironment obtained from a bladder biopsy. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","A white male patient diagnosed with bladder urothelial carcinoma has a tumor mutational burden of 12.0 based on transcriptomic profiling of his tumor microenvironment obtained from a bladder biopsy. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Please log into the Compass platform and download the patient's transcriptomic dataset. When reviewing the data, prioritize biomarkers that signal macrophage activation, interferon-gamma activity, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular findings with the patient’s clinical history and current presentation to construct a comprehensive immunologic profile. This profile will be essential in assessing the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9306c5-ar-9306c5c.pkl. "
BLCA,,,,NR,"In a white male patient with bladder urothelial carcinoma, a bladder biopsy transcriptomic analysis of the tumor immune microenvironment revealed that the tumor mutation burden data was not available (TMB: nan). Based on these findings, what is the likelihood that the patient will benefit from Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a bladder biopsy transcriptomic analysis of the tumor immune microenvironment revealed that the tumor mutation burden data was not available (TMB: nan). Based on these findings, what is the likelihood that the patient will benefit from Atezolizumab therapy? Please access the Compass platform and download the patient’s transcriptomic dataset. As you review the data, focus primarily on biomarkers indicating macrophage activation, interferon-gamma activity, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, combine these molecular results with the patient’s clinical history and current symptoms to develop a detailed immunologic profile. This comprehensive profile will be instrumental in evaluating the potential response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9410b8-ar-9410b86.pkl. "
BLCA,5.0,0.117647059,desert,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor microenvironment from a bladder biopsy shows a tumor mutational burden (TMB) of 5.0. Based on this profile, what is the likelihood that he will respond favorably to atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of his tumor microenvironment from a bladder biopsy shows a tumor mutational burden (TMB) of 5.0. Based on this profile, what is the likelihood that he will respond favorably to atezolizumab therapy? Please log into the Compass platform and download the patient’s transcriptomic dataset. While reviewing the dataset, prioritize the evaluation of biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to create a comprehensive immunologic profile. This profile will be critical in assessing the patient’s potential responsiveness to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/943df5-ar-943df5c.pkl. "
BLCA,11.0,0.215686275,excluded,NR,"For an African American male with bladder urothelial carcinoma whose kidney biopsy transcriptomic analysis shows a tumor mutation burden of 11, what is the expected likelihood of a positive response to atezolizumab therapy?","For an African American male with bladder urothelial carcinoma whose kidney biopsy transcriptomic analysis shows a tumor mutation burden of 11, what is the expected likelihood of a positive response to atezolizumab therapy? Please log into the Compass platform to retrieve the patient’s transcriptomic dataset. When reviewing the data, focus on biomarkers linked to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, combine these molecular insights with the patient’s clinical history and present symptoms to develop a detailed immunologic profile. This profile is essential for determining the likelihood of a positive response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/94859b-ar-94859b4.pkl. "
BLCA,,0.431372549,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reports a tumor mutational burden (TMB) as “nan.” Based on this data, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reports a tumor mutational burden (TMB) as “nan.” Based on this data, what is the likelihood of a positive response to Atezolizumab therapy? Please access the Compass platform to obtain the patient's transcriptomic dataset. Focus your review on biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once you’ve analyzed these molecular indicators, integrate them with the patient’s clinical history and current symptoms to develop a comprehensive immunologic profile. This profile will be crucial for evaluating the likelihood of a favorable response to immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9539a4-ar-9539a4f.pkl. "
BLCA,,0.196078431,excluded,NR,"For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment—profiled from a ureter biopsy—shows an unreported (nan) TMB, how likely is he to benefit from treatment with atezolizumab?","For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment—profiled from a ureter biopsy—shows an unreported (nan) TMB, how likely is he to benefit from treatment with atezolizumab? Please log in to the Compass platform and retrieve the patient’s transcriptomic dataset. Carefully examine the data for biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. After your analysis, correlate these molecular findings with the patient's clinical history and current symptoms to develop a detailed immunologic profile. This integrated profile is essential for assessing the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/957378-ar-957378b.pkl. "
BLCA,17.0,1.725490196,excluded,NR,"For a Caucasian male with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile reveals a tumor mutational burden of 17.0, how likely is he to respond to Atezolizumab therapy?","For a Caucasian male with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile reveals a tumor mutational burden of 17.0, how likely is he to respond to Atezolizumab therapy? Access the Compass platform and retrieve the patient's transcriptomic dataset. Analyze the data to identify biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to develop a comprehensive immunologic profile. This evaluation will help determine the potential effectiveness of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/961d04-ar-961d04c.pkl. "
BLCA,22.0,4.431372549,desert,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. Tumor transcriptomic profiling from his bladder biopsy indicates a TMB of 22. Based on this data, how likely is he to benefit from Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. Tumor transcriptomic profiling from his bladder biopsy indicates a TMB of 22. Based on this data, how likely is he to benefit from Atezolizumab therapy? Please log into the Compass platform to retrieve this patient’s transcriptomic data. Review the data to detect biomarkers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular insights with the patient’s clinical history and current symptoms to assemble a detailed immunologic profile. This approach will guide our assessment of the potential benefit of immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/972530-ar-9725303.pkl. "
BLCA,,1.921568627,excluded,NR,"For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis indicated an unavailable TMB value, how might this impact the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis indicated an unavailable TMB value, how might this impact the likelihood of a favorable response to Atezolizumab therapy? Please access the Compass platform to obtain the patient's transcriptomic data. Once retrieved, analyze the data for biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, correlate these molecular findings with the patient’s clinical history and current symptoms to create a comprehensive immunologic profile. This profile will help us determine if the patient is a good candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/978a58-ar-978a587.pkl. "
BLCA,18.0,2.862745098,excluded,R,"A patient diagnosed with bladder urothelial carcinoma underwent transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, which revealed a tumor mutational burden of 18.0. Could you provide an assessment of the potential response to Atezolizumab therapy in this case?","A patient diagnosed with bladder urothelial carcinoma underwent transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, which revealed a tumor mutational burden of 18.0. Could you provide an assessment of the potential response to Atezolizumab therapy in this case? Please log into the Compass platform to retrieve the patient's transcriptomic data. After obtaining the data, please assess biomarkers relevant to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Incorporate these molecular findings with the patient's clinical history and current symptoms to develop a detailed immunologic profile. This comprehensive profile will assist in evaluating the patient’s suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/97a00e-ar-97a00e0.pkl. "
BLCA,5.0,0.725490196,excluded,NR,"In a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 5.0. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 5.0. Based on these findings, what is the likelihood that the patient will respond to Atezolizumab therapy? Please access the Compass platform to retrieve the patient's transcriptomic data. Once obtained, evaluate the biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and present symptoms to craft a comprehensive immunologic profile. This profile will guide our assessment of their suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/99a46b-ar-99a46b9.pkl. "
BLCA,4.0,0.862745098,inflamed,NR,"In a white male patient with bladder urothelial carcinoma and a tumor mutational burden (TMB) of 4.0 obtained from a bladder biopsy, how likely is the patient to respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma and a tumor mutational burden (TMB) of 4.0 obtained from a bladder biopsy, how likely is the patient to respond to Atezolizumab therapy? Please log into the Compass platform to access the patient’s transcriptomic data. After retrieving the data, assess the expression of markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, combine these molecular insights with the patient's clinical history and current symptoms to develop a detailed immunologic profile. This profile will help us determine if the patient is a good candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9a2cf3-ar-9a2cf3c.pkl. "
BLCA,5.0,0.647058824,excluded,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of his tumor immune microenvironment from a kidney biopsy indicates a tumor mutation burden of 5.0. Based on these findings, is there evidence to suggest that he would respond favorably to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of his tumor immune microenvironment from a kidney biopsy indicates a tumor mutation burden of 5.0. Based on these findings, is there evidence to suggest that he would respond favorably to Atezolizumab therapy? Please log into the Compass platform to retrieve the patient's transcriptomic data. Once accessed, evaluate the expression levels of markers indicative of macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. Integrate these molecular findings with the patient’s clinical history and current symptomatology to construct a comprehensive immunologic profile, which will guide the assessment of the patient's suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9aa6a0-ar-9aa6a09.pkl. "
BLCA,12.0,0.588235294,inflamed,NR,"For a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic analysis (obtained via kidney biopsy) indicates a tumor mutational burden of 12.0, how likely is he to respond to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic analysis (obtained via kidney biopsy) indicates a tumor mutational burden of 12.0, how likely is he to respond to atezolizumab therapy? Please access the Compass platform to retrieve the patient’s transcriptomic data. Review the data to assess expression levels of markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to develop a comprehensive immunologic profile, which will assist in determining their eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9cafb9-ar-9cafb90.pkl. "
BLCA,,,,NR,"A Caucasian male patient with bladder urothelial carcinoma underwent a liver biopsy, and the transcriptomic profiling of his tumor immune microenvironment indicated an undefined tumor mutational burden. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma underwent a liver biopsy, and the transcriptomic profiling of his tumor immune microenvironment indicated an undefined tumor mutational burden. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Please log into the Compass platform to retrieve the patient’s transcriptomic dataset. Once accessed, evaluate the expression levels of biomarkers linked to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular insights with the patient's clinical history and current symptoms to construct a detailed immunologic profile. This profile will be instrumental in determining whether the patient qualifies for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9d2494-ar-9d24941.pkl. "
BLCA,,,desert,NR,"We have a Caucasian female patient with bladder urothelial carcinoma. A kidney biopsy provided a transcriptomic profile of her tumor’s immune microenvironment, but the tumor mutational burden is reported as not available. Could you advise on the likelihood that she will respond to atezolizumab therapy?","We have a Caucasian female patient with bladder urothelial carcinoma. A kidney biopsy provided a transcriptomic profile of her tumor’s immune microenvironment, but the tumor mutational burden is reported as not available. Could you advise on the likelihood that she will respond to atezolizumab therapy? Log into the Compass platform to access the patient's transcriptomic dataset. Review the expression levels of biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular findings with the patient's clinical history and current symptoms to build a comprehensive immunologic profile. This integrated profile will help determine if the patient is a suitable candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9dacca-ar-9daccaf.pkl. "
BLCA,10.0,,inflamed,NR,"For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile reveals a tumor mutational burden (TMB) of 10.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile reveals a tumor mutational burden (TMB) of 10.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please log into the Compass platform and retrieve the patient’s transcriptomic dataset. Assess the expression levels of biomarkers indicating macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to create a comprehensive immunologic profile. This profile will assist in determining whether the patient is a suitable candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9e11ec-ar-9e11ec6.pkl. "
BLCA,6.0,0.431372549,desert,NR,"I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. Her bladder biopsy transcriptomic analysis of the tumor immune microenvironment indicates a tumor mutational burden of 6.0. Based on these findings, would you consider her a likely responder to Atezolizumab therapy?","I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. Her bladder biopsy transcriptomic analysis of the tumor immune microenvironment indicates a tumor mutational burden of 6.0. Based on these findings, would you consider her a likely responder to Atezolizumab therapy? Please access the Compass platform to obtain the patient’s transcriptomic dataset. Evaluate the expression levels of biomarkers related to macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these molecular findings with a review of the patient’s clinical history and current symptoms to develop a detailed immunologic profile. This profile will help us determine the patient’s eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/9fb814-ar-9fb814c.pkl. "
BLCA,,3.333333333,desert,NR,"For a white female patient with bladder urothelial carcinoma who underwent transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, where the tumor mutational burden (TMB) was not determined, how should we assess her likelihood of responding to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma who underwent transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, where the tumor mutational burden (TMB) was not determined, how should we assess her likelihood of responding to Atezolizumab therapy? Please log into the Compass platform to retrieve the patient's transcriptomic data. Next, assess the expression levels of biomarkers linked to macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and the activity of cytotoxic T cells. Then, integrate these molecular insights with the patient’s clinical history and current symptoms to create a detailed immunologic profile. This profile will be instrumental in determining if the patient qualifies for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a1871f-ar-a1871f4.pkl. "
BLCA,15.0,0.921568627,inflamed,NR,"I have a Caucasian female patient with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 15 mutations per megabase. Based on these findings, is she likely to respond to Atezolizumab therapy?","I have a Caucasian female patient with bladder urothelial carcinoma (BLCA). A transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 15 mutations per megabase. Based on these findings, is she likely to respond to Atezolizumab therapy? Please log into the Compass platform to retrieve the patient’s transcriptomic data. Review the expression levels of biomarkers associated with macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Then, combine these molecular findings with the patient’s clinical history and current symptoms to develop a comprehensive immunologic profile that will help determine eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a1e62d-ar-a1e62d3.pkl. "
BLCA,8.0,1.411764706,excluded,NR,"For a white male patient with bladder urothelial carcinoma whose lymph node biopsy transcriptomic profile reveals a tumor mutational burden of 8.0, how might this TMB value inform the likelihood of a successful response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose lymph node biopsy transcriptomic profile reveals a tumor mutational burden of 8.0, how might this TMB value inform the likelihood of a successful response to Atezolizumab therapy? Please access the Compass platform to obtain the patient’s transcriptomic data. Once retrieved, evaluate the expression levels of biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Then integrate these molecular findings with the patient’s clinical history and current symptoms to assemble a detailed immunologic profile, which will aid in determining their suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a32177-ar-a321770.pkl. "
BLCA,6.0,0.68627451,,NR,"For a Caucasian male patient with bladder urothelial carcinoma and a tumor mutational burden (TMB) of 6.0 as determined by transcriptomic profiling of the tumor immune microenvironment, how might these findings influence his likelihood of responding to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma and a tumor mutational burden (TMB) of 6.0 as determined by transcriptomic profiling of the tumor immune microenvironment, how might these findings influence his likelihood of responding to Atezolizumab therapy? Please log in to the Compass platform to retrieve the patient’s transcriptomic data. After obtaining the data, assess the expression levels of biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Next, correlate these molecular findings with the patient’s clinical history and present symptoms to construct a comprehensive immunologic profile that will help determine their eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a424c7-ar-a424c75.pkl. "
BLCA,19.0,0.882352941,,R,A white male patient with bladder urothelial carcinoma has a tumor mutational burden of 19.0 based on transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy. Could this patient be considered a likely candidate for atezolizumab therapy?,"A white male patient with bladder urothelial carcinoma has a tumor mutational burden of 19.0 based on transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy. Could this patient be considered a likely candidate for atezolizumab therapy? Log in to the Compass platform to obtain the patient's transcriptomic data. Once you have the data, evaluate the expression levels of biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Then, integrate these molecular results with the patient's clinical history and current symptoms to build a detailed immunologic profile. This profile will be used to assess the patient's suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a535fc-ar-a535fcd.pkl. "
BLCA,12.0,0.725490196,,NR,"A white male patient with bladder urothelial carcinoma (BLCA) underwent transcriptomic profiling of the tumor immune microenvironment from a separate biopsy, revealing a tumor mutational burden (TMB) of 12.0. Based on this TMB and current evidence, how likely is he to respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma (BLCA) underwent transcriptomic profiling of the tumor immune microenvironment from a separate biopsy, revealing a tumor mutational burden (TMB) of 12.0. Based on this TMB and current evidence, how likely is he to respond to Atezolizumab therapy? Please access the Compass platform to retrieve the patient’s transcriptomic data. Next, assess the expression levels of biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell function. Finally, integrate these molecular findings with the patient’s clinical history and current symptoms to develop a comprehensive immunologic profile. This profile will inform the evaluation of the patient’s eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a90d73-ar-a90d73f.pkl. "
BLCA,,1.529411765,excluded,NR,"I have a white male patient with bladder urothelial carcinoma. The tumor immune microenvironment analysis, performed on a kidney biopsy, did not yield a measurable tumor mutational burden (TMB). Based on these findings, can we predict whether the patient is likely to respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. The tumor immune microenvironment analysis, performed on a kidney biopsy, did not yield a measurable tumor mutational burden (TMB). Based on these findings, can we predict whether the patient is likely to respond to Atezolizumab therapy? Please log into the Compass platform and retrieve the patient’s transcriptomic data. Then, evaluate the biomarker expression levels related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T cell activity. Finally, integrate these molecular findings with the patient's clinical history and current symptoms to construct an in-depth immunologic profile, which will assist in determining the patient’s suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a913c6-ar-a913c61.pkl. "
BLCA,3.0,0.352941176,,NR,"I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile indicates a TMB of 3.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile indicates a TMB of 3.0. Based on these findings, what is the likelihood that he will respond to Atezolizumab therapy? Please access the Compass platform and extract the patient's transcriptomic data. Next, assess the expression levels of biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular insights with the patient's clinical history and current signs and symptoms to develop a comprehensive immunologic profile that will help determine if the patient is a good candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/a9ca85-ar-a9ca853.pkl. "
BLCA,18.0,2.0,,NR,"I have a Caucasian male patient with bladder urothelial carcinoma whose lymph node biopsy transcriptomic profiling of the tumor immune microenvironment indicates a tumor mutation burden of 18.0. Based on this information, what is the likelihood that he will respond to atezolizumab therapy?","I have a Caucasian male patient with bladder urothelial carcinoma whose lymph node biopsy transcriptomic profiling of the tumor immune microenvironment indicates a tumor mutation burden of 18.0. Based on this information, what is the likelihood that he will respond to atezolizumab therapy? Please log in to the Compass platform and retrieve the patient's transcriptomic dataset. Evaluate the expression levels of biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient's clinical history and current symptoms to construct a detailed immunologic profile. This profile will assist in determining whether the patient is a suitable candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aabf4a-ar-aabf4af.pkl. "
BLCA,15.0,1.725490196,excluded,R,"A white male patient with bladder urothelial carcinoma had a kidney biopsy for transcriptomic profiling of the tumor immune microenvironment, which revealed a tumor mutational burden of 15.0. Based on these findings, what is the likelihood of this patient responding to atezolizumab therapy?","A white male patient with bladder urothelial carcinoma had a kidney biopsy for transcriptomic profiling of the tumor immune microenvironment, which revealed a tumor mutational burden of 15.0. Based on these findings, what is the likelihood of this patient responding to atezolizumab therapy? Log in to the Compass platform and access the patient’s transcriptomic data. Assess the expression levels of biomarkers involved in macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, combine these molecular findings with the patient’s clinical history and current symptoms to develop a comprehensive immunologic profile. This profile will help determine if the patient is an appropriate candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aaf505-ar-aaf505c.pkl. "
BLCA,,0.039215686,inflamed,NR,"A white male patient diagnosed with bladder urothelial carcinoma (BLCA) underwent a lymph node biopsy, and transcriptomic profiling of the tumor immune microenvironment reported a tumor mutation burden (TMB) value of nan. Based on these findings, can we determine if the patient is likely to benefit from Atezolizumab therapy?","A white male patient diagnosed with bladder urothelial carcinoma (BLCA) underwent a lymph node biopsy, and transcriptomic profiling of the tumor immune microenvironment reported a tumor mutation burden (TMB) value of nan. Based on these findings, can we determine if the patient is likely to benefit from Atezolizumab therapy? Access the Compass platform and retrieve the patient's transcriptomic data. Evaluate the biomarker expression levels associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to construct a comprehensive immunologic profile. This profile will guide the decision on whether immune checkpoint inhibitor therapy is appropriate for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ab8052-ar-ab8052a.pkl. "
BLCA,,,excluded,NR,"I have a white female patient diagnosed with bladder urothelial carcinoma. The transcriptomic profile of her tumor immune microenvironment, obtained via bladder biopsy, indicates a tumor mutation burden (TMB) value that is not available. Based on these findings, can you help assess her likelihood of responding to atezolizumab therapy?","I have a white female patient diagnosed with bladder urothelial carcinoma. The transcriptomic profile of her tumor immune microenvironment, obtained via bladder biopsy, indicates a tumor mutation burden (TMB) value that is not available. Based on these findings, can you help assess her likelihood of responding to atezolizumab therapy? Please log into the Compass platform and retrieve the patient's transcriptomic data. Review the levels of biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, combine these molecular insights with the patient’s clinical history and presenting symptoms to develop a detailed immunologic profile. This comprehensive profile will help determine if the patient is a suitable candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/abc151-ar-abc151b.pkl. "
BLCA,6.0,0.745098039,,NR,"We have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy yielded a tumor mutational burden of 6.0. Based on these findings, how would you assess the likelihood of a response to atezolizumab therapy?","We have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy yielded a tumor mutational burden of 6.0. Based on these findings, how would you assess the likelihood of a response to atezolizumab therapy? Log in to the Compass platform and access the patient's transcriptomic data. Evaluate the biomarker levels linked to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to construct a detailed immunologic profile that will inform our assessment of their eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ad83c9-ar-ad83c9c.pkl. "
BLCA,,,,NR,"For a white female patient with bladder urothelial carcinoma, how should we interpret a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy that reports a tumor mutational burden (TMB) as “nan” in terms of predicting her response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, how should we interpret a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy that reports a tumor mutational burden (TMB) as “nan” in terms of predicting her response to Atezolizumab therapy? Please sign in to the Compass platform and retrieve the patient’s transcriptomic data. Carefully assess the biomarker levels associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, combine these molecular insights with the patient’s clinical history and current symptoms to develop a comprehensive immunologic profile that will help determine their suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae0262-ar-ae02629.pkl. "
BLCA,,,,NR,"Does this Black or African American male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a ureter biopsy shows an undetermined tumor mutational burden, appear likely to benefit from Atezolizumab therapy?","Does this Black or African American male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a ureter biopsy shows an undetermined tumor mutational burden, appear likely to benefit from Atezolizumab therapy? Please log into the Compass platform and access the patient's transcriptomic data. Evaluate the biomarker levels related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular findings with the patient's clinical history and current symptoms to create a comprehensive immunologic profile, which will inform the decision on their suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae1690-ar-ae16904.pkl. "
BLCA,,,,NR,"In a white female patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis from a bladder biopsy reported a tumor mutation burden (TMB) value of ""nan."" How should we interpret this result in terms of predicting her response to atezolizumab therapy?","In a white female patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis from a bladder biopsy reported a tumor mutation burden (TMB) value of ""nan."" How should we interpret this result in terms of predicting her response to atezolizumab therapy? Please access the Compass system to retrieve the patient's transcriptomic data. Review the biomarker levels that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, combine these molecular insights with the patient’s clinical history and current symptoms to develop a detailed immunologic profile that will help determine their eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ae4da2-ar-ae4da27.pkl. "
BLCA,4.0,,excluded,R,"In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy revealed a tumor mutational burden (TMB) of 4.0. How likely is this patient to respond to atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy revealed a tumor mutational burden (TMB) of 4.0. How likely is this patient to respond to atezolizumab therapy? Log in to the Compass system to obtain the patient’s transcriptomic data. Carefully evaluate the biomarker levels associated with macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular findings with the patient’s clinical history and present symptoms to create a detailed immunologic profile that will inform their eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/aec738-ar-aec7380.pkl. "
BLCA,14.0,2.196078431,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of a bladder biopsy revealed a tumor mutational burden of 14.0. Based on this information, how likely is it that he will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of a bladder biopsy revealed a tumor mutational burden of 14.0. Based on this information, how likely is it that he will respond to Atezolizumab therapy? Access the Compass system to retrieve the patient's transcriptomic data. Evaluate the levels of biomarkers related to macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular findings with the patient's clinical history and current symptoms to develop a comprehensive immunologic profile that will help determine their eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/af42c1-ar-af42c15.pkl. "
BLCA,7.0,0.352941176,,NR,"A Caucasian male with bladder urothelial carcinoma (BLCA) underwent a lung biopsy, and analysis of the tumor immune microenvironment revealed a tumor mutation burden (TMB) of 7.0. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy?","A Caucasian male with bladder urothelial carcinoma (BLCA) underwent a lung biopsy, and analysis of the tumor immune microenvironment revealed a tumor mutation burden (TMB) of 7.0. Based on this information, what is the likelihood that he will respond to Atezolizumab therapy? Please access the Compass system to retrieve the patient’s transcriptomic data. Then, evaluate biomarkers related to macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell function. Finally, integrate these molecular findings with the patient’s clinical history and current symptoms to construct a comprehensive immunologic profile to assess their eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b0a83e-ar-b0a83e5.pkl. "
BLCA,3.0,0.843137255,inflamed,NR,"I have a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA). A lung biopsy provided transcriptomic profiling of the tumor immune microenvironment, yielding a tumor mutation burden (TMB) of 3.0 mutations per megabase. Based on this profile, how likely is she to respond to Atezolizumab therapy?","I have a Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA). A lung biopsy provided transcriptomic profiling of the tumor immune microenvironment, yielding a tumor mutation burden (TMB) of 3.0 mutations per megabase. Based on this profile, how likely is she to respond to Atezolizumab therapy? Please log in to the Compass system to obtain the patient’s transcriptomic data. Review and analyze biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Finally, synthesize these molecular findings with the patient’s clinical history and current symptoms to develop a detailed immunologic profile, which will help determine their candidacy for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b0d11d-ar-b0d11db.pkl. "
BLCA,11.0,1.509803922,,R,"For a white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy revealed a tumor mutational burden of 11.0. Based on this TMB value, how likely is it that the patient would respond favorably to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy revealed a tumor mutational burden of 11.0. Based on this TMB value, how likely is it that the patient would respond favorably to Atezolizumab therapy? Please access the Compass system to retrieve the patient's transcriptomic data. Evaluate the data for biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, integrate these molecular findings with the patient's clinical history and current symptoms to construct a detailed immunologic profile that will inform their eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b15ac6-ar-b15ac6e.pkl. "
BLCA,4.0,,excluded,NR,A Caucasian female patient with bladder urothelial carcinoma has a tumor mutational burden (TMB) of 4.0 based on transcriptomic analysis of her tumor immune microenvironment from a bladder biopsy. How might this TMB value inform her expected response to Atezolizumab therapy?,"A Caucasian female patient with bladder urothelial carcinoma has a tumor mutational burden (TMB) of 4.0 based on transcriptomic analysis of her tumor immune microenvironment from a bladder biopsy. How might this TMB value inform her expected response to Atezolizumab therapy? Access the Compass system and retrieve the patient's transcriptomic data. Then, evaluate this data for biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Finally, correlate these molecular findings with the patient's clinical history and current symptoms to develop a comprehensive immunologic profile that will guide decisions regarding their eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b15ad0-ar-b15ad09.pkl. "
BLCA,,,,NR,"For a white female patient diagnosed with bladder urothelial carcinoma, whose transcriptomic profiling from a bladder biopsy indicates a tumor mutational burden value of ""nan,"" how should we interpret her likelihood of responding to Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma, whose transcriptomic profiling from a bladder biopsy indicates a tumor mutational burden value of ""nan,"" how should we interpret her likelihood of responding to Atezolizumab therapy? Please log in to the Compass system to obtain the patient’s transcriptomic data. Review the data for biomarkers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to construct a detailed immunologic profile. This profile will help us determine the patient’s suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b2e4a0-ar-b2e4a08.pkl. "
BLCA,,0.862745098,desert,R,"In a White male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling from a bladder biopsy revealed a tumor mutational burden (TMB) value reported as 'nan'. How should we interpret this result in relation to his potential response to Atezolizumab therapy?","In a White male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling from a bladder biopsy revealed a tumor mutational burden (TMB) value reported as 'nan'. How should we interpret this result in relation to his potential response to Atezolizumab therapy? Please access the Compass system to retrieve the patient’s transcriptomic data. Evaluate the data for evidence of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular insights with the patient’s clinical history and current symptoms, creating a detailed immunologic profile to assess their eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b2f1d0-ar-b2f1d0e.pkl. "
BLCA,18.0,,desert,R,"I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile shows a tumor mutational burden (TMB) of 18.0. Based on these findings, is it reasonable to expect a favorable response to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile shows a tumor mutational burden (TMB) of 18.0. Based on these findings, is it reasonable to expect a favorable response to Atezolizumab therapy? Access the Compass system to retrieve the patient's transcriptomic profile. Analyze the data for markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to construct a comprehensive immunologic profile that will help determine their suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b3c022-ar-b3c0229.pkl. "
BLCA,19.0,,excluded,R,"A white male patient with bladder urothelial carcinoma has a tumor mutation burden (TMB) of 19.0 as determined by transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy. Based on this molecular profile, could we expect a favorable response to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a tumor mutation burden (TMB) of 19.0 as determined by transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy. Based on this molecular profile, could we expect a favorable response to Atezolizumab therapy? Log into the Compass system to retrieve the patient’s transcriptomic data. Review the profile to identify markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, correlate these molecular insights with the patient’s clinical history and current symptoms to create a comprehensive immunologic profile. This profile will inform decisions regarding their suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b419a8-ar-b419a8f.pkl. "
BLCA,35.0,,excluded,R,"In a White male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) of 35.0. Does this genomic profile suggest a higher likelihood of response to Atezolizumab therapy?","In a White male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) of 35.0. Does this genomic profile suggest a higher likelihood of response to Atezolizumab therapy? Access the Compass system to obtain the patient’s transcriptomic data. Carefully review this profile for markers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these molecular findings with the patient’s clinical history and current symptoms to develop a comprehensive immunologic profile. This integrated analysis will help us decide if the patient is a suitable candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b470eb-ar-b470eb8.pkl. "
BLCA,5.0,,inflamed,NR,"In a Caucasian male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy indicates a tumor mutational burden of 5.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy indicates a tumor mutational burden of 5.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Please log into the Compass system and retrieve the patient’s transcriptomic data. Review the profile carefully, specifically checking for signs of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to create a complete immunologic profile. This comprehensive assessment will help determine whether the patient is an appropriate candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b4c7a0-ar-b4c7a00.pkl. "
BLCA,5.0,0.333333333,desert,NR,"A white male patient with bladder urothelial carcinoma has undergone transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, which shows a tumor mutational burden (TMB) of 5.0. Based on these findings, how likely is he to respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has undergone transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, which shows a tumor mutational burden (TMB) of 5.0. Based on these findings, how likely is he to respond to Atezolizumab therapy? Please access the Compass system and obtain the patient's transcriptomic data. Evaluate the profile with close attention to indicators such as macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Next, correlate these molecular markers with the patient's clinical history and current symptoms to develop a comprehensive immunologic profile. This integrated analysis is crucial to assess the patient’s candidacy for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b8070b-ar-b8070b7.pkl. "
BLCA,16.0,3.764705882,inflamed,NR,"A Caucasian male patient with biopsy-confirmed bladder urothelial carcinoma has a tumor mutational burden of 16.0 based on transcriptomic profiling of the tumor immune microenvironment. Considering these findings, what is the anticipated response to Atezolizumab therapy in this patient?","A Caucasian male patient with biopsy-confirmed bladder urothelial carcinoma has a tumor mutational burden of 16.0 based on transcriptomic profiling of the tumor immune microenvironment. Considering these findings, what is the anticipated response to Atezolizumab therapy in this patient? Please log into the Compass system and retrieve the patient's transcriptomic data. Carefully assess the profile with a focus on markers such as macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to develop a comprehensive immunologic profile. This detailed analysis is essential for determining the patient’s suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b8101c-ar-b8101c5.pkl. "
BLCA,8.0,0.882352941,excluded,NR,"In a patient diagnosed with bladder urothelial carcinoma whose biopsy-derived transcriptomic analysis indicates a tumor mutation burden of 8.0, how likely is it that they would respond to atezolizumab therapy?","In a patient diagnosed with bladder urothelial carcinoma whose biopsy-derived transcriptomic analysis indicates a tumor mutation burden of 8.0, how likely is it that they would respond to atezolizumab therapy? Please log into the Compass system and extract the patient’s transcriptomic data. Review the transcriptomic profile, paying particular attention to markers of macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Then, correlate these molecular findings with the patient’s clinical history and current symptoms to construct a detailed immunologic profile. This comprehensive analysis is necessary to assess the patient’s eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/b963dd-ar-b963dda.pkl. "
BLCA,5.0,0.901960784,inflamed,NR,"For a White male patient with bladder urothelial carcinoma, whose biopsy transcriptomic analysis reveals a tumor mutation burden of 5.0, what is the likelihood that he will respond to atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma, whose biopsy transcriptomic analysis reveals a tumor mutation burden of 5.0, what is the likelihood that he will respond to atezolizumab therapy? Please access the Compass system to retrieve the patient’s transcriptomic data. Then, review this data with a focus on markers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these molecular findings with the patient's clinical history and current symptoms to develop a comprehensive immunologic profile. This evaluation is essential to determine the patient's eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ba1a34-ar-ba1a34b.pkl. "
BLCA,5.0,,excluded,NR,"I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. A kidney biopsy provided a transcriptomic analysis of her tumor immune microenvironment, showing a tumor mutational burden of 5.0. Based on this data, how likely is she to respond to atezolizumab therapy?","I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. A kidney biopsy provided a transcriptomic analysis of her tumor immune microenvironment, showing a tumor mutational burden of 5.0. Based on this data, how likely is she to respond to atezolizumab therapy? Please use the Compass system to obtain the patient's transcriptomic data. Focus your review on markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular findings with the patient's clinical history and present symptoms to create a detailed immunologic profile. This thorough evaluation will help determine if the patient is a suitable candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ba7176-ar-ba7176a.pkl. "
BLCA,7.0,0.745098039,desert,NR,"For a white female patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutation burden (TMB) of 7.0. Based on these findings, how likely is it that she will respond to Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutation burden (TMB) of 7.0. Based on these findings, how likely is it that she will respond to Atezolizumab therapy? Please utilize the Compass system to retrieve the patient’s transcriptomic data, paying particular attention to markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular findings with the patient’s clinical history and current symptoms to develop a comprehensive immunologic profile. This evaluation will assist in determining whether the patient is an appropriate candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bc8dc3-ar-bc8dc3a.pkl. "
BLCA,,,excluded,NR,"A Caucasian male with bladder urothelial carcinoma (BLCA) underwent transcriptomic profiling of his tumor's immune microenvironment from a bladder biopsy, which resulted in a tumor mutational burden (TMB) value reported as ""nan."" Can we determine the likelihood of response to Atezolizumab therapy based on these findings?","A Caucasian male with bladder urothelial carcinoma (BLCA) underwent transcriptomic profiling of his tumor's immune microenvironment from a bladder biopsy, which resulted in a tumor mutational burden (TMB) value reported as ""nan."" Can we determine the likelihood of response to Atezolizumab therapy based on these findings? Please access the patient's transcriptomic data using the Compass system, focusing on markers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these molecular insights with the patient's clinical history and present symptoms to develop a detailed immunologic profile, which will help determine if they are a candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bcb07b-ar-bcb07ba.pkl. "
BLCA,9.0,,desert,NR,"We have a white male patient with bladder urothelial carcinoma whose tumor transcriptomic analysis from a bladder biopsy indicates a TMB of 9.0. Based on these findings, what is the anticipated likelihood of response to Atezolizumab therapy?","We have a white male patient with bladder urothelial carcinoma whose tumor transcriptomic analysis from a bladder biopsy indicates a TMB of 9.0. Based on these findings, what is the anticipated likelihood of response to Atezolizumab therapy? Access the patient's transcriptomic data via the Compass system, concentrating on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Integrate these molecular findings with the patient’s clinical history and current symptoms to compile a detailed immunologic profile, which will assist in evaluating their suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bcbc79-ar-bcbc795.pkl. "
BLCA,20.0,1.254901961,inflamed,NR,"A white female patient with bladder urothelial carcinoma (BLCA) has undergone a bladder biopsy, and her transcriptomic profile indicates a tumor mutational burden (TMB) of 20.0. Could you determine the likelihood of her responding to atezolizumab therapy based on this information?","A white female patient with bladder urothelial carcinoma (BLCA) has undergone a bladder biopsy, and her transcriptomic profile indicates a tumor mutational burden (TMB) of 20.0. Could you determine the likelihood of her responding to atezolizumab therapy based on this information? Please access the patient's transcriptomic data through the Compass system, focusing on markers that indicate macrophage activation, interferon-gamma signaling, genomic integrity, cell proliferation, and cytotoxic T-cell activity. Once gathered, integrate these molecular insights with the patient’s clinical history and present symptoms to create a comprehensive immunologic profile. This profile will be instrumental in determining their eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bda79f-ar-bda79f9.pkl. "
BLCA,10.0,0.784313725,excluded,NR,We have a white female patient with bladder urothelial carcinoma. Her transcriptomic profile from a lymph node biopsy shows a tumor mutational burden of 10. Could you please evaluate whether she is likely to respond to atezolizumab therapy?,"We have a white female patient with bladder urothelial carcinoma. Her transcriptomic profile from a lymph node biopsy shows a tumor mutational burden of 10. Could you please evaluate whether she is likely to respond to atezolizumab therapy? Please retrieve the patient's transcriptomic data via the Compass system, specifically examining markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once collected, integrate these molecular findings with the patient’s clinical history and current presentation to develop a comprehensive immunologic profile. This profile will help determine the patient's suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/be83ea-ar-be83eae.pkl. "
BLCA,35.0,3.745098039,excluded,R,"I have a white male patient diagnosed with bladder urothelial carcinoma whose tumor biopsy transcriptomic profile indicates a tumor mutational burden of 35.0. Based on these findings, what is the likelihood that he would benefit from atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma whose tumor biopsy transcriptomic profile indicates a tumor mutational burden of 35.0. Based on these findings, what is the likelihood that he would benefit from atezolizumab therapy? Please access the patient's transcriptomic data using the Compass system. Specifically, review markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular findings with the patient's clinical history and current symptoms to form a comprehensive immunologic profile. This profile will be used to assess the patient’s eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bf1a3a-ar-bf1a3ae.pkl. "
BLCA,6.0,1.450980392,excluded,NR,"For a white female patient with bladder urothelial carcinoma whose biopsy-based transcriptomic profiling revealed a tumor mutational burden of 6.0, would you consider Atezolizumab a likely effective treatment option?","For a white female patient with bladder urothelial carcinoma whose biopsy-based transcriptomic profiling revealed a tumor mutational burden of 6.0, would you consider Atezolizumab a likely effective treatment option? Please retrieve the patient's transcriptomic data from the Compass system. Carefully evaluate markers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these molecular findings with the patient's clinical history and current symptoms to develop a comprehensive immunologic profile. This profile will be essential for determining the patient's eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/bfdffb-ar-bfdffb9.pkl. "
BLCA,3.0,0.294117647,desert,NR,"I have a Caucasian female patient with bladder urothelial carcinoma. A transcriptomic analysis of her tumor microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 3.0. Based on these findings, how likely is she to benefit from Atezolizumab therapy?","I have a Caucasian female patient with bladder urothelial carcinoma. A transcriptomic analysis of her tumor microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 3.0. Based on these findings, how likely is she to benefit from Atezolizumab therapy? Retrieve the patient's transcriptomic data from the Compass system. Then, review markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After this analysis, combine the molecular data with the patient’s clinical history and current symptoms to create a detailed immunologic profile. This comprehensive profile will be used to assess the patient’s eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0d625-ar-c0d625a.pkl. "
BLCA,5.0,1.176470588,desert,NR,"For a Caucasian male patient with bladder urothelial carcinoma whose biopsy transcriptomic profile shows a tumor mutational burden of 5.0, how might this TMB value inform the likelihood of responding to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma whose biopsy transcriptomic profile shows a tumor mutational burden of 5.0, how might this TMB value inform the likelihood of responding to atezolizumab therapy? Access the patient's transcriptomic data from the Compass system. Next, evaluate the markers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to develop a detailed immunologic profile. This profile will help determine the patient's eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0da5d-ar-c0da5d4.pkl. "
BLCA,5.0,0.960784314,desert,NR,"For a Caucasian male patient with bladder urothelial carcinoma, the transcriptomic profile of the tumor immune microenvironment obtained from a nano-biopsy shows a tumor mutational burden of 5.0 mutations per megabase. Based on these findings, how likely is the patient to respond to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, the transcriptomic profile of the tumor immune microenvironment obtained from a nano-biopsy shows a tumor mutational burden of 5.0 mutations per megabase. Based on these findings, how likely is the patient to respond to atezolizumab therapy? Retrieve the patient’s transcriptomic data using the Compass system. Review the data for markers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, correlate these molecular findings with the patient’s clinical history and symptoms to create a comprehensive immunologic profile. This profile will be used to assess whether the patient qualifies for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c0ef41-ar-c0ef41a.pkl. "
BLCA,5.0,1.098039216,excluded,R,"A Caucasian male patient with bladder urothelial carcinoma has a tumor mutation burden of 5.0, as determined from transcriptomic analysis of the tumor immune microenvironment obtained via bladder biopsy. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a tumor mutation burden of 5.0, as determined from transcriptomic analysis of the tumor immune microenvironment obtained via bladder biopsy. Based on these findings, how likely is the patient to respond to Atezolizumab therapy? Using the Compass system, access the patient’s transcriptomic data. Carefully evaluate this data for signs of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and symptoms to formulate a detailed immunologic profile, which will determine eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c1251c-ar-c1251c7.pkl. "
BLCA,5.0,1.411764706,excluded,R,I have a white male patient with bladder urothelial carcinoma. The transcriptomic analysis of his tumor immune microenvironment from a kidney biopsy shows a tumor mutational burden (TMB) of 5.0. Could you provide your assessment of his potential response to Atezolizumab therapy?,"I have a white male patient with bladder urothelial carcinoma. The transcriptomic analysis of his tumor immune microenvironment from a kidney biopsy shows a tumor mutational burden (TMB) of 5.0. Could you provide your assessment of his potential response to Atezolizumab therapy? Access the patient’s transcriptomic data using the Compass platform. Evaluate this data for markers indicating macrophage activation, interferon-gamma signaling pathways, genomic stability, cell proliferation rates, and cytotoxic T-cell activity. Next, integrate these molecular findings with the patient’s clinical history and reported symptoms to construct a comprehensive immunologic profile. This profile will help determine whether the patient meets the criteria for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c1b27b-ar-c1b27bc.pkl. "
BLCA,,,excluded,R,"A white male patient with bladder urothelial carcinoma underwent transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden was reported as ""nan."" How should this result be interpreted with respect to predicting his likelihood of response to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma underwent transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden was reported as ""nan."" How should this result be interpreted with respect to predicting his likelihood of response to Atezolizumab therapy? Please retrieve the patient's transcriptomic data via the Compass platform. Review this data for indicators such as macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation rates, and cytotoxic T-cell activity. Then, combine these molecular findings with the patient's clinical history and symptom profile to develop a detailed immunologic assessment. This comprehensive profile will inform the decision regarding the patient’s eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c2a182-ar-c2a1820.pkl. "
BLCA,3.0,0.196078431,desert,NR,"For a patient with bladder urothelial carcinoma whose transcriptomic analysis from a bladder biopsy shows a tumor mutational burden of 3.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a patient with bladder urothelial carcinoma whose transcriptomic analysis from a bladder biopsy shows a tumor mutational burden of 3.0, what is the likelihood of a favorable response to Atezolizumab therapy? Retrieve the patient’s transcriptomic data using the Compass platform. Analyze this data for markers such as macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation rates, and cytotoxic T-cell activity. Next, integrate these molecular findings with the patient's clinical history and symptoms to construct a comprehensive immunologic profile. This profile will help determine the patient's suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c57ead-ar-c57eadb.pkl. "
BLCA,10.0,,desert,NR,"In a white male patient with bladder urothelial carcinoma, the transcriptomic profile from a ureter biopsy of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 10.0. Based on this information, can we predict his likelihood of responding to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, the transcriptomic profile from a ureter biopsy of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 10.0. Based on this information, can we predict his likelihood of responding to Atezolizumab therapy? Please obtain the patient’s transcriptomic data through the Compass platform. Evaluate this data for markers such as macrophage activation, interferon-gamma signaling, genomic stability, cellular proliferation rates, and cytotoxic T-cell activity. Then, correlate these molecular findings with the patient’s clinical history and current symptoms to assemble a detailed immunologic profile. This integrated profile will assist in determining the patient’s eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c69253-ar-c692536.pkl. "
BLCA,3.0,0.450980392,excluded,NR,"For a white male patient with bladder urothelial carcinoma, whose lymph node biopsy-based transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutational burden of 3.0, how likely is it that he will respond to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose lymph node biopsy-based transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutational burden of 3.0, how likely is it that he will respond to atezolizumab therapy? Please use the Compass platform to retrieve the patient's transcriptomic data. Analyze this data for indicators including macrophage activation, interferon-gamma signaling, genomic stability, cellular proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to develop a comprehensive immunologic profile that will guide decision-making regarding immune checkpoint inhibitor therapy eligibility.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c6eff0-ar-c6eff05.pkl. "
BLCA,3.0,0.607843137,inflamed,R,"In a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 3.0 mutations per megabase. Based on these findings, what is the anticipated likelihood of response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 3.0 mutations per megabase. Based on these findings, what is the anticipated likelihood of response to Atezolizumab therapy? Access the Compass platform to obtain the patient's transcriptomic data. Review this information for markers such as macrophage activation, interferon-gamma signaling, genomic stability, cellular proliferation, and cytotoxic T-cell activity. Next, correlate these molecular insights with the patient’s clinical history and current symptoms to create a detailed immunologic profile. This comprehensive evaluation will assist in determining the patient's suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/c919ae-ar-c919aeb.pkl. "
BLCA,11.0,1.352941176,inflamed,NR,"I have an African American female patient with Bladder Urothelial Carcinoma. A transcriptomic analysis of her tumor immune microenvironment from a lung biopsy reveals a tumor mutational burden of 11.0. Based on this information, what is the likelihood that she will respond favorably to atezolizumab therapy?","I have an African American female patient with Bladder Urothelial Carcinoma. A transcriptomic analysis of her tumor immune microenvironment from a lung biopsy reveals a tumor mutational burden of 11.0. Based on this information, what is the likelihood that she will respond favorably to atezolizumab therapy? Log in to the Compass platform and retrieve the patient's transcriptomic data. Carefully examine this data for indicators such as macrophage activation, interferon-gamma signaling, genomic stability, cellular proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to develop a detailed immunologic profile. This profile will be used to assess the patient’s eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cabb6d-ar-cabb6d5.pkl. "
BLCA,,0.843137255,desert,NR,"In a white male patient with bladder urothelial carcinoma, a lymph node biopsy provided a transcriptomic profile of the tumor immune microenvironment revealing an undefined tumor mutational burden. Based on this information, how likely is it that the patient will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a lymph node biopsy provided a transcriptomic profile of the tumor immune microenvironment revealing an undefined tumor mutational burden. Based on this information, how likely is it that the patient will respond to Atezolizumab therapy? Please access the Compass platform and retrieve the patient's transcriptomic profile. Review the data for markers indicating macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular insights with the patient’s clinical history and current symptoms to develop a comprehensive immunologic profile. This profile will help determine whether the patient is a suitable candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cb132b-ar-cb132b0.pkl. "
BLCA,,,,NR,"I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic profile of the tumor immune microenvironment was obtained from a liver biopsy, and the tumor mutational burden (TMB) was reported as ""nan."" Could you help assess the likelihood that this patient would respond to atezolizumab therapy?","I have a Caucasian male patient diagnosed with bladder urothelial carcinoma. A transcriptomic profile of the tumor immune microenvironment was obtained from a liver biopsy, and the tumor mutational burden (TMB) was reported as ""nan."" Could you help assess the likelihood that this patient would respond to atezolizumab therapy? Access the Compass platform to obtain the patient’s transcriptomic profile. Carefully examine this data for indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these molecular findings with the patient’s clinical history and current symptoms to construct a detailed immunologic profile. This profile will be instrumental in assessing the patient’s eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cc4675-ar-cc4675f.pkl. "
BLCA,26.0,4.960784314,inflamed,R,"I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. A tumor sample obtained from a ureter biopsy revealed a high tumor mutational burden of 26.0. Based on her transcriptomic profile of the tumor immune microenvironment, how likely is she to benefit from Atezolizumab therapy?","I have a Caucasian female patient diagnosed with bladder urothelial carcinoma. A tumor sample obtained from a ureter biopsy revealed a high tumor mutational burden of 26.0. Based on her transcriptomic profile of the tumor immune microenvironment, how likely is she to benefit from Atezolizumab therapy? Please log in to the Compass platform to retrieve the patient's transcriptomic profile. Review the data looking for signs of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular findings with the patient’s clinical history and current symptoms to develop a comprehensive immunologic profile. This analysis will be key in evaluating whether the patient qualifies for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cc7a42-ar-cc7a42d.pkl. "
BLCA,14.0,0.843137255,inflamed,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic analysis of the tumor’s immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 14.0. Based on this information, what is the likelihood that the patient will respond favorably to atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic analysis of the tumor’s immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 14.0. Based on this information, what is the likelihood that the patient will respond favorably to atezolizumab therapy? Log in to the Compass platform and access the patient's transcriptomic profile. Carefully review the data for indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to create a comprehensive immunologic profile. This assessment is essential to determine whether the patient is a suitable candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ce39dd-ar-ce39dd7.pkl. "
BLCA,,,excluded,NR,"For a White male patient with bladder urothelial carcinoma whose transcriptomic profiling of the tumor immune microenvironment from a lung biopsy shows an indeterminate tumor mutational burden, is there evidence to suggest that he would likely respond favorably to Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma whose transcriptomic profiling of the tumor immune microenvironment from a lung biopsy shows an indeterminate tumor mutational burden, is there evidence to suggest that he would likely respond favorably to Atezolizumab therapy? Please access the Compass platform and retrieve the patient's transcriptomic profile. Review the data for evidence of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient's clinical history and current symptoms to assemble a detailed immunologic profile. This evaluation will help determine if the patient is an appropriate candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/cf018f-ar-cf018fe.pkl. "
BLCA,4.0,0.764705882,desert,R,"For a white female patient diagnosed with bladder urothelial carcinoma, whose tumor transcriptomic profiling from a ureter biopsy reveals a tumor mutational burden of 4.0, how likely is she to respond to atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma, whose tumor transcriptomic profiling from a ureter biopsy reveals a tumor mutational burden of 4.0, how likely is she to respond to atezolizumab therapy? Please log in to the Compass platform to obtain the patient’s transcriptomic profile. Review this data for indications of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular findings with the patient’s clinical history and current symptoms to develop a comprehensive immunologic profile. This assessment will help determine the patient’s eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d02712-ar-d027124.pkl. "
BLCA,3.0,0.607843137,excluded,NR,"A white male patient with bladder urothelial carcinoma has a tumor transcriptomic profile showing a tumor mutational burden of 3.0 from a bladder biopsy. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma has a tumor transcriptomic profile showing a tumor mutational burden of 3.0 from a bladder biopsy. Based on these findings, how likely is the patient to respond to Atezolizumab therapy? Please access the Compass platform to retrieve the patient’s transcriptomic profile. Evaluate this data for signs of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to create a comprehensive immunologic assessment. This evaluation will inform the decision regarding the patient’s suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d135d5-ar-d135d58.pkl. "
BLCA,22.0,,,NR,"In a white male patient with bladder urothelial carcinoma, a biopsy transcriptomic analysis has revealed a tumor mutational burden of 22.0. Based on these findings, how likely is it that the patient would respond to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a biopsy transcriptomic analysis has revealed a tumor mutational burden of 22.0. Based on these findings, how likely is it that the patient would respond to atezolizumab therapy? Access the Compass platform to retrieve the patient’s transcriptomic profile. Analyze the data for indications of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, correlate these molecular findings with the patient’s clinical history and current symptoms to develop a comprehensive immunologic evaluation. This assessment will aid in determining the patient’s appropriateness for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d1bd63-ar-d1bd637.pkl. "
BLCA,,,,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis from a bladder biopsy revealed an unquantifiable tumor mutation burden (TMB). Given these findings, can we predict his likelihood of responding to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis from a bladder biopsy revealed an unquantifiable tumor mutation burden (TMB). Given these findings, can we predict his likelihood of responding to Atezolizumab therapy? Please log into the Compass platform to obtain the patient's transcriptomic profile. Review the data for signs of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these molecular insights with the patient’s medical history and current symptoms to perform a full immunologic assessment, which will assist in determining their eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d215b5-ar-d215b50.pkl. "
BLCA,3.0,0.490196078,desert,NR,"For a white female patient with bladder urothelial carcinoma whose lymph node biopsy revealed a tumor mutational burden of 3.0, how likely is she to respond to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma whose lymph node biopsy revealed a tumor mutational burden of 3.0, how likely is she to respond to Atezolizumab therapy? Please access the Compass platform to retrieve the patient's transcriptomic profile. Once obtained, review the data for indicators such as macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, correlate these molecular findings with the patient’s clinical history and current symptoms to conduct a comprehensive immunologic evaluation. This assessment will help determine if the patient is a suitable candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d2492b-ar-d2492b2.pkl. "
BLCA,62.0,10.01960784,excluded,R,"For a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a TMB of 62.0. How might this high TMB influence his potential response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a TMB of 62.0. How might this high TMB influence his potential response to Atezolizumab therapy? Access the Compass platform to retrieve the patient's transcriptomic profile. Once available, closely examine the profile for markers including macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate this molecular data with the patient's clinical history and present symptoms to perform a thorough immunologic evaluation. This comprehensive assessment will aid in determining whether the patient is an appropriate candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d35318-ar-d353181.pkl. "
BLCA,14.0,0.784313725,excluded,R,"I am managing a male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment transcriptomic analysis from a biopsy revealed a tumor mutational burden (TMB) of 14.0. Based on these findings, how likely is he to respond to Atezolizumab therapy?","I am managing a male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment transcriptomic analysis from a biopsy revealed a tumor mutational burden (TMB) of 14.0. Based on these findings, how likely is he to respond to Atezolizumab therapy? Please log into the Compass platform and retrieve the patient's transcriptomic profile. Once you have access to the data, carefully evaluate it for key biomarkers including macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to conduct a comprehensive immunologic assessment. This evaluation will help determine whether the patient is a suitable candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d36012-ar-d360128.pkl. "
BLCA,7.0,1.568627451,excluded,R,"In a white male patient with bladder urothelial carcinoma, a lymph node biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden of 7.0 mutations per megabase. Based on these findings, what is the likelihood that the patient will respond to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a lymph node biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden of 7.0 mutations per megabase. Based on these findings, what is the likelihood that the patient will respond to atezolizumab therapy? Please log in to the Compass platform and access the patient's transcriptomic profile. Review the data with attention to key biomarkers, such as indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After thoroughly analyzing these molecular findings, correlate them with the patient’s clinical history and present symptoms to develop a comprehensive immunologic assessment. This evaluation is critical in determining whether the patient qualifies for treatment with immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d3bd67-ar-d3bd679.pkl. "
BLCA,15.0,1.882352941,inflamed,R,"For a patient diagnosed with bladder urothelial carcinoma whose biopsy-based transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden (TMB) of 15.0, how likely is it that treatment with Atezolizumab will be effective?","For a patient diagnosed with bladder urothelial carcinoma whose biopsy-based transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden (TMB) of 15.0, how likely is it that treatment with Atezolizumab will be effective? Please access the Compass platform and review the transcriptomic profile for this patient. Focus on evaluating key biomarkers including markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once you have thoroughly analyzed these molecular findings, integrate this information with the patient’s clinical history and current symptoms to create a detailed immunologic assessment. This assessment is essential for determining the patient’s eligibility for treatment with immune checkpoint inhibitors.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d43f89-ar-d43f893.pkl. "
BLCA,5.0,0.529411765,excluded,NR,"In a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic analysis from a kidney biopsy indicates a TMB of 5.0, what is the likelihood that he will respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic analysis from a kidney biopsy indicates a TMB of 5.0, what is the likelihood that he will respond to Atezolizumab therapy? Please log in to the Compass platform and review this patient's transcriptomic profile. While doing so, focus on evaluating biomarkers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After you have thoroughly examined these molecular findings, combine them with the patient’s clinical history and current symptoms to develop a comprehensive immunologic assessment. This evaluation is critical for determining the patient’s eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d4c083-ar-d4c0837.pkl. "
BLCA,,0.196078431,inflamed,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of a bladder biopsy revealed a tumor mutation burden (TMB) reading of ""nan."" Based on this result, could you provide insight into the likelihood of this patient responding to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A transcriptomic analysis of a bladder biopsy revealed a tumor mutation burden (TMB) reading of ""nan."" Based on this result, could you provide insight into the likelihood of this patient responding to Atezolizumab therapy? Please access the Compass platform and review the patient's transcriptomic profile. Focus your evaluation on biomarkers indicating macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these molecular findings with the patient's clinical history and current symptoms to create a comprehensive immunologic assessment. This integrated evaluation is essential for determining the patient's eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d636e3-ar-d636e34.pkl. "
BLCA,,,excluded,NR,"I have a Caucasian female patient diagnosed with Bladder Urothelial Carcinoma (BLCA). Transcriptomic analysis of her tumor immune microenvironment from a ureter biopsy indicates a tumor mutational burden (TMB) reported as ""nan."" Could you help determine whether this patient is likely to respond to Atezolizumab therapy?","I have a Caucasian female patient diagnosed with Bladder Urothelial Carcinoma (BLCA). Transcriptomic analysis of her tumor immune microenvironment from a ureter biopsy indicates a tumor mutational burden (TMB) reported as ""nan."" Could you help determine whether this patient is likely to respond to Atezolizumab therapy? Please log into the Compass platform and review the patient's transcriptomic profile. When assessing the data, pay close attention to biomarkers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T‐cell activity. Integrate these molecular findings with the patient’s clinical history and current symptoms to develop a comprehensive immunologic evaluation. This detailed assessment is critical for determining if the patient is an appropriate candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d697ba-ar-d697ba7.pkl. "
BLCA,24.0,,inflamed,R,"For a white male patient diagnosed with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment indicates a tumor mutational burden of 24 mutations per megabase, based on current evidence, how likely is it that he will respond favorably to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment indicates a tumor mutational burden of 24 mutations per megabase, based on current evidence, how likely is it that he will respond favorably to Atezolizumab therapy? Please access the Compass platform and examine the patient's transcriptomic data. Focus on markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these molecular insights with the patient’s clinical history and present symptoms to form a thorough immunologic assessment. This evaluation is essential to determine the patient’s suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d7d57e-ar-d7d57ee.pkl. "
BLCA,,1.411764706,desert,NR,"I have a white male patient with bladder urothelial carcinoma whose transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutation burden value reported as ""nan."" Based on this result, how should I interpret his potential response to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutation burden value reported as ""nan."" Based on this result, how should I interpret his potential response to Atezolizumab therapy? Please log into the Compass platform and review the patient's transcriptomic profile. Specifically, assess markers that indicate macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate this molecular data with the patient’s clinical history and present symptoms to develop a comprehensive immunologic evaluation. This analysis is essential for assessing the patient’s eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d86389-ar-d86389d.pkl. "
BLCA,8.0,0.725490196,desert,NR,"I am evaluating a Caucasian male patient with urothelial carcinoma of the bladder whose tumor immune microenvironment was profiled via a ureter biopsy, revealing a tumor mutation burden (TMB) of 8.0 mutations per megabase. Based on these findings, is he likely to respond to atezolizumab therapy?","I am evaluating a Caucasian male patient with urothelial carcinoma of the bladder whose tumor immune microenvironment was profiled via a ureter biopsy, revealing a tumor mutation burden (TMB) of 8.0 mutations per megabase. Based on these findings, is he likely to respond to atezolizumab therapy? Log in to the Compass platform and access the patient’s transcriptomic profile. Carefully evaluate markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, correlate these molecular findings with the patient’s clinical history and presenting symptoms to construct a detailed immunologic assessment. This analysis is crucial for determining the patient’s suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/d98bac-ar-d98bac0.pkl. "
BLCA,4.0,0.274509804,,NR,"In a white male patient with bladder urothelial carcinoma (BLCA), a kidney biopsy transcriptomic profile revealed a tumor mutational burden (TMB) of 4.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA), a kidney biopsy transcriptomic profile revealed a tumor mutational burden (TMB) of 4.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy? Please access the Compass platform and retrieve the patient’s transcriptomic profile. Carefully examine markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to develop a comprehensive immunologic assessment. This evaluation is essential to determine the patient’s eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/da4d89-ar-da4d892.pkl. "
BLCA,14.0,2.921568627,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis revealed a tumor mutational burden of 14.0, is there evidence to suggest he might respond favorably to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis revealed a tumor mutational burden of 14.0, is there evidence to suggest he might respond favorably to Atezolizumab therapy? Access the Compass platform to obtain the patient’s transcriptomic data. Review markers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to create a comprehensive immunologic assessment. This process is necessary to determine if the patient qualifies for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dab9ca-ar-dab9ca8.pkl. "
BLCA,5.0,0.666666667,excluded,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 5.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 5.0. Based on these findings, how likely is the patient to respond to Atezolizumab therapy? Please log into the Compass platform to retrieve the patient's transcriptomic data. Evaluate the markers related to macrophage activation, interferon-gamma signaling, genomic stability, cellular proliferation, and cytotoxic T-cell activity. Next, combine these molecular insights with the patient's clinical background and current symptoms to form a detailed immunologic evaluation. This comprehensive assessment is essential for determining the patient’s eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dad5c2-ar-dad5c29.pkl. "
BLCA,10.0,0.509803922,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. A bladder biopsy provided transcriptomic profiling of the tumor immune microenvironment, which indicated a tumor mutational burden of 10.0. Based on this TMB value, how likely is it that he would respond effectively to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A bladder biopsy provided transcriptomic profiling of the tumor immune microenvironment, which indicated a tumor mutational burden of 10.0. Based on this TMB value, how likely is it that he would respond effectively to Atezolizumab therapy? Please access the Compass platform to obtain the patient's transcriptomic data. Analyze the key markers for macrophage activation, interferon-gamma signaling, genomic stability, cellular proliferation, and cytotoxic T-cell activity. Then, integrate these molecular results with the patient’s clinical history and current symptoms to develop a detailed immunologic profile. This comprehensive assessment is necessary to determine whether the patient qualifies for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/db3f50-ar-db3f50c.pkl. "
BLCA,,1.431372549,excluded,NR,"A white male patient with bladder urothelial carcinoma underwent a kidney biopsy for transcriptomic profiling of the tumor immune microenvironment, which reported a tumor mutation burden (TMB) of nan. Based on this data, could you provide your assessment of the potential responsiveness to Atezolizumab therapy?","A white male patient with bladder urothelial carcinoma underwent a kidney biopsy for transcriptomic profiling of the tumor immune microenvironment, which reported a tumor mutation burden (TMB) of nan. Based on this data, could you provide your assessment of the potential responsiveness to Atezolizumab therapy? Access the Compass platform and retrieve the patient’s transcriptomic data. Evaluate the expression of key markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Next, integrate these molecular findings with the patient's clinical history and current symptoms to create a detailed immunologic profile. This evaluation is essential to determine if the patient meets the criteria for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dcae54-ar-dcae54f.pkl. "
BLCA,,,,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. Transcriptomic profiling of his tumor immune microenvironment, obtained from a lymph node biopsy, reported a tumor mutational burden value of ""nan."" Based on this data, how might we assess his likelihood of responding to atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. Transcriptomic profiling of his tumor immune microenvironment, obtained from a lymph node biopsy, reported a tumor mutational burden value of ""nan."" Based on this data, how might we assess his likelihood of responding to atezolizumab therapy? Please log into the Compass platform to retrieve the patient’s transcriptomic data. Carefully assess the expression levels of markers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular indicators with the patient’s clinical history and current symptoms to construct a comprehensive immunologic profile. This profile is critical for determining whether the patient qualifies for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/dee101-ar-dee1011.pkl. "
BLCA,19.0,3.235294118,inflamed,NR,"In a White male patient with bladder urothelial carcinoma, whose tumor transcriptomic profile from a bladder biopsy shows a tumor mutational burden (TMB) of 19.0, how likely is he to respond to atezolizumab therapy?","In a White male patient with bladder urothelial carcinoma, whose tumor transcriptomic profile from a bladder biopsy shows a tumor mutational burden (TMB) of 19.0, how likely is he to respond to atezolizumab therapy? Log into the Compass platform and retrieve the patient’s transcriptomic data. Review the expression levels of markers linked to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Combine these molecular findings with the patient’s clinical history and current symptoms to develop a comprehensive immunologic profile. This integrated profile will help determine the patient’s suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/df3e42-ar-df3e42c.pkl. "
BLCA,5.0,0.549019608,desert,NR,"I have a patient diagnosed with bladder urothelial carcinoma whose ureter biopsy transcriptomic analysis of the tumor immune microenvironment indicates a tumor mutational burden (TMB) of 5.0. Based on this molecular profile, how likely is the patient to benefit from Atezolizumab therapy?","I have a patient diagnosed with bladder urothelial carcinoma whose ureter biopsy transcriptomic analysis of the tumor immune microenvironment indicates a tumor mutational burden (TMB) of 5.0. Based on this molecular profile, how likely is the patient to benefit from Atezolizumab therapy? Please log into the Compass platform and access the patient's transcriptomic data. Then, evaluate the expression levels of markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Integrate these molecular findings with the patient's clinical history and current symptoms to construct a comprehensive immunologic profile. This profile will be used to assess the patient's eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e07c45-ar-e07c456.pkl. "
BLCA,2.0,,excluded,NR,"For a white female patient diagnosed with bladder urothelial carcinoma, the tumor biopsy shows a tumor mutational burden of 2.0. Based on these findings, what is the likelihood that she will respond favorably to Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma, the tumor biopsy shows a tumor mutational burden of 2.0. Based on these findings, what is the likelihood that she will respond favorably to Atezolizumab therapy? Please access the patient's transcriptomic data via the Compass platform. Assess the expression levels of markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular findings with the patient’s clinical history and current symptoms to develop a detailed immunologic profile. This profile will inform our evaluation of whether the patient is eligible for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e0c49e-ar-e0c49ea.pkl. "
BLCA,14.0,2.274509804,inflamed,R,"I have a white male patient diagnosed with bladder urothelial carcinoma. A bladder biopsy provided a transcriptomic profile of his tumor immune microenvironment, and his tumor mutational burden is recorded at 14.0. Based on this information, how likely is he to respond to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. A bladder biopsy provided a transcriptomic profile of his tumor immune microenvironment, and his tumor mutational burden is recorded at 14.0. Based on this information, how likely is he to respond to Atezolizumab therapy? Please retrieve the patient's transcriptomic dataset from the Compass platform. Analyze the expression of markers related to macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Once these molecular markers have been evaluated, integrate the findings with the patient’s clinical history and current symptoms to create a comprehensive immunologic profile. This profile will assist in determining the patient's eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e1eb5d-ar-e1eb5d9.pkl. "
BLCA,17.0,0.862745098,inflamed,NR,"I am managing a white female patient diagnosed with bladder urothelial carcinoma (BLCA). Transcriptomic profiling from a nanobiopsy of her tumor immune microenvironment reveals a tumor mutational burden (TMB) of 17. Based on these findings, could you provide your insight into her potential response to Atezolizumab therapy?","I am managing a white female patient diagnosed with bladder urothelial carcinoma (BLCA). Transcriptomic profiling from a nanobiopsy of her tumor immune microenvironment reveals a tumor mutational burden (TMB) of 17. Based on these findings, could you provide your insight into her potential response to Atezolizumab therapy? Please retrieve the patient’s transcriptomic dataset from the Compass platform. Evaluate the expression levels of markers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. After assessing these molecular markers, integrate the results with the patient’s clinical history and current symptoms to develop a comprehensive immunologic profile, which will help determine their suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e3210d-ar-e3210d3.pkl. "
BLCA,,,,NR,"In a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy indicates that the tumor mutational burden (TMB) is not available. Based on these findings, what is the likelihood that the patient would respond favorably to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy indicates that the tumor mutational burden (TMB) is not available. Based on these findings, what is the likelihood that the patient would respond favorably to Atezolizumab therapy? Access the patient’s transcriptomic data from the Compass platform. Please analyze markers for macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, correlate these molecular findings with the patient’s clinical history and current symptoms to develop a detailed immunologic profile, which will aid in assessing their eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e3d426-ar-e3d4266.pkl. "
BLCA,6.0,0.470588235,excluded,NR,"A Caucasian male patient with bladder urothelial carcinoma has a tumor mutation burden of 6.0, as determined by transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy. Based on current evidence, what is the likelihood that he will respond to Atezolizumab therapy?","A Caucasian male patient with bladder urothelial carcinoma has a tumor mutation burden of 6.0, as determined by transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy. Based on current evidence, what is the likelihood that he will respond to Atezolizumab therapy? Please retrieve the patient’s transcriptomic data from the Compass platform. Evaluate indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Once you have this data, correlate the molecular findings with the patient’s clinical history and present symptoms to construct a comprehensive immunologic profile. This profile will help determine the patient’s suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e41b1e-ar-e41b1e7.pkl. "
BLCA,9.0,2.176470588,desert,R,"In a white female patient with bladder urothelial carcinoma, where the tumor transcriptomic profile from a bladder biopsy indicates a tumor mutational burden (TMB) of 9.0 mutations/Mb, what is the likelihood that she will respond to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma, where the tumor transcriptomic profile from a bladder biopsy indicates a tumor mutational burden (TMB) of 9.0 mutations/Mb, what is the likelihood that she will respond to Atezolizumab therapy? Please access the patient's transcriptomic data from the Compass platform. Review the data for markers associated with macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient's clinical history and current symptoms to develop a comprehensive immunologic profile. This profile will assist in assessing the patient’s eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e50d15-ar-e50d15f.pkl. "
BLCA,5.0,0.098039216,excluded,NR,"For a white female patient diagnosed with bladder urothelial carcinoma (BLCA), whose kidney biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden (TMB) of 5.0, what is the likelihood of response to Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma (BLCA), whose kidney biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden (TMB) of 5.0, what is the likelihood of response to Atezolizumab therapy? Please retrieve the patient's transcriptomic dataset from the Compass platform and evaluate it for indicators of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell function. Then, combine these molecular insights with the patient’s clinical history and present symptoms to develop a detailed immunologic profile. This profile will be used to determine the patient’s suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e56c96-ar-e56c96c.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, whose liver biopsy transcriptomic profile of the tumor immune microenvironment indicates a tumor mutational burden (TMB) of 5.0, what is the likelihood of achieving a therapeutic response with atezolizumab?","For a white male patient diagnosed with bladder urothelial carcinoma, whose liver biopsy transcriptomic profile of the tumor immune microenvironment indicates a tumor mutational burden (TMB) of 5.0, what is the likelihood of achieving a therapeutic response with atezolizumab? Access the patient’s transcriptomic dataset from the Compass platform and analyze it for markers of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Merge these molecular findings with the patient’s medical history and current symptoms to create a comprehensive immunologic profile. This profile will help determine if the patient is a suitable candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e5bc41-ar-e5bc417.pkl. "
BLCA,,,desert,R,I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). The transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy shows that the tumor mutational burden (TMB) is not available. How should we interpret this result in terms of predicting his potential response to Atezolizumab therapy?,"I have a white male patient diagnosed with bladder urothelial carcinoma (BLCA). The transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy shows that the tumor mutational burden (TMB) is not available. How should we interpret this result in terms of predicting his potential response to Atezolizumab therapy? Retrieve the patient's transcriptomic data from the Compass platform and evaluate it for markers related to macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, combine these molecular insights with the patient’s medical history and current symptoms to develop a comprehensive immunologic profile. This profile will be used to assess whether the patient is a suitable candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e71235-ar-e712352.pkl. "
BLCA,,,,NR,"I have a white male patient with bladder urothelial carcinoma. A kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutational burden was reported as ""nan."" How should we interpret these findings regarding his potential response to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. A kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutational burden was reported as ""nan."" How should we interpret these findings regarding his potential response to Atezolizumab therapy? Please access the patient's transcriptomic data on the Compass platform and assess it for markers of macrophage activation, interferon‐gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, integrate these molecular findings with the patient's clinical history and present symptoms to develop a comprehensive immunologic profile. This profile will help determine whether the patient is an appropriate candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7bcab-ar-e7bcab0.pkl. "
BLCA,7.0,1.37254902,inflamed,NR,"Given a white male patient with Bladder Urothelial Carcinoma, whose tumor immune microenvironment transcriptomic profile from a kidney biopsy shows a tumor mutational burden of 7.0, how likely is it that he will respond to Atezolizumab therapy?","Given a white male patient with Bladder Urothelial Carcinoma, whose tumor immune microenvironment transcriptomic profile from a kidney biopsy shows a tumor mutational burden of 7.0, how likely is it that he will respond to Atezolizumab therapy? Please log into the Compass platform and review the patient's transcriptomic profile, specifically looking for markers indicative of macrophage activation, interferon-gamma signaling, genomic stability, cell proliferation, and cytotoxic T-cell activity. Then, correlate these molecular findings with the patient’s clinical history and current symptoms to develop an integrated immunologic profile. This comprehensive profile will assist in determining if the patient is a suitable candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7bf6c-ar-e7bf6c0.pkl. "
BLCA,1.0,0.196078431,inflamed,NR,"Given a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis indicates a tumor mutational burden of 1.0, how likely is he to respond to atezolizumab therapy?","Given a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis indicates a tumor mutational burden of 1.0, how likely is he to respond to atezolizumab therapy? Log into the Compass platform and review the patient's transcriptomic data with a specific focus on markers for macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Then, integrate these molecular findings with the patient's clinical history and current symptoms to create a comprehensive immunologic profile. This profile will help determine whether the patient is an appropriate candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e7e4f7-ar-e7e4f7c.pkl. "
BLCA,,,excluded,NR,"In a white male patient diagnosed with bladder urothelial carcinoma (BLCA), the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows an undefined tumor mutational burden (TMB: nan). Based on this information, how might we assess the likelihood of a therapeutic response to Atezolizumab?","In a white male patient diagnosed with bladder urothelial carcinoma (BLCA), the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows an undefined tumor mutational burden (TMB: nan). Based on this information, how might we assess the likelihood of a therapeutic response to Atezolizumab? Please log into the Compass platform and examine the patient’s transcriptomic data, paying close attention to indicators of macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. After reviewing these molecular markers, correlate your findings with the patient’s clinical history and current symptoms to develop a detailed immunologic profile. This comprehensive evaluation will assist in determining whether the patient qualifies for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e9475f-ar-e9475f7.pkl. "
BLCA,6.0,1.019607843,excluded,NR,"I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated via bladder biopsy, revealing a tumor mutational burden of 6.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment was evaluated via bladder biopsy, revealing a tumor mutational burden of 6.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy? Please access the Compass platform to review the patient's transcriptomic data, focusing on markers such as macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Once you have analyzed these molecular features, integrate your findings with the patient's clinical history and current symptoms to develop a comprehensive immunologic profile. This profile will be essential in determining the patient's eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e94c30-ar-e94c30c.pkl. "
BLCA,3.0,0.705882353,excluded,NR,"For a white female patient with bladder urothelial carcinoma, the tumor biopsy transcriptomic profile indicates a tumor mutation burden of 3.0. Based on this data, could you evaluate her likelihood of responding to atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, the tumor biopsy transcriptomic profile indicates a tumor mutation burden of 3.0. Based on this data, could you evaluate her likelihood of responding to atezolizumab therapy? Access the Compass platform to examine the patient's transcriptomic data with an emphasis on markers such as macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. After reviewing these molecular characteristics, combine your findings with the patient's clinical history and current symptoms to construct a detailed immunologic profile. This synthesized profile will play a crucial role in evaluating the patient's suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e97af0-ar-e97af0f.pkl. "
BLCA,7.0,1.333333333,desert,NR,A Caucasian male patient with bladder urothelial carcinoma (BLCA) has a tumor transcriptomic profile from a biopsy showing a TMB of 7.0. How might this TMB level inform his likelihood of responding to Atezolizumab therapy?,"A Caucasian male patient with bladder urothelial carcinoma (BLCA) has a tumor transcriptomic profile from a biopsy showing a TMB of 7.0. How might this TMB level inform his likelihood of responding to Atezolizumab therapy? Please log into the Compass platform and review the patient's transcriptomic data, focusing specifically on markers related to macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. After completing your molecular analysis, integrate these findings with the patient’s clinical history and current symptoms to create a detailed immunologic profile. This comprehensive profile will be crucial in assessing the patient's eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/e9ae8b-ar-e9ae8be.pkl. "
BLCA,14.0,2.764705882,inflamed,R,A  White male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 14.0 based on the transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy. How likely is he to respond to Atezolizumab therapy?,"A  White male patient with bladder urothelial carcinoma (BLCA) has a tumor mutational burden of 14.0 based on the transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy. How likely is he to respond to Atezolizumab therapy? Please access the Compass platform and review the patient's transcriptomic data. Concentrate on the markers that indicate macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. After completing this molecular analysis, correlate the findings with the patient’s clinical history and present symptoms to develop a detailed immunologic profile. This profile is essential for evaluating the patient’s suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eaa477-ar-eaa477a.pkl. "
BLCA,2.0,0.058823529,excluded,NR,"I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor microenvironment, obtained via kidney biopsy, shows a tumor mutational burden of 2.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy?","I have a white male patient with bladder urothelial carcinoma. A transcriptomic analysis of his tumor microenvironment, obtained via kidney biopsy, shows a tumor mutational burden of 2.0. Based on these findings, what is the likelihood that he will respond to atezolizumab therapy? Please log into the Compass platform and thoroughly review the patient's transcriptomic data. Pay close attention to markers that reflect macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Once the molecular analysis is complete, integrate these findings with the patient's clinical history and current symptoms to construct a detailed immunologic profile. This evaluation will be crucial in determining the patient’s eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eb2962-ar-eb29625.pkl. "
BLCA,,,,NR,"I have a Caucasian male diagnosed with bladder urothelial carcinoma, and his tumor biopsy transcriptomic analysis shows that the tumor mutational burden (TMB) is not available. Based on this information, how would you evaluate his likelihood of responding to Atezolizumab therapy?","I have a Caucasian male diagnosed with bladder urothelial carcinoma, and his tumor biopsy transcriptomic analysis shows that the tumor mutational burden (TMB) is not available. Based on this information, how would you evaluate his likelihood of responding to Atezolizumab therapy? Please access the Compass platform and perform a comprehensive review of the patient’s transcriptomic data. Focus specifically on markers associated with macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. After completing the molecular assessment, integrate your findings with the patient’s clinical history and current symptoms to develop a detailed immunologic profile. This profile is essential for determining the patient’s suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eb587a-ar-eb587a6.pkl. "
BLCA,,,,NR,I have a White male patient diagnosed with bladder urothelial carcinoma. Transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy indicates that his tumor mutational burden is not detectable. Could you assess his potential response to Atezolizumab therapy?,"I have a White male patient diagnosed with bladder urothelial carcinoma. Transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy indicates that his tumor mutational burden is not detectable. Could you assess his potential response to Atezolizumab therapy? Access the Compass platform and conduct a thorough review of the patient’s transcriptomic data. Pay particular attention to markers linked to macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. After the molecular analysis, correlate your findings with the patient’s clinical history and current symptoms to develop a detailed immunologic profile. This profile is critical for assessing the patient’s eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ee3844-ar-ee3844c.pkl. "
BLCA,1.0,0.039215686,inflamed,NR,"For a white male patient with bladder urothelial carcinoma, a lung biopsy provided transcriptomic data on the tumor immune microenvironment, indicating a tumor mutational burden of 1.0. Based on this information, what is the likelihood that the patient will respond favorably to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, a lung biopsy provided transcriptomic data on the tumor immune microenvironment, indicating a tumor mutational burden of 1.0. Based on this information, what is the likelihood that the patient will respond favorably to atezolizumab therapy? Please log into the Compass platform and perform a comprehensive review of the patient’s transcriptomic data. Focus specifically on markers associated with macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to create a detailed immunologic profile. This profile is essential for determining the patient's suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ef0e3d-ar-ef0e3d2.pkl. "
BLCA,14.0,,desert,NR,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma, with a transcriptomic profile from a ureter biopsy revealing a tumor mutational burden (TMB) of 14.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma, with a transcriptomic profile from a ureter biopsy revealing a tumor mutational burden (TMB) of 14.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please access the Compass platform and review the patient’s transcriptomic data, paying special attention to markers for macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Then, correlate these molecular findings with the patient's clinical history and present symptoms to construct a comprehensive immunologic profile. This detailed profile will inform our assessment of the patient’s candidacy for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/eff2ce-ar-eff2ce3.pkl. "
BLCA,14.0,1.098039216,inflamed,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, whose kidney biopsy transcriptomic analysis reveals a tumor mutational burden (TMB) of 14.0, how likely is it that he will respond to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, whose kidney biopsy transcriptomic analysis reveals a tumor mutational burden (TMB) of 14.0, how likely is it that he will respond to Atezolizumab therapy? Please log into the Compass platform and review the patient’s transcriptomic profile, with a focus on markers related to macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell activity. Next, integrate these molecular findings with the patient’s clinical history and current symptoms to develop a comprehensive immunologic profile. This profile will be used to determine the patient’s suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f20b82-ar-f20b827.pkl. "
BLCA,9.0,,excluded,R,"I have a Black/African American patient diagnosed with bladder urothelial carcinoma. The tumor's transcriptomic profile from a bladder biopsy indicates a tumor mutational burden (TMB) of 9.0. Based on these findings, is the patient likely to benefit from Atezolizumab therapy?","I have a Black/African American patient diagnosed with bladder urothelial carcinoma. The tumor's transcriptomic profile from a bladder biopsy indicates a tumor mutational burden (TMB) of 9.0. Based on these findings, is the patient likely to benefit from Atezolizumab therapy? Please access the Compass platform and review the patient's transcriptomic data, specifically examining markers for macrophage activation, interferon‑gamma signaling, genomic integrity, cell proliferation, and cytotoxic T‑cell activity. Then, correlate these molecular findings with the patient's medical history and current symptoms to develop a detailed immunologic profile. This profile will help determine if the patient is an appropriate candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f275eb-ar-f275eb8.pkl. "
BLCA,8.0,,desert,NR,"I am managing a white male patient with bladder urothelial carcinoma. The transcriptomic analysis of his bladder tumor biopsy shows a tumor mutational burden of 8.0. Based on these findings, can you provide an assessment of his likely response to atezolizumab therapy?","I am managing a white male patient with bladder urothelial carcinoma. The transcriptomic analysis of his bladder tumor biopsy shows a tumor mutational burden of 8.0. Based on these findings, can you provide an assessment of his likely response to atezolizumab therapy? Access the Compass platform and examine the patient's transcriptomic data, focusing on indicators of macrophage activation, interferon‑gamma signaling, genomic integrity, cell proliferation, and cytotoxic T‑cell activity. Next, compare these molecular results with the patient's clinical history and current symptoms to construct a comprehensive immunologic profile. This profile will be used to assess the patient's eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f28c01-ar-f28c015.pkl. "
BLCA,7.0,0.803921569,desert,NR,"For a White female patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) of 7.0, what is the likelihood that she will respond favorably to Atezolizumab therapy?","For a White female patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) of 7.0, what is the likelihood that she will respond favorably to Atezolizumab therapy? Please log into the Compass platform and review the patient's transcriptomic data, paying particular attention to markers related to macrophage activation, interferon‑gamma signaling, genomic integrity, cell proliferation, and cytotoxic T‑cell activity. Then, correlate these molecular findings with the patient's clinical history and current symptoms to develop a detailed immunologic profile. This profile will help determine if the patient qualifies for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f2aae1-ar-f2aae14.pkl. "
BLCA,4.0,,excluded,NR,"We have an Asian female patient diagnosed with bladder urothelial carcinoma. Her tumor immune microenvironment analysis, obtained from a kidney biopsy, revealed a tumor mutational burden (TMB) of 4.0. Based on these findings, what is the likelihood that she will respond to atezolizumab therapy?","We have an Asian female patient diagnosed with bladder urothelial carcinoma. Her tumor immune microenvironment analysis, obtained from a kidney biopsy, revealed a tumor mutational burden (TMB) of 4.0. Based on these findings, what is the likelihood that she will respond to atezolizumab therapy? Please access the Compass platform and examine the patient's transcriptomic data, paying special attention to markers of macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell function. Next, integrate these molecular findings with the patient’s clinical history and current symptoms to create a comprehensive immunologic profile. This profile will be used to assess the patient's eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f3a9bc-ar-f3a9bce.pkl. "
BLCA,7.0,0.529411765,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma who has a tumor immune microenvironment transcriptomic profile obtained from a kidney biopsy demonstrating a tumor mutational burden of 7.0, how likely is this patient to respond to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma who has a tumor immune microenvironment transcriptomic profile obtained from a kidney biopsy demonstrating a tumor mutational burden of 7.0, how likely is this patient to respond to Atezolizumab therapy? Please log in to the Compass platform and review the patient's transcriptomic profile, focusing on markers for macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell function. Then, correlate these molecular findings with the patient’s clinical history and current symptoms to develop a detailed immunologic profile. This profile will inform the evaluation of the patient's suitability for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/f82bbd-ar-f82bbdc.pkl. "
BLCA,,5.921568627,inflamed,R,"I have a white male patient diagnosed with bladder urothelial carcinoma. Transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy shows that the tumor mutational burden (TMB) value is not available (nan). Based on this information, how can we assess his likely response to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. Transcriptomic analysis of his tumor immune microenvironment from a bladder biopsy shows that the tumor mutational burden (TMB) value is not available (nan). Based on this information, how can we assess his likely response to Atezolizumab therapy? Please access the Compass platform and review the patient's transcriptomic data. Focus on biomarkers related to macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell function. Then, integrate these molecular findings with the patient’s clinical history and current symptoms to construct a comprehensive immunologic profile. This profile will assist in assessing the patient’s eligibility for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fb7aec-ar-fb7aec7.pkl. "
BLCA,5.0,,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment, assessed via transcriptomic profiling from a biopsy, shows a tumor mutational burden of 5.0, what is the likelihood that he will respond to atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment, assessed via transcriptomic profiling from a biopsy, shows a tumor mutational burden of 5.0, what is the likelihood that he will respond to atezolizumab therapy? Please log into the Compass platform and review the patient's transcriptomic data, paying particular attention to biomarkers that indicate macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell function. After gathering these molecular insights, integrate them with the patient’s clinical history and current symptoms to assemble a detailed immunologic profile. This integrated assessment will help determine whether the patient is an appropriate candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fd9476-ar-fd94761.pkl. "
BLCA,7.0,0.352941176,desert,NR,"I have a white female patient with a diagnosis of bladder urothelial carcinoma. Her tumor's immune microenvironment was profiled via transcriptomic analysis from a bladder biopsy, revealing a tumor mutational burden of 7.0. Based on this information, what is the likelihood that she will respond to Atezolizumab therapy?","I have a white female patient with a diagnosis of bladder urothelial carcinoma. Her tumor's immune microenvironment was profiled via transcriptomic analysis from a bladder biopsy, revealing a tumor mutational burden of 7.0. Based on this information, what is the likelihood that she will respond to Atezolizumab therapy? Please log in to the Compass platform and carefully evaluate the patient’s transcriptomic data. Specifically, review biomarkers that reflect macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell function. Then, combine these molecular findings with the patient’s clinical history and current symptoms to develop a comprehensive immunologic profile. This approach will assist in determining if the patient is a suitable candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/fed609-ar-fed6099.pkl. "
BLCA,10.0,,desert,R,A White male patient with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile indicating a TMB of 10. Could you provide insights on whether this patient is likely to respond to Atezolizumab therapy?,"A White male patient with bladder urothelial carcinoma has a tumor immune microenvironment transcriptomic profile indicating a TMB of 10. Could you provide insights on whether this patient is likely to respond to Atezolizumab therapy? Access the Compass platform and review the patient's transcriptomic data, with a focus on biomarkers for macrophage activation, interferon‑gamma signaling, genomic stability, cell proliferation, and cytotoxic T‑cell function. Next, integrate these molecular findings with the patient’s clinical history and current symptoms to construct a detailed immunologic profile. This comprehensive assessment will help determine whether the patient is an appropriate candidate for immune checkpoint inhibitor therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/ffa5c7-ar-ffa5c7c.pkl. "
